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The Tat (Trans activator) protein of the human immunodeficiency virus type 
1 (HIV-1) is a 101 amino acid polypeptide acting as a powerful 
transcriptional activator of viral gene expression. The protein binds a highly 
structured region of nascent RNA transcripts and, from here, directs the 
assembly of processive transcription complexes and promotes chromatin 
modification at the HIV-1 LTR (Long Terminal Repeat) promoter. Besides 
this fundamental role in the control of HIV-1 gene expression, Tat also 
possesses the unusual property of trafficking in and out of the cells. In 
particular, the capacity of being internalized by the cells when present in the 
extracellular compartment, which depends on the integrity of the basic 
domain of the protein (aa 49-57), has been extensively characterized and 
constitutes the basis for its biotechnological utilization for the delivery of 
heterologous proteins, drugs, viral vectors and nanoparticles (Becker-Hapak 
et al. 2001; Tasciotti et al. 2003; Fittipaldi and Giacca 2005; Tasciotti and 
Giacca 2005). Some of the studies that elucidated the molecular 
mechanisms of extracellular Tat internalization also noticed that cells 
constitutively expressing Tat release this protein into the cell culture 
supernatant (Becker-Hapak et al. 2001; Tyagi et al. 2001; Tasciotti et al. 
2003; Tasciotti and Giacca 2005). However, the mechanisms underlying 
extracellular Tat release have so far remained elusive.  
The aim of this project was to explore the molecular mechanisms 
responsible for Tat export from the expressing cells, with the ultimate 
purpose to understand the significance of such mechanism in the biology of 
HIV-1 infection and exploit the ensuing information for the improvement of 
the trafficking properties of Tat-fused protein cargos.  







1) When cells were transfected with expression vectors encoding fusion 
constructs corresponding to a reporter protein fused to full-length HIV-1 Tat 
or to an 11 amino acid peptide encompassing its basic domain, a significant 
fraction of these proteins was found in the cell culture supernatants. 
Secretion had a rapid kinetics, different from that of proteins secreted 
through the endoplasmic reticulum (ER)-Golgi route, and was dependent on 
the integrity of the Tat basic domain. 
2) Neither drugs blocking canonical protein secretion nor drugs interfering 
with intracellular vesicle trafficking blocked extracellular Tat release, 
indicating that this process occurred through a Golgi-independent, 
unconventional secretion route. 
3) Tat and Tat-fusion protein release was impaired by ouabain. This drug is 
a specific inhibitor of the cellular Na+,K+-ATPase, an enzyme built into the 
plasma membrane which catalyzes ATP hydrolysis coupled with Na+ and K+ 
transfer through the membrane against the electrochemical gradient. 
Ouabain is known to also impair the unconventional secretion of FGF-2 
(Fibroblast Growth Factor 2) (Florkiewicz et al. 1998; Dahl et al. 2000).  
4) The Tat basic domain was found to specifically bind the catalytic (alpha) 
subunit of the Na+,K+-ATPase. This interaction appeared essential for 
extracellular Tat release and was disrupted by ouabain treatment. 
5) Interaction between Tat and the Na+,K+-ATPase required integrity of the 
Carboxy-terminal domain of the latter protein. In particular, this region 
contains three short intracytoplasmic peptide stretches (of 19, 12, and 16 
amino acids) that are juxtaposed in the protein three-dimensional structure, 
which were all required to bind Tat.  
6) Intracellular expression of a novel fusion protein corresponding to a linear 
combination of the three Tat-binding, Na+,K+-ATPase peptide regions 







7) A mixture of soluble synthetic peptides corresponding to the three Tat-
binding, Na+,K+-ATPase peptide regions blocked Tat release. 
8) The same mixture of peptides, when added to CD4+ T-cells infected with 
a wild type strain (HIV-1BRU) impaired HIV-1 infection. 
Taken together, these results shed light on the molecular mechanism 
responsible for extracellular Tat release, disclose the importance of inhibiting 
this process in the viral life cycle and identify a novel tool for 
































HIV life cycle 
The Human Immunodeficiency Virus type 1 and 2 (HIV-1 and HIV-2) 
belongs to the Lentiviral genus of Retroviridae, and is the etiological agents 
of the Acquired Immunodeficiency Syndrome (AIDS). HIV establishes a 
persistent infection by means of provirus integration in the host genome and 
rapid mutation of viral genes encoding for proteins eliciting host immune 
response. Even in presence of effective antiviral treatment and strong 
immune response, however, the ability of the virus to establish a latent 
infection during the early stages of the disease grants the persistence of the 
virus in the host organism. 
The HIV genome is 10 kilobases long and encodes a number of structural 
proteins as well as several regulatory and accessory proteins which are not 
found in gamma- and alpha-retroviruses (Fig. 1.1); consequently, HIV 
replication cycle is far more complex, showing many regulatory mechanisms 
and strategies aimed at viral persistence.  
Viral replication requires the transcription of the proviral genome and the 
synthesis of several proteins necessary for the assembly and the budding of 
the viral progeny. HIV transcription depends upon the interaction between a 
number of cellular transcription factors and co-activators with regulatory 
sequences contained in the viral Long Terminal Repeat (LTR) promoter; 
such interactions lead to the assembly of a stable transcription complex 
stimulating several transcription rounds by RNA polymerase II.  
The structural genes, gag, pol and env, common to all other retroviruses, 
encode the proteins necessary for virion assembly, as well as the enzymes 
required for genome replication, proviral integration and polyprotein 
cleavage. The gag, pol and env genes are transcribed into polyproteins that 







proteases. The gag gene encodes the core proteins (Capsid CA, 
Nucleocapsid NC and p6) and the Matrix protein (MA), while the env gene 
encodes the glycoproteins gp120 and gp41, and the pol gene encodes three 
essential enzymes for viral replication: Reverse Transcriptase (RT), Integrase 
(IN) and Protease (PR). 
In addition to these structural genes, the HIV genome expresses several 
accessory and regulatory proteins: Vif (Viral infectivity Factor), Vpr (Viral 
Protein R), Vpu (Viral Protein U) (HIV-1), Vpx (Viral Protein X) (HIV-2), Tat, 




Fig. 1.1: HIV-1 genome  
 
 
HIV has been reported to infect a broad range of cellular types in vitro; 
however, in vivo, infection is restricted to CD4+ T-lymphocytes and cells of 
the monocyte-macrophage lineage. 
Infection starts with the fusion between HIV envelope and the cell plasma 
membrane; the surface gp120 protein on the viral envelope binds the CD4 
receptor on the host cell surface, inducing conformational changes and 
promoting the binding to chemokine receptors that serve as co-receptors for 
HIV-1 infection (Kwong et al. 1998). These co-receptors are both critical for 
virus entry, and crucial for determining the tropism among CD4+ cell types. 
HIV-1 uses for its infection two chemokine receptors: CCR5, which binds 
macrophage-tropic (R5) viruses, and CXCR4, which binds T-cell tropic (X4) 
viruses. While R5 viruses are responsible of mucosal and intravenous 
transmission of HIV-1, X4 isolates appear only in the late stages of infection, 







Viral gp120 is bound to gp41, a transmembrane protein which assembles as 
a trimer on the virion envelope. The interaction between gp120, CD4 and 
the co-receptor induces a conformational change in gp41, leading to the 
exposition of three peptide fusion domains. These domains are able to spear 
the plasma membrane and promote the fusion of the viral envelope, leading 
to the release of the HIV core in the host cytoplasm (Chan and Kim 1998). 
Upon entry, the virus undergoes the uncoating process, which generates the 
viral reverse transcription complex, composed by the viral genome, RT, IN, 
MA, NC, Vpr and other host proteins (Karageorgos et al. 1993); MA protein 
is then phosphorylated and interacts with actin microfilaments (Bukrinskaya 
et al. 1998), while Vpr serves to stabilize the reverse transcription complex 
(Ohagen and Gabuzda 2000). 
The completion of the reverse transcription leads to the formation of the 
Pre-integration complex (PIC), which is composed of viral cDNA, IN, MA, Vpr 
and RT (Miller et al. 1997). As HIV, unlike classical retroviruses, is able to 
infect non-dividing cells, such as differentiated macrophages, the PIC needs 
to be translocated in the nucleus through an intact nuclear envelope. Viral 
proteins Vpr, IN and MA possess in their sequence a nuclear localization 
signal, and are all involved in mediating nuclear import of the PIC (Bukrinsky 
et al. 1993; Heinzinger et al. 1994; Gallay et al. 1997); however, whether 
these proteins act in a cooperative manner, or have individual roles in 
different target cells is still unclear. 
Inside the nucleus, IN mediates the integration of the viral DNA in the 
cellular genome. IN, as well as other proteins involved in PIC formation, 
binds specific sequences at the end of the viral cDNA, named “att sites”, and 
removes two nucleotides left by the terminal transferase activity of RT. No 
primary sequence of the cellular DNA has been shown as a preferential 










Fig. 1.2: scheme of the different fates of the viral DNA after 
retrotranscription (Butler et al. 2001) 
 
Other than integration, the viral DNA may follow three different fates, 
neither leading to the formation of a functional provirus (Fig. 1.2). The viral 
ends may join to form a 2-LTR ring, or the viral genome may undergo 
homologous recombination, producing a single LTR ring, or the viral DNA 
may integrate into itself, forming a rearranged circular structure. All these 
circular structures are non infectious, even if some of them are transcribed 
and produce Tat and Nef proteins (Wu and Marsh 2001). 
Eukaryotic DNA inside cells is assembled into nucleosomes to form 
chromatin, which can be found in at least two different functional forms: a 
condensed form, named heterochromatin, generally lacking transcriptional 
activity, and a decondensed form (euchromatin) that provides the necessary 
environment for DNA regulatory processes such as transcription. As HIV 
integrates randomly in the host cell genome, the provirus can be found in 
chromatin domains with different condensation states; integration in 
heterochromatic regions may lead to latent infections, while viral integration 
in euchromatin may lead to transcriptionally active form of infection (Adams 







The 5’ LTR of the integrated provirus acts as the viral promoter, as it 
contains the binding sites for several positive transcription factors; in the 
absence of the viral Tat protein, however, the binding of such factors is not 
sufficient to promote the active transcription of viral genes. The binding of 
transcription factors to the promoter elements results in the correct 
positioning of RNA polymerase II complex at the initiation site and in the 
assembly of a pre-initiation complex. At this point transcription starts in a 
non-processive way, as the polymerase produces mostly short, non 
polyadenylated RNAs containing at the 5’ end a hairpin structure, named 
trans-activation-responsive region (TAR). Tat is a powerful trans-activator of 
provirus transcription, acting by binding the TAR region and promoting the 
production of poly-adenylated, full-length RNA viral genome. 
Tat-activated transcription gives birth to different transcripts derived from 
the splicing of the viral genome; the first transcripts to appear after infection 
are completely spliced and are exported into the cytoplasm following the 
fate of cellular mRNAs (Cullen 1998). These are the shortest viral mRNAs, 
and encode for Tat, Rev and Nef proteins. Incompletely spliced RNAs cannot 
be exported from the nucleus as they are blocked by the cellular machinery 
controlling the integrity of splicing processes; unspliced and single spliced 
transcripts persist in the nucleus due to the presence of defective splice 
sites, and to the inhibitory effected exerted by Rev on the splicing process 
(Luo et al. 1994; Powell et al. 1997). Longer transcripts encode for Gag, Pol 
and Env proteins, as well as they constitute the viral genome; thus, they are 
necessary for the production of a viral progeny. The export of these 
transcripts into the cytoplasm depends on the expression of the Rev protein 
(Pomerantz et al. 1992), which is able to shuttle between the nucleus and 
the cytoplasm. Rev binds the viral transcripts through the interaction with an 
RNA stem-loop structure named Rev responsive element (RRE), located in 
the env gene (Malim et al. 1990). Upon binding to the RRE, Env protein 







proteins. Ran is a small GTP/GDP binding protein, whose GDP binding form 
is mainly located in the cytoplasm; Ran-GTP, instead, is mainly found in the 
nucleus. The Rev/CRM-1/Ran-GTP complex associated with the viral RNA 
interacts with the pore complex allowing nuclear export, coupled to the 
hydrolysis of Ran-bound GTP (Cullen 1998). By this mechanism, Rev 
promotes the cytoplasmic translocation of unspliced or single spliced viral 
RNAs, allowing the synthesis of all required viral proteins. 
 
Fig. 1.3: overview of HIV-1 life cycle (reproduced from Quade Paul, 
Echo Medical Media) 
 
 
Upon translation, all viral proteins necessary for virion assembly together 
with RNA genomes are transported to the plasma membrane, close to lipid 
rafts domain where the building of the viral particles takes place. The 







the Gag-Pol polyproteins are targeted to the membrane by means of 
myristylation of Gag, resulting in the attachment of the secretory vesicles to 
the plasma membrane (Gottlinger et al. 1989). The resulting virions budding 
from the membrane are still incomplete, and their maturation is exploited by 
the viral Protease, which first cleaves Gag-Pol and then, from the Gag and 
Pol precursors, originates several products: the single core proteins, the MA 
protein and the viral enzymes. The proteolytic activity ends when the virion 








During the replication cycle, the auxiliary proteins of HIV-1 play a crucial role 
in regulating the different steps of the intracellular viral pathway. 
Nef is encoded by completely spliced transcripts and is targeted to the 
plasma membrane by myristylation of its N-terminus. The first demonstrated 
activity of Nef is the down-regulation of CD4 receptor. Even if the real 







supposed to protect the infected cells from the immune system and to 
facilitate the release of the virions. In addition to CD4, Nef has been 
demonstrated to promote degradation of MHC-I  that presents viral epitopes 
to cytotoxic T lymphocytes (CTLs), thus impairing the CTL-mediated immune 
response leading to the lysis of HIV infected cells (Collins et al. 1998). Vif 
protein is a small protein of 23 Kda affecting infectivity but not viral particle 
production. As the protein is encoded by single-spliced viral transcript, its 
expression is Rev-dependent. Upon expression, the protein accumulates in 
the cytoplasm and interacts with the plasma membrane through its C-
terminal region. While mutant viruses lacking Vif show regular cell-to-cell 
transmission, they show diminished infectivity. It has been recently 
demonstrated that Vif promotes the degradation of APOBEC3G, a cellular 
factor involved in the RNA editing process (Sheehy et al. 2002); in the 
absence of Vif,  this factor is packaged into virions and introduces point 
mutations in the viral RNA, thus impairing virion infectivity. 
Vpr is expressed at later stages of the life cycle and is packaged in all HIV-1 
virions by the p6 core protein. Vpr is incorporated in the PIC complex and 
contributes to its nuclear import, thus promoting HIV-1 replication in non-
dividing cells (Popov et al. 1998). Moreover, Vpr induces cell cycle arrest in 
the G2 phase, by inhibiting the p34-cyclin B kinase activity (Re et al. 1995). 
As the LTR is more active in the G2 phase, viral transcription is enhanced in 
cells blocked by the action of Vpr. 
Vpu is a transmembrane protein found only in HIV-1. like Nef, Vpu exerts 
CD4 downregulating activity, promoting its ubiquitination and subsequent 
proteasomal degradation (Margottin et al. 1998). In addition, Vpu enhances 
virus release inducing the budding and the detachment of virions from the 
plasma membrane. 
For more detailed insights into other properties of the HIV-1 accessory 







Role of intercellular protein trafficking in the biology of complex 
retroviruses 
The relatively simple life cycle delineated above is not a fully adequate 
description of the replication cycle of all the members of the Retroviridae 
family of viruses. Retroviruses belonging to the complex retroviruses 
category, which includes all lentiviruses and spumaviruses, as well as HTLV-I 
(Human T-cell Leukaemia Virus) and related viruses, are distinguished from 
MLV (Murine Leukaemia Virus) and other simple retroviruses by a number of 
characteristics. These include the peculiar genomic characterization with the 
presence of accessory genes, the complex pattern of splicing of the mRNA of 
genomic length and the special regulation of both transcription and splicing. 
In addition, the accessory proteins of these viruses exert a number of effects 
on the infected cells, ranging from modulation of the immune response to 
inhibition of apoptosis (Cullen 1991a; Cullen 1991c).  
While the biological activity of regulatory proteins in complex retroviruses in 
terms of transcriptional regulation and/or modulation of viral functions has 
been widely dissected and understood, only in recent years the focus has 
shifted to the notion that several of these proteins (namely, HIV-1 Tat, Vpr 
and Nef, HTLV-1 Tax and HFV -Human Foamy Virus- Bet) can be detected in 
the extracellular environment, and could be responsible of a number of 
pleiotropic effects, often observed during the time course of the infection, 
and not directly related to the cytopathic effects of the viruses.   
The notion that a protein could have distinct functions inside and outside the 
cell membrane is not new, and has been recently proposed that this duality 
of roles could be part of a general regulation of complex functions, such as 
organ development or tissue homeostasis (Radisky et al. 2009).  
The biological significance of intercellular trafficking of these proteins is still 
unclear. However, this characteristic elicits interest, since it might be 







The main features of the retroviral proteins showing the capacity of 
intercellular trafficking are summarized in the following Sections.  
HIV-1 Tat 
Similar to most animal DNA viruses, upon infection of the host cell, HIV-1 
needs to carry out transcription of viral genes using the cellular 
transcriptional apparatus as well as cellular transcription factors and co-
activators.  
The Tat proteins of HIV-1 and HIV-2 serve as powerful transcriptional 
activators of viral transcription; Tat is a small protein of 86-101 aminoacids 
(the widely used HXB2 strain contains a point mutations thereby stopping at 
aminoacid 86) (Neuveut and Jeang 1996; Jeang et al. 1999); the coding 
sequence is encoded by two exons. The expression of Tat is essential for the 
transcription of viral genes and thereby for viral replication. 
So far no crystal structure of the protein has been produced; NMR (Nuclear 
Magnetic Resonance) spectroscopy (Bayer et al. 1995) and structural 
prediction point out a highly flexible structure and does not indicate any 
evident secondary structure. Five different domains have been identified, 
based on the amino acid distribution in the protein sequence, and on 
conservation studies comparing homologous proteins from other lentiviruses 
(Fig. 1.5). In the first exon (aa 1-72) there are an N-terminal acidic domain 
(aa 1-21), a cystein-rich domain (aa 22-37), a core region (aa 38-48) and a 
basic domain, highly conserved and rich in Arginine and Lysine residues (aa 
49-57). The second exon starts at position 73 and has a variable sequence 
among different strains. The minimal LTR transactivating domain is fully 









Fig. 1.5: HIV-1 tat protein domains (the sequence of the basic domain is 
highlighted) 
 
Tat- mediated transcriptional activation 
Following reverse-transcription and integration into the host genome, the 
HIV-1 proviral sequence is organized in a chromatin structure which is 
repressive of viral transcription (Marzio and Giacca 1999; He et al. 2002); 
such repression is relieved by a number of extracellular stimuli leading to 
cellular activation. Tat transactivation of viral gene expression is a critical 
step in the life cycle of the virus.  
In spite of continuous HIV-1 replication in all phases of disease, the activity 
of the LTR promoter at the single cell level is strictly regulated and 
significantly correlated with the level of host cell activation. The expression 
of a sufficient amount of the Tat protein leads to a very strong activation of 
the LTR, making this sequence a highly efficient promoter of viral 
expression. At the 5’ end of all viral mRNAs, Tat interacts with TAR, a region 
comprising nucleotides 1-60 (considering 1 the first nucleotide of the 
transcribed RNA) (Berkhout et al. 1989; Cullen 1990). The Tat-TAR 
interaction occurs between the basic domain of the protein and three 
nucleotides that form a bulge near the apex of the TAR stem (Rana and 
Jeang 1999). The control of transcription is obtained through the concerted 
action of several cellular transcription factors, bound to regulatory 
sequences in the LTR. The main function of Tat is to induce a chromatin 
modification at the LTR promoter, and to mediate the recruitment of an 







A number of cellular proteins have been reported to interact with Tat and to 
modulate its transcriptional activity. These proteins include general 
transcription factors (TATA binding protein -TBP-, TAFII250, TFIIB, TFIIH) 
(Kashanchi et al. 1994; Veschambre et al. 1995; Parada and Roeder 1996; 
Veschambre et al. 1997; Weissman et al. 1998), RNA polymerase II (Wu-
Baer et al. 1995), Sp1 (Jeang et al. 1993), the cyclin subunit of positive 
transcription elongation factor (PTEFB) cyclinT1 (Wei et al. 1998), and 
several different co-activators possessing histone acetyl-transferase (HAT) 
activity. 
In particular, Tat activates HIV transcription from the LTR through at least 
two different mechanisms (Marcello et al. 2001). 
The first one involves cellular HATs and their recruitment at the level of the 
LTR promoter; here they can relieve the repression induced by chromatin 
conformation on the HIV promoter (Verdin 1991; Verdin et al. 1993). Such 
repressive activity and the consequent viral latency have been ascribed to 
the positioning of nucleosomes in the promoter region. Whichever the site of 
integration is, nucleosomes in the 5’ LTR are positioned with respect of the 
cis-acting regulatory elements, and define two nucleosome-free regions, 
encompassing nucleotides -256 to -3 and +141 to +256 (Van Lint et al. 
1996); these regions are separated by a nucleosome named nuc-1 blocking 
efficient transcription in the silent provirus. Nuc-1 is rapidly and efficiently 
disrupted during transcriptional activation, leaving a large open chromatin 












Fig. 1.6: Tat recruits HATs thus determining the acetylation of the 
N-terminal tails of histone 3 and 4 
(A) Nuc-1 blocking efficient transcription in the silent provirus 
(B) Nuc-1 is rapidly and efficiently disrupted during transcriptional activation 
 
 
The positioning of nuc-1 on the transcription start site, and its disruption 
during transcriptional activation show the critical role played by chromatin 
modification in viral latency and the subsequent switch to active viral 
replication. 
Complexes containing HATs mitigate nucleosomal repression at the level of 
specific promoters by means of acetylation of the N-terminal tails of 
histones, thus inducing destabilization of histone-DNA interactions. The HAT 
proteins involved in the TAR-dependent Tat transactivation include p300 and 
the cAMP-response element binding protein (CREB)-binding protein (CBP) 
(Marzio et al. 1998), the p300/CBP associated factor P/CAF (Benkirane et al. 
1998), the general control non-derepresssible-5 (GCN-5) (Col et al. 2001), 
the TIP60 protein (Kamine et al. 1996), and the general transcription factor 
TAFII250 (Weissman et al. 1998). As a consequence of Tat-mediated 







nucleosomes are acetylated and viral expression is activated (Lusic et al. 
2003). 
The second mechanism mediating Tat-induced activation is the interaction 
with human cyclin T1 (Wei et al. 1998), the cyclin subunit of CDK9 (Cyclin 
Dependent Kinase 9) in PTEFB. A homologous of this complex was originally 
identified in D. melanogaster as a kinase necessary for the transcription of 
several genes (Marshall and Price 1992). 
HIV-1 LTR contains several binding sites for a number of transcription 
factors (such as AP-1 (activator protein 1), COUP-TF (Chicken ovalbumin 
upstream promoter transcription factor), Ets, LEF-1 (lymphoid enhancer 
binding factor 1) NFAT (Nuclear factor of activated T-cell 1), Rel/NFkB, Sp1, 
USF (upstream stimulatory factor) and TFIID). However, in the absence of 
Tat expression, there is no viral expression and the LTR promoter produces 
only short, non polyadenylated RNA comprising the TAR structure (Cullen 
1991b). DNA footprinting experiment have demonstrated that such DNA 
sites are  bound to cellular transcription factors in both silent and activated 
HIV-1 infected cells (Demarchi et al. 1993), suggesting a mechanism of 
transcriptional regulation going beyond chromatin accessibility to 
transcription factors. The inability to produce full length mRNA is due to the 
lack of processivity of the hypo-phosphorilated RNA polymerase II. When 
Tat is expressed, it interacts with both the TAR element and the cyclin T1, 
thus promoting CDK9-mediated phosphorylation of the RNA polymerase II 
CTD (Carboxy Terminal Domain) and overcoming the low processivity of the 
enzyme. The interaction between Tat and cyclin T1 increases the specificity 
and the affinity of binding of Tat to the TAR element, thus forming a ternary 
complex which guarantees the presence on the HIV promoter of the kinase 
activity required for efficient viral transcription (Fig. 1.7). Moreover, Tat 
shifts the equilibrium towards CTD phosphorylation, by inhibiting a CTD 








Fig. 1.7: Tat binding to cyclinT1/CDK9 complex promotes the 
hyperphosphorylation of the RNA polymerase II CTD 
 
 
PTEFB kinase activity also results in the dissociation of NTEF, negative 
transcription elongation factor which associates with the CTD impairing the 
processivity of RNA polymerase II (Fujinaga et al. 2004). This complex is 
found associated with the viral LTR in the early phases of viral transcription 
(Ping and Rana 2001): one of its components, named DSIF (DRB sensitivity 
inducing factor) specifically binds the hypophosphorylated CTD, while NELF 
(negative elongation factor) associates with the TAR region through an RNA 
recognition domain. When Tat recruits PTEFB at the site of viral 
transcription, CDK9 phosphorylates DSIF, NELF and the CTD thus relieving 
NTEF mediated inhibition of RNA polymerase II processivity. 
Tat also possesses a direct role in the activation of viral gene expression by 
modifying the site of CDK9-induced phosphorylation on the CTD of RNA 
polymerase II (Zhou et al. 2000), and stimulating the activity of the mRNA 
capping enzyme Mce1 (Chiu et al. 2002). In the absence of Tat, CDK9 only 
phosphorylates the CTD on Ser2; when Tat is present, however, CDK9 
changes its substrate specificity and phosphorylates the CTD at Serine2 and 
Serine5, thus promoting polymerase hyperphosphorylation. As the 







hyperphosphorylation results in an added stability of Mce1 to the 
transcription machinery leading to a higher guanylyl transferase activity. 
Moreover, Tat binds directly to Mce1 with its C-terminal domain, stimulating 
its enzymatic activities and promoting its recruitment to the transcription 
initiation site. Finally, capping promotes efficient splicing and 
polyadenylation of viral RNAs protecting them from exonucleolytic decay. 
The activity of Tat on cellular HATs in not limited to the promotion of their 
association with the LTR promoter: Tat is also a substrate for acetylation by 
p300/CBP, PCAF and GCN5 (Kiernan et al. 1999; Ott et al. 1999; Col et al. 
2001; Bres et al. 2002; Dorr et al. 2002; Mujtaba et al. 2002). p300/CBP and 
GCN5 acetylate lysines 50 and 51 within the basic, RNA binding domain, 
regulating the binding with the TAR structure; pCAF instead acetylates lysine 
28 in the activation domain, thus modulating the interaction of Tat with the 
CDK9/cyclin T1 complex. Mutation in these lysines impairs virus replication. 
The effects of acetylation at different lysine residues are various: acetylation 
of lysine 28 impairs Tat interaction with PCAF, while strengthening the 
binding with PTEFB; while acetylation of Lys 50 promotes the dissociation 
from the TAR (Kiernan et al. 1999) and creates a new binding site for PCAF 
(Mujtaba et al. 2002). 
The proposed model (Bres et al. 2002) (Figure 1.8) for the events triggered 
by Tat at the 5’ LTR is the following: non acetylated Tat binds PCAF and is 
acetylated at lysine 28; following acetylation, Tat dissociates from PCAF and 
binds PTEFB, and the latter complex interacts with the TAR RNA, leading to 
the hyperphosphorylation of the CTD of RNA polymerase II, which is 
associated with the site of initiation. Subsequently, p300 acetylates lysine 
50, inducing the dissociation from the TAR and the formation of a 
TAT/PTEFB/PCAF complex which remains associated with the elongation 
machinery. GCN5 also acetylates Tat on Lysine 50 and 51, leading to 








Fig. 1.8: proposed model for the modulation of Tat activity by 
cellular HATs PCAF and p300 (Bres et al. 2002) 
 
 
Pleiotropic activities of extracellular Tat 
Besides being a powerful regulator of viral transcription, Tat also possesses 
the peculiar property of entering cells when present in the extracellular 
medium (Frankel and Pabo 1988; Green and Loewenstein 1988). The early 
experiments were performed by assessing the ability of exogenous Tat to 
activate an LTR-driven reporter gene, thus implying that not only the protein 
is able to cross the cell membrane, but also that it is transported in the 
nucleus in a transcriptionally active form (Frankel and Pabo 1988).  
In addition to entering cells when present in the extracellular compartment, 
that has been demonstrated to be secreted from expressing cells, following 







peptide necessary for “classical” secretion (Chang et al. 1997; Tyagi et al. 
2001). 
Recent findings have suggested that Tat is displayed on the envelope of 
HIV-1 virions (Marchio et al. 2005). Thus, once it is released from HIV-1 
infected cells, Tat interacts with heparan sulfate proteoglycans (HSPGs) on 
the cell surface and accumulates on cell membrane lipid rafts. An additional 
event that supports the presence of Tat on viral envelope is that the 
intracellular Gag polyprotein associates with lipid rafts (Ono and Freed 2005) 
and virion budding occurs through these membrane microdomains, 
producing viruses with cholesterol-rich membranes (Nguyen and Hildreth 
2000; Campbell et al. 2001). The presence of Tat on the viral surface might 
have an effect on HIV infectivity by facilitating virus adsorption with its 
HSPG binding activity (Nappi et al. 2009). Moreover, recent evidence 
suggest that the presence of Tat bound to extracellular HSPGs of endothelial 
cells, may promote adhesion and subsequent extravasation of lymphoid cells 
(Urbinati et al. 2009). 
The fact that a viral peptide possesses the ability to easily cross cell 
membranes thus allowing its intercellular trafficking raises several questions 
about whether this ability could have been evolved to enhance viral 
infectivity, or to somehow interfere with the host immune response. A 
reasonable possibility is that HIV-1 evolved this property in order to prime 
non infected cells for their primary infection, thus creating a tissue 
environment suitable for viral replication. Several evidences have been 
reported on the ability of Tat to induce the transcription of cellular genes. In 
this manner, secreted Tat present in the extracellular environment might 
exert a number of pleiotropic effects. Indeed, Tat induces the secretion of 
cytokines (Zauli et al. 1992; Lotz et al. 1994; Nabell et al. 1994; Scala et al. 
1994; Westendorp et al. 1994; Opalenik et al. 1995) and their receptors 
(Pocsik et al. 1992; Puri and Aggarwal 1992; Purvis et al. 1992), modulates 







1990; Ensoli et al. 1993; Zauli et al. 1993; Lafrenie et al. 1997), possesses 
angiogenic activity both in vitro and in vivo (Albini et al. 1995; Albini et al. 
1996; Corallini et al. 1996), and inhibits antigen-specific lymphocyte 
proliferation (Viscidi et al. 1989; Subramanyam et al. 1993). 
 
 
Fig. 1.9: Role of intra- and extracellular Tat in AIDS progression 
and in AIDS-associated pathologies 
 
 
Probably some of the above mentioned effects have important implications 
for the pathogenesis of HIV disease in an autocrine or paracrine fashion, in 
particular in the neuropathogenic role of HIV in the infection of the central 
nervous system (Sabatier et al. 1991; Taylor et al. 1992; Weeks et al. 1995). 
Whether these effects are mediated by the interaction of Tat with cell 
surface receptors (Vascular endothelial growth factor receptor -VEGFR- 1 
and 2, integrin and chemokine receptors above others) and the consequent 







transcriptional activation following Tat internalization remains poorly 
understood.  
In addition to the above effects, Tat release might be involved in the 
induction of immunosuppression during the course of HIV disease. 
Neurodegenerative disorders 
AIDS-related neurodegenerative disorders are found in one third of adults 
and half of the children affected with the disease. Productive infection of the 
central nervous system (CNS) occurs in macrophages and microglia, but is 
also found in astrocytes. The deterioration of brain tissue (leading do 
dysfunction of cognition, dementia and eventually paralysis) however is 
found even in absence of a productive infection in the neuronal tissue, or of 
malignancies and opportunistic infections (Price et al. 1988). The 
discrepancy between the lack of detectable HIV-1 and the severity of brain 
damage in infected individuals has led to the hypothesis that damage might 
due to the release of viral products from HIV-infected cells as macrophages 
or microglia; such molecules could trigger a pathological alteration of 











Transforming growth factor-β1 (TGF-β1) gene expression is stimulated in 
HIV-1 positive individuals (Kekow et al. 1990); it has been suggested that 
this growth factor could act as a chemoactractant, recruiting infected 
monocytes in the brain, thus enhancing CNS dysfunction, and altering the 
expression of neurotoxic cytokines. Moreover, monocyte infiltration in the 
CNS, even in the absence of monocyte infection, is associated with AIDS- 
induced dementia, probably due to the toxic effect exerted by monocyte-
derived molecules. 
As the Tat protein, upon secretion from infected cells, can penetrate 
uninfected cells, it could alter the expression of several genes. For example, 
its upregulating effect on TGF-β1 (Rasty et al. 1996) and MCP-1 (monocyte 
chemoactractant protein-1) (Conant et al. 1998) were demonstrated both in 
vitro and in the mouse brain, thus suggesting a key role for secreted Tat in 
monocytic infiltration and in subsequent neurotoxin release. 
 
 




Extracellular Tat also up-regulates CCR5 chemokine receptor on human 
peripheral blood monocytes, an event capable of enhancing the migratory 
response and the transmigration of these cells across a tissue model of 







induce the expression and the extracellular release from activated 
macrophages and astrocytes of Tumor Necrosis Factor-α (TNF-α), the levels 
of which closely correlate with the severity of dementia (Chen et al. 1997; 
New et al. 1998). 
 
 
Fig. 1.12: Tat neurotoxic activities 
(A) Tat interaction with astrocytes   
(B) Tat neurotoxic effect is mediated by an interplay between different cell types 
triggered by Tat pleiotropic activities (King et al. 2006) 
 
 
In order to better define the functional damage induced by Tat in the CNS, 
several groups have examined both neuronal injury and spatial learning. 







attenuation of spatial learning and correlates with the suppression of Long 
Term Potentiation (LTP) (Li et al. 2004). Unlike what had been previously 
described by other authors (Sabatier et al. 1991), in this study the intra-
hippocampal injection of Tat did not lead to neuronal cell loss, thus 
suggesting that Tat induces neuronal dysfunction before causing neuronal 
cell death. 
Kaposi’s sarcoma 
Kaposi’s sarcoma (KS) is an angioproliferative disease very frequent and 
aggressive when found in HIV infected individuals. All forms of KS possess 
similar histological features, showing the presence of spindle-shaped cells, 
vascular smooth cell, endothelial cells, fibroblasts, inflammatory cells and 
high vascularization. KS lesions are associated with infection by HHV8 
(human herpes virus 8) and are characterized by a complex interplay of 
cytokines (Interleukin (IL)-1, IL-6, Interferon (IFN) - α, TNF-α), angiogenic 
growth factors (among others, FGF-2, vascular endothelial growth factor 
(VEGF)-A and VEGF-C), extracellular matrix components and integrins (Fife 
and Bower 1996; Nickoloff and Foreman 1996).  
The evidence that KS is much more frequent and aggressive in HIV infected 
individuals originally led to the hypothesis that somehow HIV infection itself 
might play an important role in favoring KS onset and progression. 
Tat mimics the activity of fibronectin and vitronectin by binding their cell 
surface receptors through its RGD (Arg-Gly-Asp) motif; however, the heparin 
binding activity of its basic domain is also involved in the process of 
migration (Barillari et al. 1993).  
Moreover, Tat is able to mimic extracellular proteins involved in adhesion, 
migration and growth of both KS and endothelial cells, thus potentially 
enhancing angiogenesis and KS progression. However Tat is not able to 







inflammatory cytokines (IFN-γ, TNF-α and IL-1β) (Fiorelli et al. 1999), which 
in turn activate the release of FGF-2. 
In addition to cellular adhesion, integrins play a key role in angiogenesis, by 
modulating migration, apoptosis and response to growth factors of 
endothelial cells. Tat RGD domain is able to induce endothelial cells 
migration, mimicking the effect of vitronectin and fibronectin, stimulating the 
expression of matrix metalloproteinase (MMP)-2 (Toschi et al. 2001), and of 
focal adhesion kinases necessary for the invasion of the extracellular matrix. 
In addition to these activities, the binding of Tat to integrins enhance the 
cellular response to FGF-2 (Barillari et al. 1999). 
The basic domain of Tat binds extracellular matrix heparan-sulfate 
proteoglycans (HSPGs) thus facilitating the interaction between the RGD 
domain and the integrins; on the other hand, binding of Tat to the HSPG 
retrieves soluble FGF-2 from the extracellular matrix, thus promoting cell 
growth (Folkman et al. 1988) (similar to Tat, FGF-2 binds HSPG upon 
secretion). Finally, the basic domain can bind the VEGFR-2, thus stimulating 




Fig. 1.13: Model for the role of Tat in the pathogenesis of acquired 







The immune response 
Several studies on HIV-infected patients showed a marked increase of the 
inflammatory response in the brain tissue, due to the effect of Tat on the 
expression of several pro-inflammatory cytokines and growth factors, such 
as the aforementioned IFN-γ, TNF-α, IL-1β, as well as TGF-β, IL-2, IL-6, IL-
8, IL-10, CXC-chemokine receptor 4, IL-2 and IL-4 and TNF-α receptors. 
Moreover, HIV infected individuals display a significant immune 
hyperactivation, leading to lymphocyte proliferation, expression of T cell 
activation antigens and increased cytokine expression. 
During the early stages of HIV infection, Tat is selectively taken up by 
mature dendritic cells (Fanales-Belasio et al. 2002), where it induces a 
upregulation of the major MHC genes and of Th1 cytokines and β 
chemokines, therefore promoting the antigen presenting capacity of these 
cells, and enhances the recruitment of T cells by means of reprogramming 
gene expression in dendritic cells (Izmailova et al. 2003). Since the 
chemokines induced by Tat recruit activated T cells and macrophages, HIV 
can use the dendritic cells as vehicles to infect its ultimate targets of 
infections. 
As HIV cannot infect resting T- cells, Tat could also facilitate the spread of 
HIV infection by upregulating the expression of IL-2, thus promoting the 
priming of naive T-cells (Ott et al. 1997). 
A number of different and sometimes controversial studies suggest several 
immunosuppressive activities for extracellular Tat, which may account for 
the immunosuppression observed in AIDS disease. 
These activities range from apoptosis of peripheral blood cells (Li et al. 
1995), to impairment of natural killers (NK) cells (Poggi et al. 1998; Zocchi 
et al. 1998), to the inhibition of antigen-specific T-cell activation response 
(Viscidi et al. 1989), to the upregulation of the production in peripheral 







immunosuppressive cytokine the levels of which correlate with disease 
progression in HIV infected individuals. 
Despite this intense research on the properties of extracellular Tat, however, 
the issue whether Tat might be directly involved in the induction of 
immunosuppression in HIV-1 infected patients still remains unsolved.  
HIV-1 Vpr 
Vpr is a small protein of 96 aminoacids (14 kDa) rich in basic residues, which 
is well conserved in HIV-1, HIV-2 and SIV (Simian Immunodeficiency Virus) 
(Tristem et al. 1992). Its real functions during the natural course of infection 
are still under debate; nonetheless, the role of Vpr in AIDS pathogenesis 
appears crucial, as vpr null mutants show decreased viral replication and 
delayed disease progression in rhesus monkeys experimentally infected with 
SIV (Tristem et al. 1992). As a result of extensive study in a number of in 
vitro, in vivo and ex-vivo systems, Vpr has been shown to play, despite its 
small size, a wide number of functions during viral replication, ranging from 
nuclear import of the pre-integration complex, to cell cycle progression, to 
transactivation of the viral LTR as well as of host genes.  
Intracellular activities of Vpr 
Along the viral life cycle, a first activity of Vpr is to influence  the fidelity of 
reverse transcription: in addition to a potential role in the initiation step of 
the reverse transcription (Stark and Hay 1998), Vpr was shown to modulate 
the in vivo mutation rate of HIV-1 by interacting with the nuclear form of 
uracil DNA glycosylase (UNG2) (Mansky et al. 2000), an enzyme involved in 
the base excision repair pathway that specifically removes the RNA base 
uracil from DNA. The association of Vpr with UNG2 in virus-producing cells 
allows the incorporation of a catalytically active enzyme into HIV-1 particles, 
where UNG2 may directly influence the reverse transcription accuracy 







primary macrophages and nondividing cells (which express low levels of 
UNG and contain relatively high levels of dUTP) (Sandgren et al. 2002).  
Despite the lack of any identifiable canonical nuclear localization signal 
(NLS), Vpr displays evident karyophilic properties and is rapidly targeted to 
the host cell nucleus after infection (Lochelt et al. 1993). One possibility is 
that Vpr primarily serves to dock the PIC at the nuclear envelope, while IN 
and MA act in cooperation with the central DNA flap to target the viral DNA 
to the nucleus. 
In addition to its non conventional NLS for targeting into the nucleus, Vpr is 
a dynamic mobile protein able to shuttle between the nucleus and 
cytoplasmic compartments (Jenkins et al. 2001; Sherman et al. 2001; 
Sherman et al. 2003). The exact role of the nuclear export signal (NES) in 
the function of Vpr is not known but since Vpr is rapidly imported into the 
nucleus after biosynthesis, the NES could redirect it into the cytoplasm for 
subsequent incorporation into virions during the late budding step of the 
virus life cycle (Jenkins et al. 2001; Sherman et al. 2003). 
A further important biological activity of SIV and HIV Vpr proteins is related 
to their ability to induce an arrest in the G2 phase of the cell cycle of 
infected proliferating human and simian T cells (Di Marzio et al. 1995; He et 
al. 1995; Jowett et al. 1995; Re et al. 1995; Bartz et al. 1996; Planelles et al. 
1996). The biological significance of this arrest during the natural infection is 
not well understood, but as the HIV-1 LTR seems to be more active in the 
G2 phase, the G2 arrest may confer a favorable cellular environment for 
efficient transcription of HIV-1. Such increase transcriptional activity from 
the viral LTR in arrested cells expressing Vpr (Subbramanian et al. 1998; 
Gummuluru and Emerman 1999; Hrimech et al. 1999), could be mediated 
through cis-acting elements, found in the LTR promoter which are bound by 
Vpr.  
Though no specific DNA sequence targeted by Vpr has been yet identified 







acids; Vpr may function as an adaptor molecule for an efficient recruitment 
of transcriptional co-activators (such as GRE, p300/CBP) to the HIV-1 LTR 
promoter and thus enhances viral replication. Additionally, it may be 
involved in the activation of host cell genes inducing cellular pathways in 
relation with the AIDS pathogenesis. 
HIV infection causes a depletion of CD4+ T cells in AIDS patients, which 
results in a weakened immune system, impairing its ability to fight 
infections. The major mechanism for CD4+ T cell depletion is programmed 
cell death, or apoptosis; even though the exact contribution of Vpr as a pro-
apoptotic factor responsible for the T cell depletion observed in the natural 
course of HIV infection is still unknown, it was repeatedly evidenced that Vpr 
has cytotoxic potential and is able to induce apoptosis in many in vitro 
systems. However, controversial results indicating that Vpr can also act as 
negative regulator of T cell apoptosis have been reported (Ayyavoo et al. 
1997; Conti et al. 1998). 
Other laboratories have then shown that synthetic Vpr, as well as truncated 
Vpr polypeptides, are able to induce apoptosis by directly acting on the 
mitochondria, leading to the permeabilization of the mitochondrial 
membrane and subsequent dissipation of the mitochondrial transmembrane 
potential (∆Ψm) (Jacotot et al. 2000). This direct effect of Vpr is related to 
its ability to interact physically with the adenine nucleotide translocator 
(ANT), a component of the permeability transition pore of mitochondria 
localized in the inner mitochondrial membrane. The interaction between Vpr 
and ANT triggers permeabilization of the inner membrane followed by 
permeabilization of the outer mitochondrial membrane with consequent 
release of soluble intermembrane proteins, such as cytochrome c and 








Fig.  1.14: Overview of Vpr biological activities 
 
Cytotoxic effect of extracellular Vpr  
Extracellular or free Vpr that exists in cell-free and virus-free state was 
detected in great amounts in sera and cerebrospinal fluid (CSF) of HIV-1 
infected patients (Levy et al. 1994). However, it has not yet been clearly 
established whether extracellular Vpr results from breakdown of infected 
cells and virus particles or release from infected cells. Interestingly, some 
studies found that purified intracellular Vpr could enter the cells when added 
to cultured cells (Levy et al. 1995; Huang et al. 2000).  
The carboxyl-terminal end of Vpr was shown to cause structural defects in 
cell membranes, indicated by osmotic sensitivity and gross cell enlargement 
(Macreadie et al. 1995); these effects were dependent on the sequence 
HFRIGCRHSRIG, containing two H(S/F)RIG motifs (Macreadie et al. 1995). 
When extracellular peptides containing the above sequence were added, 







and death in a variety of yeast cells (Macreadie et al. 1996). Extracellular 
addition of synthetic Vpr peptides containing the H (F/S) RIG repeat motif 
showed similar consequence in mammalian cells. When this peptide was 
added externally to human CD4+ cells, it induced mitochondrial membrane 
permeabilization, dissipation of mitochondrial transmembrane potential, 
morphological changes, the formation of apoptotic bodies and breaks of 
DNA chain (Arunagiri et al. 1997). 
According to these last findings, the existence of circulating Vpr in infected 
individuals, might also explain the toxic effects exerted by Vpr on bystander, 
uninfected cells. 
Vpr and AIDS dementia complex 
Relatively high levels of Vpr were detected in the CSF of HIV-infected 
patients with neurological defects (Levy et al. 1995); as macrophages and 
microglia of human brain are infiltrated during HIV-1 infection (Nottet and 
Gendelman 1995; Nottet 1999), these cells are thought to release 
extracellular Vpr to the CSF. Additionally, infected astrocytes may also 
release Vpr (for a review on the effect of HIV on the neural tissue, see 
(Jones and Power 2006)). 
Based on several studies demonstrating the neurotoxicity of extracellular 
Vpr, the protein was then shown to exhibit channel-forming capacity in the 
membrane of intact cells when added extracellularly. Moreover, recombinant 
extracellular Vpr associated directly with the plasmalemma of hippocampal 
neurons caused a large inward cation current and depolarization of the 
plasmalemma, finally resulting in cell death (Piller et al. 1998). The first 40 
amino acid residues of N-terminal domain of Vpr (N40) affect the ion 
channel activity thus showing cytotoxic effects, while the C-terminal domain 
is involved in rectification of Vpr currents. Moreover, the N40 has the 







plasmalemma and cell death in cultured hippocampal neurons (Piller et al. 
1999). 
Extracellular Vpr also showed toxic effects on brain activity; when added to 
mixed embryonic rat brain cultures, Vpr-induced cell death was observed. 
Similarly, Vpr-induced cell death was also observed in enriched primary 
cortical rat astrocytes, and it was considered that death was mainly caused 
by necrotic mechanism (Huang et al. 2000). On the other hand, extracellular 
Vpr was shown to induce the death of human neuronal cells through 
apoptosis (Patel et al. 2000).  
HIV-1–associated nephropathy 
HIV-associated nephropathy (HIVAN) is unique in that the etiology of 
podocyte injury is genetically well defined, namely caused by HIV-1 itself. 
Patients with HIVAN present with heavy proteinuria and rapid progression to 
end-stage renal failure with collapsing focal segmental glomerulosclerosis 
and microcystic tubular dilation (Bourgoignie 1990; Humphreys 1995; 
Klotman 1999; Ross and Klotman 2002; Kimmel et al. 2003; Weiner et al. 
2003; Ross and Klotman 2004). 
Transgenic mice carrying the HIV-1 long terminal repeat, tat and vpr, but 
not mice that carrying an HIV-1 genome defective in vpr, develop 
glomerulosclerosis. Selective podocyte expression of either Vpr or Nef alone 
can induce podocyte injury that leads to glomerulosclerosis; in addition, a 
prominent synergistic effect of these two proteins on podocyte injury was 
reported (Zuo et al. 2006). 
Role of Vpr in AIDS-related insulin resistance/lipodystrophy syndrome 
Recent advances in the development of the nucleotide and non-nucleotide 
analogues acting as reverse transcriptase inhibitors (NRTIs) and the non-
peptidic viral protease inhibitors (PI), and their introduction in the 







dramatically improved the clinical course of the disease and prolonged life 
expectancy in patients with AIDS. The increase in life expectancy associated 
with the long-term use of the above antiviral agents, however, has 
generated novel morbidities and complications. Central among them is the 
quite common AIDS-related insulin resistance and lipodystrophy syndrome, 
which is characterized by a striking phenotype and marked metabolic 
disturbances.  
A role for the Vpr protein in these disorders has been suggested by a recent 
study which investigated the capacity of Vpr to co-activate the glucocorticoid 
receptor, which potentiates the action of glucocorticoid hormones, thereby 
inducing tissue glucocorticoid hypersensitivity (Kino and Chrousos 2004). Vpr 
interacts with novel 14-3-3 proteins, promoting their interaction with Cdc 
(Cell division cycle) 25 and subsequently suppressing their transcriptional 
activity by segregating Cdc25 into the cytoplasm. The same study also 
showed that Vpr suppresses the association of 14-3-3 with other partner 
molecules, in particular the FoxO (Forkhead box O) transcription factors. 
Since the FoxO proteins function as negative transcription factors for insulin, 
Vpr may cause resistance of tissues to insulin. Through these two newly 
identified functions of Vpr, namely, coactivation of glucocorticoid receptor 
activity and inhibition of insulin effects on FoxO proteins, Vpr may 
participate in the development of AIDS-related insulin 
resistance/lipodystrophy syndrome. 
Effects on immune system 
Cellular immunity, specifically MHC-restricted CTL responses, is thought to 
play an intrinsic role in protection and clearance of many viral infections. 
Though HIV-1 infection is controlled by the immune response initially, the 
immune system fails to clear the virus and ultimately loses control of viremia 
through unclear mechanisms (Koup et al. 1994; Pantaleo et al. 1994; Fauci 







and Walker 2003; Nickle et al. 2003). Furthermore, there is evidence that 
the host immune response is compromised early in HIV infection.  
Vpr could be a possible important player in the compromised immune 
control of HIV as it exerts significant effects on cellular proliferation, 
differentiation, regulation of apoptosis, modulation of cytokine production 
and transcription in vitro. Many of these Vpr-mediated cellular events have 
been observed in a wide variety of cell lineages, suggesting that Vpr targets 
basic eukaryotic cellular pathways. 
As an extracellular delivered protein, Vpr down-modulates the expression of 
several immunologically important molecules including CD40, CD80, CD83 
and CD86 costimulatory molecules on MDM and MDDC (monocyte-derived 
dendritic cells) (Muthumani et al. 2005), suggesting that Vpr could interfere 
with DC (dendritic cells) functions or maturation, or both. 
The potential consequences of failed APC maturation during HIV infection 
could be significant: for instance, Vpr-mediated CD40 repression could 
contribute to the inability of the host immune system to continue to mount 
an effective response against HIV, as the engagement of CD40L on APC by 
CD40 on CD4+ or CD8+ cells were shown to ‘condition’ the APCs for antigen-
specific CTL activation, and facilitate induction of a memory T cell response.  
The CD80 and CD86 molecules are surface glycoproteins and members of 
the immunoglobulin superfamily, which are only expressed on professional 
APCs (Sharpe and Freeman 2002). Blocking these costimulatory signals 
leads to T cell unresponsiveness; therefore, despite efficient migration of 
APCs into regional lymph nodes, the effects of Vpr may influence both 
presentation and activation of T cells, thus influencing viral clearance. This 
unique property of Vpr could ensure infection in a T cell rich environment 
without immune clearance and favor viral propagation.  
Similarly, it has been observed that Vpr affects the expression of the CD33 
antigen, a transmembrane surface protein specific for myeloid lineage cells, 







Thus, Vpr can affect dendritic cell/macrophage maturation and activation in 
vitro, and this effect could in vivo lead to diminished T-cell activation and 
consequently T cell non-responses, providing an interesting mechanism for 
HIV evasion from the host’s immune system. 
In conclusion, the release from infected cells, the capacity to enter other 
cells or form ion channels in the membrane of living cells, and the cytotoxic 
effects of extracellular Vpr strongly suggest that Vpr has cytotoxic effects on 
bystander cells during HIV infection, thus potentially contributing to the 
severe multiorgan complications often observed during the course of AIDS. 
HIV-1 Nef 
The accessory protein Nef was originally discovered as a “negative factor” 
that inhibited viral replication (hence the name). Later, it became clear that 
Nef positively affects viral replication and infectivity (Miller et al. 1994a; 
Miller et al. 1994b). HIV-1 and SIV Nef proteins are small (25- to 34-kDa), 
myristoylated proteins that reside both in the cytoplasm and in association 
with the cytosolic face of cell membranes.  
A structural model of the conformation of the full-length Nef polypeptide 
predicts that the surface of the protein consists of a linear array of potential 
protein-protein interaction domains and that this surface is quite flexible. 
Interestingly, it has been speculated that the overall flexibility of Nef enables 
the protein to switch between multiple conformations and that its structural 
organization may be dictated by its binding partner(s). 
Even if no enzymatic activity has been directly attributed to the Nef protein, 
extensive studies of Nef biology have revealed several conserved motifs that 
mediate physical association with cellular factors. Consequently, Nef could 
function as a molecular adaptor, altering cellular pathways (such as protein 
trafficking events, signal transduction cascades, and apoptotic pathways) via 







demonstrated that Nef contributes to HIV pathogenesis by several 
mechanisms. 
Intracellular activities of Nef 
Nef was shown to promote viral infection by activating CD4+ T lymphocytes, 
making them more susceptible to infection, by means of altering signal 
transduction pathways downstream of the T-cell receptor (Skowronski et al. 
1993; Baur et al. 1994). Nef has been reported to interact with the T-cell 
signaling pathway leading to the upregulation of Fas ligand (FasL) (Xu et al. 
1999)  and therefore promoting CTL apoptosis. In addition, Nef may play a 
role in the spread of HIV-1 through its specific effects on DCs, which can 
capture HIV-1 particles through a DC-specific receptor (DC-SIGN) and later 
transmit the virus to target cells without becoming productively infected 
(transcytosis).  
HIV-1 Nef reduces the surface expression of MHC-I (Schwartz et al. 1996), 
preventing the exposure of viral antigens on the surface of HIV-infected 
cells, thus allowing HIV-infected cells to escape recognition and lysis by anti-
HIV CTLs in vitro (Collins et al. 1998). There is evidence that the ability of 
Nef to disrupt MHC-I antigen presentation is very important for viral disease 
pathogenesis in vivo (Carl et al. 2001; Munch et al. 2001; Swigut et al. 
2004).  
By affecting the MHC-I surface expression, Nef may protect the HIV-infected 
cell from both adaptive and innate cell-mediated immunity. 
The CD4 protein is a coreceptor required for HIV infection; however, its 
continued presence on the surface of an HIV-infected cell after viral entry is 
problematic because coexpression of CD4 and the viral envelope disrupts the 
trafficking of both proteins; moreover, the presence of CD4 on the cell 
membrane reduces the ability of the newly formed particle to properly bud 







dramatically decreases the half-life of CD4 that has reached the cell surface, 
by targeting CD4 for degradation in an acidic compartment.  
Several models for Nef-mediated CD4 transport have been proposed, each 
based on a familiar premise: Nef binds the cytoplasmic tail of CD4 and 
recruits a cellular factor(s) to transport CD4 from the cell surface to 
lysosomes for degradation.  
 
 
Fig 1.15: Overview of Nef biological activities 
 
Pathological effects of extracellular Nef 
Cell depletion, often observed in the immune system of HIV infected 
individuals, is likely to be predominantly a bystander effect because the 
number of cells dying far outnumbers that of the HIV-infected cells, and is 
not confined to CD4 cells. There is increasing evidence of indirect killing of 
bystander cells by extracellular or cell surface-associated components of HIV 







Perturbation of membrane structure 
The myristylated N-terminal region of Nef has severe membrane disordering 
properties (Curtain et al. 1994), and, when present in the extracellular 
medium, causes rapid lysis of a wide range of CD4+ and CD4- cells in vitro, 
suggesting a role for extracellular Nef in the depletion of bystander cells, 
tissue atrophy, and in delaying the death of HIV-infected cells. 
Thymic atrophy and loss of T cells in peripheral lymphoid organs, with 
resultant immunodeficiency, has been seen in transgenic mice expressing 
the nef gene alone (Skowronski et al. 1993; Lindemann et al. 1994; Hanna 
et al. 1998) suggesting that Nef could be directly responsible for the 
depletion of lymphocytes and thymocytes during HIV infection. A number of 
studies suggest that the cytopathic effects of Nef could be related to its 
being targeted to the plasma membranes and other cellular membranes by 
the sequence at the N-terminus which has an N-myristoyl group attached at 
Gly-2. The N-terminal region of Nef shows striking homology to the bee 
venom mellitin, and when myristylated at the N-terminus has a dramatic 
disordering effect on lipid bilayers (Curtain et al. 1994). Full length 
myristylated Nef is released into the extracellular medium when expressed in 
mammalian cells (Guy et al. 1990), where it could exert cytolytic effects. As 
a matter of fact, addition of myristylated N-terminal peptides of Nef to the 
extracellular medium of human erythrocytes, CD4+ CEM (Human acute 
lymphoblastic T-cell Leukaemia) cells or PBMC (peripheral blood monocyte 
cells), caused very rapid hemolysis or cell lysis in a dose dependent manner 
(Curtain et al. 1997).  
The myristylated N-terminal Nef peptide-mediated death of a variety of cells 
could, at least in part, explain the death of various cell types within lymphoid 
organs during HIV-infection, while soluble or cell surface associated Nef 
could possibly be responsible for bystander cell killing. The early appearance 
of Nef-specific antibodies and cytotoxic T lymphocytes in the sera of two-







Cheingsong-Popov et al. 1990) suggests that Nef must be available in the 
extracellular medium. In agreement, Nef has been shown to be present in 
significant quantities in the sera of HIV-infected individuals (Fujii et al. 
1996), and on the surface of infected CD4+ cells (Fujii et al. 1993). Its 
presence in the extracellular medium could be due to the release of 
myristylated Nef in membrane vesicles, or to its incorporation as a 
component of viral particles. As viral particles mostly consist of the p20 
fragment of Nef (Pandori et al. 1996), the myristylated N-terminal fragments 
(p7) is probably cleaved off into the extracellular medium, so that significant 
quantities of p7 fragment could be available in the extracellular medium in 
view of the large amounts of virus produced in lymphoid organs during HIV 
infection (Pantaleo et al. 1993; Veazey et al. 1998). 
The severe depletion of CD4+ cells in SCID mice engrafted with HIV-infected 
human fetal liver and thymus (Liv/Thy) and PBMCs, but the lack of such cell 
depletion in tissues infected with nef-deleted HIV (Jamieson et al. 1994; 
Gulizia et al. 1997), points to a direct in vivo role for Nef in cytopathicity. A 
cytopathic role for Nef is also supported by the observation of multiple AIDS-
like pathologies such as thymic atrophy, loss of T cells and 
immunodeficiency in transgenic mice expressing the nef gene alone 
(Skowronski et al. 1993; Hanna et al. 1998). These studies clearly suggest 
that HIV Nef and the N-terminal region of Nef are directly involved in 
development of AIDS pathologies including cell depletion and tissue atrophy. 
M-tropic to T-tropic switch 
Increasing interest has been devoted to the effect of Nef on monocyte–
macrophages in AIDS pathogenesis. Treatment of human MDM with 
recombinant HIV-1 Nef protein (rNef) induces a strong inhibition of the 
replication of either macrophage (M-) or dual-tropic HIV-1 strains 
(Alessandrini et al. 2000). The resistance to HIV replication induced by rNef 







doubly infected CD4+ lymphocyte–MDM co-cultures (Alessandrini et al. 
2000).  
These data support the intriguing possibility that extracellular Nef might 
contribute to AIDS pathogenesis by inducing resistance to M-tropic HIV 
replication in MDM, thereby facilitating the switch from M- to T-tropic HIV 
that correlates commonly with AIDS progression.  
How could the switch be achieved? MDM exposed to rNef showed 
downregulation of CD4 display, reproducing a typical effect widely observed 
in CD4+ cells endogenously expressing Nef; it is conceivable that factors 
released in vivo by MDM as a result of an inflammatory stimulus (either 
dependent or not on HIV infection) attract and activate both infected and 
uninfected CD4+ lymphocytes that can be induced to productive HIV 
replication; released Nef may be internalized by uninfected macrophages 
that, as a consequence, are induced to produce additional amounts of HIV 
stimulating factors (included chemokines) becoming, at the same time, 
resistant to HIV, by means of CD4 downregulation. 
This mechanism may be at least in part the basis of the switch from M- to T-
tropic HIV strains frequently observed in seropositive patients progressing to 
AIDS. 
Extracellular Nef increases the migration of monocytes 
Infiltration of HIV-1-infected and uninfected monocytes/macrophages in 
organs and tissues is a general phenomenon observed during the 
progression of the disease. In a recent study (Lehmann et al. 2006) it was 
shown that extracellular Nef increases migration of monocytes with an effect 
which is (i) concentration-dependent, (ii) reaches the order of magnitude of 
that induced by formyl-methyonyl-leucyl-proline (fMLP) or CC chemokine 
ligand 2 (CCL2)/monocyte chemotactic protein (MCP)-1, (iii) is inhibited by 
anti-Nef monoclonal antibodies as well as by heat, and (iv) depends on a 







These data suggest that extracellular Nef may contribute to disease 
progression as well as HIV-1 spread by affecting migration of monocytes. 
HIV-associated nephropathy: role of Nef 
As mentioned above, HIVAN is the leading cause of end-stage renal failure 
in HIV-1 seropositive patients (Bourgoignie 1990; Humphreys 1995; Klotman 
1999; Ross and Klotman 2002; Kimmel et al. 2003; Weiner et al. 2003; Ross 
and Klotman 2004). Podocyte dysfunction appears to be a direct result of 
HIV-1 protein expression, specifically Nef and Vpr as well as specific host 
factors that have yet to be elucidated (Zuo et al. 2006). The mechanism by 
which Nef induces podocyte proliferation and dedifferentiation has been 
traced to its ability to activate several signaling pathways including Src-Stat3  
and ras-raf-MAPK-1, and -2 (He et al. 2004). Activation of the cAMP/PKA 
(Protein Kinase A) pathway with all-trans-retinoic acid appears to modulate 
these changes and returns podocytes to a differentiated, nonproliferating 
phenotype. 
In a study in which transgenic mice that expressed individual HIV-1 genes in 
podocytes were generated, animals that expressed Vpr or Nef developed 
podocyte injury. In contrast, none of the transgenic mice that expressed Vif, 
Tat, Rev, or Vpu developed podocyte injury (Zuo et al. 2006). 
As all nef:vpr double-transgenic mice showed more severe podocyte injury 
and glomerulosclerosis than all vpr or nef single-transgenic mice in the same 
litter, Vpr and Nef each can induce podocyte injury with a prominent 
synergistic interaction. 
HTLV-1 Tax 
HTLV-I is the etiologic agent of adult T cell Leukaemia (ATL) and HTLV-I-
associated myelopathy/tropical spastic paraparesis (HAM/TSP). 
Mitotic division of infected cells appears to be the major route of expansion 







mechanism involved in the leukaemogenic process is transactivation (see 
below) and not insertional activation or oncogene transduction as seen in 
animal leukaemias caused by gamma- and alpha-retroviruses. In addition to 
the canonical retroviral structural genes, there is a region at the 3  end of 
the genome which encodes a number of accessory proteins that play 
important roles in the transformation process; these include Tax, Rex, p12, 
p13, p30, and HBZ. 
HTLV-1 Tax is a 40-kD phosphoprotein encoded by a multiply spliced RNA. 
At its amino-terminal end, the protein contains zinc-finger-like cysteine-rich 
and histidine-rich motifs that are important for trans-activation (Smith and 
Greene 1991; Grassmann et al. 2005; Giam and Jeang 2007). 
Tax is present predominantly in the nucleus due to its NLS residing at its 
amino terminus. However, a substantial portion of the protein is also present 
in the cytoplasm due to its NES (Alefantis et al. 2003). Tax, which acts as a 
dimer, was originally discovered as a transactivator of viral RNA transcription 
from a promoter located at the 5'LTR (Felber et al. 1985), but later proved 
to modulate the synthesis or function of a wide range of cellular regulatory 
proteins (Bex and Gaynor 1998; Iha et al. 2000; Jeang 2001; Yasunaga and 
Matsuoka 2007; Boxus et al. 2008).  
Tax intracellular activities: oncogenesis 
While the pathogenesis of ATL remains incompletely understood, the viral 
regulatory protein Tax appears to play a central role as it has been shown to 
be able to transform primary lymphocytes and rat fibroblasts; in addition, 
transgenic mice models have confirmed the oncogenic properties of the 
protein in vivo. Tax functions primarily through protein-protein interactions, 
and its transformation properties are a consequence of the ability of the 
protein to deregulate the transcription of genes and signaling pathways 
involved in cellular proliferation, cell cycle control and apoptosis, including 







protein/activating transcription factor), NF-kB, AP-1, SRF (Serum response 
factor) and NFAT; and distinct cellular-signaling pathways, involving PDZ 
domain-containing proteins, Rho-GTPases and the Janus kinase (JAK)/signal 
transducer and activator of transcription (STAT), and TGF-β pathways. 
NF-κB activation by Tax results in the upregulation of expression of a large 
number of cellular genes involved in cell proliferation, including several 
cytokines and their corresponding receptor genes, including IL2 and the IL2-
R , which leads to polyclonal proliferation of HTLV-1-infected cells by 
autocrine and paracrine mechanisms (Ballard et al. 1988; Good et al. 1996). 
In addition, NF-κB stimulation causes increased expression of proteins with 
anti-apoptotic function including Bcl-xL and survivin (Kamihira et al. 2001; 
Mori et al. 2001a; Mori et al. 2001b). Many of the cellular genes deregulated 
by Tax are involved in cell cycle control, apoptosis, and DNA repair.  
 
 







Biological effects of extracellular Tax  
HTLV-1 Tax, similar to other retroviral proteins, is likely able to perform a 
variety of functions while regulating viral gene expression and promoting the 
survival of the virus within the human population.  
All Tax-mediated processes are dependent on Tax localization to the nucleus 
where it interacts with a number of cellular transcription factors during its 
course of nuclear functions. However, there is mounting evidence 
suggesting that Tax may shuttle between the nucleus and cytoplasm, 
localize to several cytoplasmic organelles with subsequent secretion from 
both Tax-transfected cells as well as HTLV-1-infected cells. 
Consistent with the concept of cellular secretion, it has been recently 
confirmed that Tax is detected in the cell culture media of Tax-transfected 
cells where Tax secretion was, at least in part, the result of a canonical 
cellular secretory pathway. This observation was supported by additional 
experimental evidence demonstrating that the presence of extracellular Tax 
was significantly decreased following treatment with the secretory pathway 
inhibitor brefeldin A (BFA) (Alefantis et al. 2005b). 
The process of Tax secretion has not been studied in great detail. While the 
presence of Tax in the extracellular space has been demonstrated, there 
have been few reports pertaining to the mechanism of Tax secretion 
(Alefantis et al. 2005a; Alefantis et al. 2005b). In this respect, the 
cytoplasmic organelles to which Tax has been shown to localize, such as the 
ER and Golgi complex, as well as the amino acid signals responsible for Tax 
targeting to these organelles, clearly warrants further examination. Full-
length Tax is secreted from both baby hamster kidney cells and a human 
kidney tumor cell line, suggesting that Tax enters the classic ER-Golgi 
secretory pathway in a leaderless manner, distinct from the pathways 
exploited by HIV-1 Tat (described below) and HFV Bet (see below) which 







Regardless of the process Tax utilizes to gain entry into the secretory 
pathway, Tax likely begins its egress through the secretory pathway in the 
ER. In this regard, Tax contains several amino acid sequences similar to 
those utilized by other proteins to initiate the secretory process through the 
ER. This signal may enable Tax to be sorted within the ER and transported 
to the Golgi in COPII vesicles.  
Neurotoxic effects. 
The activity of extracellular Tax has been central to many theories regarding 
the progression of HAM/TSP. Hypothetically, the presence of extracellular 
Tax in the CNS may be the result of either infiltrating HTLV-1- infected cells 
(CD4+ or CD8+ T cells or, possibly, other immune cell populations), including 
cells of the monocyte/macrophage lineage, or resident CNS cell populations 
that have been infected with HTLV-1 after entry of the virus into the CNS 
compartment.  
While neurons are not believed to harbor HTLV-1, both astrocytes and 
microglia have been shown to be infected by HTLV-1 in vitro and in vivo, so 
it is plausible that Tax could be released from infected astrocytes shortly 
after infection, as Tax expression in astrocytes has been demonstrated to 
have consequences for the astrocytes themselves as well as for surrounding 
cells. Whatever the source of extracellular Tax, its effects on resident CNS 
cell populations, particularly neurons, may contribute to the etiology of 
HAM/TSP: extracellular Tax has been demonstrated to induce both the 
production and secretion of TNF-α from NT2-N cells, a cell line model of 
mature primary human neurons (Cowan et al. 1997), an effect observed 
with an extracellular concentration of Tax that has been shown to 
approximate that produced by HTLV-1-infected cells (Lindholm et al. 1992; 
Cowan et al. 1997). 
Release of TNF-α may result in both an autocrine and paracrine cytokine-







system. Secretion of cytokines in response to extracellular Tax is not limited 
to neurons, as other types of resident CNS cell populations have been shown 
to respond to extracellular Tax, such as primary adult human microglial cells 
which were shown to produce and secrete TNF-α, IL-1β, and IL-6 in 
response to extracellular Tax (Dhib-Jalbut et al. 1994). The effects of 
exposure to extracellular Tax have not been limited to the CNS, since 
primary human peripheral blood macrophages have also been shown to 
produce and secrete TNF-α, IL-1β, and IL-6 in response to exposure to 
extracellular Tax (Dhib-Jalbut et al. 1994). 
The effects of extracellular Tax on a particular cell may also depend on the 
stage of cellular development. For example, extracellular Tax induces NT2-N 
cells, terminally differentiated cells from the NT2 teratocarcinoma cell line, to 
produce TNF-α. However, NT2 precursor cells do not produce TNF-α in the 
presence of extracellular Tax, suggesting that factors specific to more 
developmentally mature neurons are necessary for either the detection of 
Tax and subsequent activation of the TNF-α pathway, or factors that act in 
conjunction with Tax (Dhib-Jalbut et al. 1994). It is not known whether the 
effects of Tax on NT2-N cells occur as the result of Tax acting at the cell 
surface or after internalization. 
An equally plausible mechanism for the destruction of CNS cells observed in 
HAM/TSP may involve infiltration of HTLV-1-infected CD4+ T lymphocytes 
into the CNS. It is possible that circulating HTLV-1-infected CD4+ T cells 
migrate to the CNS, where they release Tax into the extracellular 
environment resulting in a deregulation of CNS function. Thus, infected 
astrocytes and infected circulating T lymphocytes may act as Tax-producer 
cells resulting in the up-regulation and secretion of other toxic molecules by 
resident CNS populations. Finally, extracellular Tax from Tax-producing cells 
may be engulfed by professional APCs. Tax peptide presented in the context 
of class I MHC by APCs such as DCs would result in lysis of Tax-expressing 







molecules or specific cell lysis or both could result in significant CNS damage 
similar to that observed in HAM/TSP.  
Finally, evidence has also been presented suggesting that extracellular Tax 
is able to gain entry into the cell where it may potentially resume its normal 
intracellular role as a transcriptional transactivator (Lindholm et al. 1992). 
Pro-inflammatory activity 
Secretion of cytokines in response to extracellular Tax is not limited to 
neurons, as other types of cell populations have been shown to respond to 
extracellular Tax. Specifically, extracellular Tax has been demonstrated to 
induce the production and release of several inflammatory cytokines, 
including TNF, IL-6, and granulocyte macrophage colony stimulating factor 
(GM-CSF) (Dhib-Jalbut et al. 1994); primary human peripheral blood 
macrophages have also been shown to produce and secrete, in response to 
exposure to extracellular Tax, these cytokines each having deleterious 
effects on neighboring cells. Several reports have demonstrated that soluble 
extracellular Tax induces several biological effects on target cells, including 
the production and secretion of pro-inflammatory cytokines (Dhib-Jalbut et 
al. 1994; Cowan et al. 1997). The major obstacles in treatment of patients 
with ATL include drug resistance and development of opportunistic infections 
indicating that cell-mediated immunity is severely impaired since HTLV-1-
transformed cells are resistant to most apoptosis inducing agents 
(Shimoyama 1994; Matsuoka 2002).  
Additionally, extracellular Tax has been shown to induce the production of 
Tax-specific antibodies and Tax-specific CD8+ T cells (Kubota et al. 2000), 
both of which may promote the inflammatory effects observed in HAM/TSP.  
HFV Bet 
The genome of Foamy viruses (FVs) contains several open reading frames 







env genes (Flugel et al. 1987). Only two of these ORFs are known to encode 
proteins (discussed further below). The genome of FVs is similar to that of 
other complex retroviruses, such as HIV, and contains many of the cis-acting 
sequences utilized by other retroviruses (Erlwein et al. 1998). Interestingly 
however, FVs present some peculiarities that distinguish them from the rest 
of the retroviral family (Lecellier and Saib 2000). For example, despite the 
presence of the classical early and late phases in FV infections, thus far no 
structural or functional Rev/Rex homologues have been described for these 
complex retroviruses, and the function of these proteins seems to be 
replaced by a cis-acting sequence in the FV pol domain in the viral mRNA.  
FVs encode auxiliary proteins from the 3’ end of their genome in addition to 
the structural and enzymatic gag, pol, and env genes; in the case of human 
foamy virus (HFV), the prototype of FVs, two additional open reading frames 
(ORFs) have been described, ORF1 and ORF2. Tas (transactivator of 
spumaviruses, originally called Bel1), a 36- kDa nuclear phosphoprotein, 
which is encoded by ORF1, transactivates viral gene expression by directly 
binding the viral DNA on specific sequences in the long terminal repeat 
(LTR) and in the internal promoter (Venkatesh et al. 1993; Blair et al. 1994; 
He et al. 1996). Although the product of ORF2, named Bel2, has been 
reported (Bieniasz et al. 1995), its existence has never been confirmed.  
The auxiliary Bet protein of the prototypic HFV is a 482- amino-acid (aa) 
protein generated by alternative splicing that fuses the first 88 residues of 
Tas to 394 aa of ORF2 (Muranyi and Flugel 1991). Highly expressed in 
acute-infection and chronically infected cells, Bet was also shown to be 
secreted by producing cells and internalized by naive ones (Giron et al. 
1998). Although the functions of Bet in the replication cycle remain 
unknown, its integrity is absolutely required for efficient replication of the 
feline foamy virus (Alke et al. 2001) and for that of HFV to a much lesser 







acute infection, Bet was shown to be implicated in the establishment and/or 
maintenance of viral persistence. 
As HFV Bet-expressing cell lines were shown to be resistant to productive 
HFV infection (Bock et al. 1998), the effect of Bet seems to take place 
during the early steps of infection, after virus entry but before provirus 
establishment. This protein is distributed in both the cytoplasm and the 
nucleus of HFV-infected or Bet-transfected cells, and the nuclear targeting 
results from the presence of a bipartite nuclear localization signal at the C-
terminal region, sufficient to direct heterologous reporter proteins to the 
nucleus (Lecellier et al. 2002).  
Properties of extracellular Bet 
HFV Bet follows an unconventional route to exit the cell since its secretion is 
not affected by BFA, a drug which disrupts the trafficking between the ER 
and the Golgi complex (Lippincott-Schwartz et al. 1989); once secreted, the 
protein can be internalized and has been shown  (Lecellier et al. 2002) to 
target the nuclei of recipient cells. Finally, these inter- and intracellular 
movements were also observed for the equine foamy virus Bet protein, 
strongly suggesting that these remarkable features are conserved among 
FVs (Lecellier et al. 2002). 
That Bet spreads to surrounding cells and moves into the nucleus suggests 
that these properties are relevant to some aspects of the virus cycle. It has 
been reported that Bet expression, prior to FV infection, blocks the 
replication cycle at early stages (Bock et al. 1998). The nuclear localization 
of Bet suggests that this protein affects viral replication at nuclear stages, in 
particular at the import of the preintegration complex or provirus integration 
steps. Finally, through its secretion property, Bet could act from a distance 
to limit FV propagation, one possible mechanism to establish viral 
persistence. Indeed, while a Tas-defective provirus (∆HFV) is detected in 







associated with a constant production of infectious viruses (Yu et al. 1996), 
suggesting that the molecular basis of viral persistence seems to depend on 
the cell type (Alke et al. 2001). Moreover, deleterious mutations in the Bet 
gene were detected in a simian FV isolated from a case of persistent 
zoonotic infection (Callahan et al. 1999). Therefore these observations 




Fig.  1.17: Bet biological activities 
 
Internalization of extracellular Tat and other proteins and peptides 
Several studies over the last few years have shown how Tat and other 
proteins, including the D. melanogaster homeoprotein Antennapedia, and 
the VP22 of Herpes simplex, are rapidly internalized by cells. 
This property can be ascribed to the presence of short peptides, which have 
then be used for the transduction of proteins inside cells, and have been 
collectively named “Protein Transduction Domains” (PTDs) or “cell 
penetrating peptides” (CPPs). PTDs (or CPPs) typically have a composition 







(polycationic PTDs), or an alternating pattern of polar and hydrophobic 
residues (amphipatic PTDs).  
Historically, the first CPPs were found in the primary structure of HIV Tat 
and Antennapedia, which properties will be further described below. 
Antennapedia belongs to the Homeoproteins class of transcription factors, 
which binds DNA through a specific sequence of 60 amino acids called the 
homeodomain. The third helix of the antennapedia homeodomain is involved 
in the translocation process and, in particular, the minimal protein 
transduction domain (PTD) of Antp, called penetratin, is the 16-mer peptide 
(Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Lys-Trp-Lys-Lys) 
corresponding to residues 43–58 of the third helix (Derossi et al. 1994).  
The internalization of Antp peptide is thought to follow non-saturable, dose-
dependent kinetics and is believed to occur efficiently both at 37°C and at 
4°C, suggesting and internalization mechanism independent of endocytosis 
(Derossi et al. 1994; Vives et al. 1997; Pooga et al. 1998).  
 
 
Fig. 1.18: proposed mechanism for membrane translocation of Antp 








The translocation of Antp does not involve receptors since both the reverse 
helix and the helix with D-enantiomers for the Antp peptide 43–58 were 
translocated across biological membranes.  
Due to the peculiar ability of Antp peptide to cross cell membrane in an 
energy-independent way, the formation of inverted micelles (Fig. 1.18) was 
suggested for their translocation through lipid bilayers (Derossi et al. 1996; 
Vives et al. 1997). 
VP22 is a major structural component of HSV-1 (Herpes Simplex Virus) 
possessing a remarkable property of transport between cells (Elliott and 
O'Hare 1997). VP22 is involved with different functions such as intercellular 
transport, binding to and bundling of microfilaments, inducing cytoskeleton 
collapse, nuclear translocation during mitosis, and binding to chromatin and 
nuclear membrane. VP22 has been demonstrated to mediate the trafficking 
of protein cargos to the nuclei of recipient cells (Elliott and O'Hare 1997); 
later investigations, however, have questioned such ability (Fang et al. 
1998) observing that the protein transduction activity could be an artifact of 
cell fixation (Aints et al. 1999; Elliott and O'Hare 1999); even if other works 
in the following years seem to have proven that VP22 ability to cross cell 
membranes does in facts exist (Lemken et al. 2007), the matter of whether 
VP22 could be able to transduce protein cargos remains under debate. 
The capacity of Tat to enter the cells depends upon the integrity of the so 
called basic domain, an arginine rich stretch of 9 aminoacids that also 
corresponds to the nuclear localization signal and to the TAR-binding domain 
of the protein; as a matter of fact, the works on Tat and Tat11 PTD 
demonstrated the specific role of cell surface proteoglycans, such as 
heparan sulfate (HS), as cellular receptors allowing the uptake of Tat and 
Tat11 in time-, concentration-, and temperature-dependent manner (Tyagi 
et al. 2001; Console et al. 2003). 
As for the internalization of Tat, while some works showed the involvement 







(Lundberg et al. 2003; Caron et al. 2004), Tat-mediated intracellular delivery 
of protein cargos seems to proceed mainly via the energy-dependent, 
caveolar-dependent endocytosis, with subsequent enhanced escape from 
endosome into the cell cytoplasm (Ferrari et al. 2003; Fittipaldi et al. 2003). 
Cell surface receptors for extracellular Tat internalization  
It was first suggested, in the course of early experiments on the capacity of 
Tat to be internalized from the extracellular compartment that this process 
might occur through adsorptive endocytosis. This conclusion was mainly 
based on the observations that the 72 (first exon) or 86 (full length HXB-2 
clone) protein binds non-specifically to the cell surface, with >1×107 sites 
per cell, and that its uptake is temperature and energy-dependent (Mann 
and Frankel 1991). The nature of the cell surface receptor and the 
mechanism of internalization have remained elusive until few years ago. 
Work performed by several investigators has shown that Tat binds heparin 
and that heparin/Tat interaction involves the basic domain of Tat (Mann and 
Frankel 1991; Rusnati et al. 1997; Rusnati et al. 1998; Rusnati et al. 1999; 
Hakansson and Caffrey 2003). Heparin is a close structural homologue of 
the heparan sulfate glycosaminoglycan (GAG), a major constituent of cell 
surface and extracellular matrix proteoglycans (Yanagishita and Hascall 
1992), thus suggesting that membrane-bound HS proteoglycans (HSPG) 












Direct proof for the requirement of HSPGs came from the observation that 
hamster cell lines, genetically defective in different biochemical steps of 
HSPG production, fail to internalize exogenous Tat (Fig. 1.20) (Tyagi et al. 
2001).  
 
Fig. 1.20: Hamster cell lines, genetically defective in different 
biochemical steps of HSPG production, fail to internalize exogenous 









The identification of HSPGs as the cell surface receptors for Tat 
internalization is consistent with the notion that Tat is able to enter into a 
wide variety of human, rodent and simian cell lines, indicating that it binds a 
ubiquitous cell surface molecule for cell entry, as well as with the 
observation that extracellular Tat enters most of the exposed cells. A 
common peptide motif for heparin/HS binding consists of a region rich in 
basic amino acids flanked by hydrophobic residues (Yanagishita and Hascall 
1992). The basic domain of Tat (aa 49–57) conforms to these 
characteristics. Consistently, mutation of the arginines in this domain or its 
occupancy by polysulfonated compounds prevents heparin binding and cell 
internalization of recombinant Tat, respectively (Rusnati et al. 1998). 
Tat binding to heparin/HS is not only determined by ionic interactions 
(Maccarana et al. 1993; Spillmann et al. 1998) but also requires specific 
structure recognition. Tat/HS binding affinity is proportional to the size of 
heparin oligosaccharides, with at least six saccharide residues being required 
for this interaction to occur and a proper sulfation of the oligosaccharide 
chains is required for Tat binding and internalization (Rusnati et al. 1998; 
Tyagi et al. 2001). Taking all of these considerations together, it may be 
concluded that the interaction between Tat and heparin/HS is specified by 
both charge and structure, and is determined by size, saccharide 
composition, and extent and distribution of sulfation of the GAG backbone. 
Molecular mechanism of Tat internalization  
Whereas small molecules can cross the plasma membrane through protein 
channels and pumps, macromolecules are internalized into endocytic vesicles 
derived from the plasma membrane. Endocytosis consists in the formation of 
transport vesicles containing particles and fluids; these vesicles originate 
from the invagination of the plasma membrane, which behaves as a 
dynamic structure to segregate the cytoplasm from the extracellular 







dependent endocytosis, which starts on the plasma membrane with the 
formation of clathrin-coated invaginations that pinch off to make up clathrin-
coated vesicles (Schmid 1997). Clathrin is involved in several receptor-
mediated endocytosis pathways, such as the uptake of the iron-binding 
protein transferrin, which, after interaction with the transferrin receptor, 
triggers the internalization of the ligand–receptor complex. After formation 
of the clathrin-coated pits, the vesicles shed their coat and the endosomes 
reach the sorting compartment that sorts protein in either early or recycling 
endosomes. Early endosomes develop in late endosomes and then in 
lysosomes as a result of a gradual vesicle acidification. In contrast, recycling 
endosomes carry their load back to the plasma membrane in order to re-use 
these molecules. 
Less defined are the non-classical, clathrin-independent pathways, among 
which caveolae-mediated endocytosis. Caveolae are flask-shaped, small (50–
70 nm) invaginations characterized by a special lipid composition that is 
distinct from the bulk of the plasma membrane; they constitute a subclass of 
detergent-resistant membrane domains enriched in cholesterol and 
sphingolipids, named lipid rafts (Anderson 1998). Caveolin, a cholesterol 
binding protein, is a critical component of caveolae: cells lacking caveolae, 
such as lymphocytes, produce flask-shaped invaginations only upon 
expression of this single protein (Fra et al. 1995). Caveolae are involved in 
signal transduction, cholesterol homeostasis and the intracellular transport 
of lipid raft-associated molecules, whereas proteins internalized by the 
clathrin pathway, such as transferrin, are excluded from these membrane 
domains  (Simons and Toomre 2000). Several bacterial toxins, including 
cholera toxin (Nichols and Lippincott-Schwartz 2001), and some viruses, 
including SV40 (Pelkmans et al. 2001), make use of caveolar endocytosis to 
enter the cells. In this way, they escape lysosome degradation that results 







Recent studies (Ferrari et al. 2003; Fittipaldi et al. 2003) clearly indicate that 
the internalization of Tat fusion proteins occurs through a process of 
caveolar endocytosis that emanates from cell membrane lipid rafts, and not 
by clathrin-mediated endocytosis (Fig. 1.21). 
 
 
Fig. 1.21: Internalization of Tat fusion proteins occurs through a 
process of caveolar endocytosis  
Internalized Tat co-localizes with Ctx-B (A and B) and caveolin (C), thus indicating 
that Tat endocytosis proceeds through caveolar lipid rafts; no localization occurs with 
transferrin (D), a protein known to be internalized by clathrin-mediated endocytosis 
(Fittipaldi et al. 2003) 
 
 
The question of what might be the connection between HSPGs, acting as 
membrane receptors for extracellular Tat and caveolar endocytosis remains 
open; one of the two families of cell surface HSPGs is the glypicans, which 
lack a membrane-spanning domain and are anchored to the external surface 
of the plasma membrane via glycosylphosphatidylinositol (GPI). As GPI-
anchored proteins are highly enriched in lipid rafts on the cell surface, a 
prediction could that the internalization of Tat might occur following its 
interaction with the sugar moiety of this HSPG. 
A crucial question that still remains to be answered is how the internalized 
Tat molecules escape the endosomal compartment and translocate to the 
nucleus. Whichever the molecular mechanism of nuclear translocation might 
be, it is clear that the efficiency of the process is limiting and that only a tiny 







Very recently, a model for Tat membrane insertion in response to acid pH 
has been proposed based on in vitro studies using model membranes (Yezid 
et al. 2009); upon acidification below pH 6.0, Tat inserts into membranes 
with a process relying on its Trp11. The conformational change leading to 
the exposition of Trp11 on the protein surface, allowing its interaction with 
membranes, is induced by low pH and involves a pH sensor made by 
Glu/Asp2 (the first acidic reside) and residues 55-57 (end of the basic 
domain) 
Tat as a vehicle for transcellular transduction of proteins, nucleic 
acids and other cargos in vitro and in vivo 
Given the potency of the Tat basic domain in mediating the cellular uptake 
of small and large macromolecular cargos, it is not surprising that, over the 
last few years, a large number of laboratories have exploited this system as 
a tool for transcellular transduction in cultured cells. Most of these 
applications are based on the fusion of the protein transduction domain of 
Tat to the protein of interest, either at the N-terminus or at the C-terminus, 
followed by the addition of the recombinant fusion protein to the culture 
medium of the cells of interest. Most notably, fusion or conjugation to Tat 
has been shown not only to mediate cell internalization of heterologous 
proteins (Kabouridis et al. 2002; Wang et al. 2002; Krosl et al. 2003), but 
also of larger molecules or particles, including magnetic nanoparticles (Lewin 
et al. 2000), phages and retroviral vectors (Eguchi et al. 2001; Gratton et al. 
2003), liposomes (Torchilin et al. 2001) and plasmid DNA (Ignatovich et al. 
2003), with variable efficiency. 
Besides these applications in cultured cells, Tat-mediated transcellular 
protein transduction has been shown to occur also in living animals in vivo, 
as originally suggested by the observation that the intraperitoneal injection 
of a >120-kDa β-galactosidase protein carrying the Tat basic domain is 







in mice, including the brain (Schwarze et al. 1999). As this observation was 
not confirmed in subsequent studies, however, the question about the 
possible therapeutic applications of Tat-mediated transcellular protein 
transduction in vivo remains open. 
Another potentially interesting application of the delivery of genes encoding 
Tat fusion proteins is for cancer gene therapy. In this field, one major 
limitation is the inefficiency of the currently available gene transfer vectors 
to deliver the therapeutic genes into all the transformed cells. An appealing 
possibility in this field is to extend the bystander effect of the enzyme also to 
non-transduced cells by fusing Herpes Simpex Thymidine Kinase (HSV-TK) 
to the Tat transduction domain: this approach has been shown to 
significantly increase the cytotoxic activity of TK beyond the actually 
expressing cells (Tasciotti et al. 2003; Tasciotti and Giacca 2005). 
Protein secretion 
Tat not only enters the cells when present in the extracellular environment, 
but also exits the cells through a still poorly defined, non-canonical, Golgi-
independent pathway of release (Ensoli et al. 1993; Chang et al. 1997). 
Thus, the delivery of genes encoding for Tat fusion proteins in vivo permits 
the release of these proteins outside of the expressed cells, thus allowing an 
extension of the desired effect.  
The following Chapters describe the mechanisms of canonical and non-
canonical protein secretion by the cells.  
“Classical” protein secretion: an overview 
The secretory and endocytic pathways of eukaryotic organelles consist of 
multiple compartments, each with a unique set of proteins and lipids. 
Specific transport mechanisms are required to direct molecules to defined 







compartments are maintained. Thus the localization of proteins to specific 
membranes is complex and involves multiple interactions. 
Proteins contain structural information that targets them to their correct 
destination and many targeting signals have now been defined; the 
organelles of the secretory pathway are involved in reading this signals and 
sorting of proteins to a variety of intracellular membrane compartments and 
the cell surface. For example, proteins that are transported within the 
secretory pathway are alternatively secreted from the cell, bound to the 
plasma membrane, sorted to lysosomes, or are retained as ‘‘residents’’ in 
any of the organelles. Within the ER, newly synthesized proteins are 
scrutinized to ensure they are correctly folded, undergo initial glycosylation 
before being packaged into transport intermediates or vesicles, and then 
moved forward to the entry site of the Golgi apparatus. Secretory proteins 
are then transported through the Golgi cisternae to the trans-Golgi network 
(TGN), or Golgi exit site; at the TGN proteins are sorted according to their 
final destinations. The TGN is also the site where the biosynthetic and 
endocytic pathways converge: molecules that are internalized from the cell 
surface in endocytic vesicles and transported to the early endosome where 
they can be recycled to the plasma membrane (such as recycling receptors), 
or transported to the TGN or to the lysosome via the late endosomes for 
degradation. Thus, the TGN and the early endosome represent the two 
major sorting stations of the cell. 
Protein transport in the secretory and endocytic pathways is a multi-step 
process involving the generation of transport carriers loaded with defined 
sets of cargo, the shipment of the cargo loaded transport carriers between 
compartments, and the specific fusion of these transport carriers with a 
target membrane. These processes involve a complex interplay of protein 
and lipid interactions (for an extensive review of  the components of the 
secretory pathway, and of the molecular mechanisms underlying the 







destinations, as well as of the molecules involved in the regulation of such 
processes, see (van Vliet et al. 2003)). 
 
 
Fig. 1.22: Overview of the overall process of classical secretion 
(Nickel and Rabouille 2009) 
 
 
Protein translation begins on free ribosomes in the cytosol. Proteins destined 
for secretion or for residence along the secretory pathway are targeted to 
the ER lumen by an N-terminal signal sequence (Walter and Johnson 1994). 
As the nascent polypeptide chain emerges from free ribosomes it is bound 
by the signal recognition particle (SRP) that directs the ribosome and 
nascent chain to the ER membrane. The ribosome-nascent chain-SRP 
complex then binds to the cytosolic side of the ER membrane via 
interactions with the Sec61p complex and SRP receptor (Rapoport et al. 
1996; Matlack et al. 1998). The polypeptide chain is cotranslationally 
translocated into the lumen of the ER through the Sec61p membrane 
channel, referred to as the translocon, with the assistance of the 
translocating-chain associating membrane (TRAM) protein (Gorlich and 







ER the N-terminal signal sequence of soluble proteins is cleaved by a signal-
specific peptidase (Martoglio and Dobberstein 1998). Transmembrane 
proteins are cotranslationally inserted into the membrane of the ER (Do et 
al. 1996). Within the lumen of the ER, chaperon molecules assist the folding 
as well as the quality control of the nascent polypeptide chains. 
The majority of plasma membrane and secretory proteins are glycosylated: 
N-linked oligosaccharides are added to the growing polypeptide chain as it 
enters the ER (Kornfeld and Kornfeld 1985); O-linked glycosylation begins in 
the ER or cis-Golgi where a GalNAc residue is added to a serine or threonine 
residue by polypeptide N-acetylgalactosaminyl transferase (Marth 1996).  
ER-Golgi trafficking 
Proteins are exported from the ER at specialized exit sites called transitional 
elements or transitional ER (tER) (Palade 1975), smooth ribosome-free 
sections of the ER adjacent to the rough ER. tER-derived transport vesicles 
subsequently fuse to form a network of vesicular tubular clusters (VTCs) 
(Bannykh et al. 1996), also known as pre-Golgi intermediates (Saraste and 
Kuismanen 1992) or the ER-Golgi intermediate compartment (ERGIC). The 
ERGIC compartment is a major sorting station, recycling ER proteins in 
retrograde vesicles as well as delivering secretory cargo to the cis-Golgi 
(Warren and Mellman 1999). Peripheral ERGICs move along microtubules to 
the Golgi region where they fuse to form the cis-Golgi network, (Saraste and 
Kuismanen 1992; Presley et al. 1997). 
Secretory cargos leaving the ER are packaged into vesicles possessing a 
specialized protein coat known as COP (Coat Protein) II; much debate has 
occurred over the years as to whether this transport process is selective or 
whether cargo is transported as part of a bulk flow process. It appears more 
likely that cargo leaves the ER both by selective mechanisms and bulk flow: 
highly abundant proteins could be transported by bulk flow mechanisms, 







uptake (Warren and Mellman 1999). Following budding from the ER, COPII 
vesicles lose their coats and fuse to form ERGICs (Aridor et al. 1995). 
Another COP coat, called COPI, assembles on the membranes of the ERGICs 
generating vesicles for retrieval of ER residents. 
The Golgi apparatus 
The Golgi apparatus consists of a series of flattened membrane cisternae, 
called the Golgi stack, bordered by two tubulo-vesicular networks, the cis-
Golgi network (CGN) and the trans-Golgi network (TGN). Long membrane 
tubules interconnect multiple Golgi stacks, which are arranged around the 
nucleus, close to the centrosome (Thyberg and Moskalewski 1999). The cis 
face of the Golgi, which receives cargo from the ER, is likely to arise from 
the fusion of several ERGIC elements and, as such, assists in sorting 
secretory cargo from ER residents as described in the previous section. The 
TGN sorts and packages proteins into membrane carriers destined for the 
plasma membrane, endosomes and regulated secretory granules. The TGN 
is functionally and morphologically distinct from the Golgi stack (Griffiths and 
Simons 1986): the TGN is a tubular reticular network and has coated buds 
whose coats differ from those found in the Golgi stack (Boman 2001); 
moreover, there are a number of distinct processing activities that are 
restricted to the TGN. These include: sialylation (Chege and Pfeffer 1990), 
proteolytic processing (Molloy et al. 1994), tyrosine sulphation (Baeuerle and 
Huttner 1987).  
The TGN is a highly dynamic compartment involved in sorting of cargo for 
delivery to multiple destinations (Fig. 1.23): proteins are packaged into 
membrane carriers for transport to regulated secretory granules and the 
endosome/lysosome system (Keller and Simons 1997; Traub and Kornfeld 
1997), or the apical and basolateral membranes in polarized cells. Proteins 
can also be recycled from the TGN to earlier compartments in the secretory 








Fig. 1.23: vesicular trafficking between the ER and the Golgi 
apparatus (The Cell - A Molecular Approach  Cooper, G. Sinauer 
Associates, Inc.; 2000) 
 
 
A large number of glycosidases and glycosyltransferases reside within the 
Golgi. These glycosylation enzymes modify the asparagine linked structure 
that arrives from the ER; the presence of a particular glycosyltransferase is 
often used as a marker for a particular compartment. 
Cisternae progression, proposed in the 1950s, and later refined by Morre 
(Morre and Ovtracht 1977), suggests that the individual Golgi cisternae 
move progressively through the stack carrying anterograde cargo. 
Recent studies showed that vesicular transport and cisternae maturation 
need not be mutually exclusive and may in fact be occurring simultaneously 
(Pelham and Rothman 2000). Large molecules and protein aggregates too 
large to fit into vesicles could be transported inside maturing cisternae, while 
bidirectional vesicles could provide a ‘‘fast track’’ for cargo transport through 







to Golgi membranes would constrain the vesicles, limiting the transfer of 
cargo to adjacent cisternae in the stack: budding from one cisterna and 
randomly fusing with an adjacent cisterna, these vesicles would result in net 
flow of cargo through the Golgi as newly synthesized cargo is continually 
added at the cis face and removed at the trans face.  
Proteins destined for regulated secretion aggregate in the TGN where they 
are packaged into immature secretory granules (ISGs) (Thiele et al. 1997). 
Clathrin coated vesicles form on these ISGs and recycle TGN proteins, 
resulting in further concentration of the secretory proteins in a manner 
analogous to anterograde cargo concentration by removal of ER proteins 
from ERGICs in COPI vesicles. Mature secretory granules are stored in the 
cytosol until the cell receives a signal to release their contents. Signaling 
triggers the transport of secretory granules and their fusion with the plasma 
membrane thereby releasing their contents (Burgess and Kelly 1987). 
Lysosomal enzymes are transported from the TGN in specialized vesicles. 
Unconventional pathways of protein secretion 
The vast majority of soluble proteins are characterized by an N-terminal 
signal peptide that promotes their trafficking through the ER and Golgi 
apparatus, and their subsequent delivery to the cell surface by vesicular 
transport.  Nonetheless, over the last 15 years two types of non-
conventional protein transport to the cell surface of eukaryotic cells have 
been revealed. The first type regards proteins that, despite having a signal 
peptide-driven targeting to the ER, also reach the cell surface in a COPII or 
Golgi independent pathway; crucial membrane bound proteins, such as 
CD45 (Baldwin and Ostergaard 2002) and CFTR (cystic fibrosis 
transmembrane conductance regulator) (Yoo et al. 2002), belong to this 
group. On the other hand, a number of secretory proteins, with defined 
extracellular functions, have been shown not to contain functional signal 







machinery (Cleves 1997; Hughes 1999; Nickel 2003; Prudovsky et al. 2003; 
Nickel 2005), thus pointing out the existence of an alternative pathway for 
protein secretion, independent from the ER-Golgi system (for a review of the 
mechanism of unconventional secretion, see (Nickel and Rabouille 2009)). 
Signal peptide containing proteins: bypassing COPII vesicles or Golgi 
apparatus 
Despite ER-Golgi system being very efficient and highly regulated machinery 
for the export of protein towards the cell membrane and the extracellular 
space, some signal-peptide containing proteins, directed to the ER, are able 
to exit this compartment bypassing either the Golgi compartment, or the 
COPII vesicles.  
 
 
Fig. 1.24: Unconventional export of signal-peptide-containing 
proteins (Nickel and Rabouille 2009) 
 
 
In the first case, proteins, despite containing a signal peptide, do not seem 
to be sensible to BFA, known to be an inhibitor of the ER-Golgi trafficking 
(Misumi et al. 1986). Most likely, after translocation into the ER, proteins are 
directly incorporated in COPII coated vesicles and targeted to the plasma 
membrane (Fig. 1.24, mechanism 1): such mechanism has been 







could be directed to an endosomal/lysosomal compartment that, in turn, 
fuses with the plasma membrane (Fig. 1.24, mechanism 2) (Nickel and 
Rabouille 2009). 
The second case refers to proteins which are targeted to the plasma 
membrane through non-COPII-coated vesicles: this is the case of yeast Hsp 
(Heat shock protein) 150 (Fatal et al. 2002; Karhinen et al. 2005), voltage-
sensitive potassium channel (Kv4 K+) (Hasdemir et al. 2005) and ER 
degradation-enhancing α-mannosidase like protein 1 (EDEM1) (Cali et al. 
2008). Such vesicles could be directly targeted to the plasma membrane 
(Fig. 1.24, mechanism 3) or be exported through the Golgi apparatus (Fig. 
1.24, mechanism 4).  
Secretion of proteins lacking the signal peptide for ER targeting: the 
“unconventional pathway” 
A number of cytoplasmic, nuclear or pathogen proteins, lacking an ER-signal 
peptide, have been shown to be exported from cells through an ER-Golgi 
independent pathway. Accordingly, the extracellular appearance of such 
molecules is not compromised in the presence of BFA. These observations 
led to the postulation of the existence, in eukaryotic cells, of secretory 
mechanisms that are fully functional in the absence of an intact ER/Golgi 
system and therefore have been collectively termed “unconventional” 
secretory processes (Cleves 1997; Florkiewicz et al. 1998; Andrei et al. 
1999; Hughes 1999; Landriscina et al. 2001b; Gardella et al. 2002; Nickel 
2003; Backhaus et al. 2004; Hunter-Lavin et al. 2004; Schafer et al. 2004; 
Nickel 2005). The basic observations (summarized in (Cleves 1997; Hughes 
1999)) that led to the proposal of alternative pathways of eukaryotic protein 
secretion are (a) the lack of conventional signal peptides in the secretory 
proteins examined, (b) the exclusion of these proteins from classical 
secretory organelles such as the ER and the Golgi combined with the lack of 







and (c) resistance of these export processes to BFA, a classical inhibitor of 
ER/Golgi-dependent protein secretion (Misumi et al. 1986; Lippincott-
Schwartz et al. 1989; Orci et al. 1991). Intriguingly, unconventional 
secretory proteins comprise a group of molecules of significant biomedical 
relevance such as the proangiogenic growth factor FGF-2, a direct-acting 
stimulator of angiogenesis, produced in many tumors and metastasis 
(Nugent and Iozzo 2000). Other examples include lectins of the extracellular 
matrix (galectin family) involved in tumor-mediated immune suppression 
(Perillo et al. 1995), inflammatory cytokines such as IL-1β (Braddock and 
Quinn 2004) and macrophage migration inhibitory factor (MIF) (Lue et al. 
2002) as well as a family of stage-regulated surface molecules from 
Leishmania parasites termed hydrophilic acylated surface proteins (HASPs) 
implicated in host cell infection (McKean et al. 2001). 
 
 
Fig. 1.25: The process of non classical protein secretion (Nickel 2003; 
Nickel and Rabouille 2009) 
 
 
It is nowadays clear that the possibility of exporting proteins that lack the 







bacteria, lower eukaryotes and protozoa) and seems to be a general 
phenomenon that could operate by several routes and affect many proteins. 
The most relevant proteins known to be secreted by unconventional means 
will be discussed in detail below.  
protein 
name 
function organism type 
FGF-1 Mitogenic and angiogenic growth factor mammals 
FGF-2 angiogenic growth factor mammals 
galectin-1 extracellular matrix mammals 
HASPB Leishmania outer wall component leishmania 
IL-1B cytokine mammals 
MIF cytokine mammals 
Bet viral accessory protein 
Human Foamy 
Virus 











Ovine Mx1 antiviral protein mammals 
thioredoxin cytokine mammals 
Syntaxin-2 





En2 homeoprotein mammals 
HMG homeoprotein mammals 





Table 1.1: state of the art on the main proteins known to be 








Cytokines: interleukin-1β, thioredoxin and macrophage migration inhibitory 
factor 
In 1987, Dinarello and colleagues first demonstrated that IL-1, a cytokine 
(Dinarello 1991; Dinarello 1997) lacking a classical signal peptide for 
ER/Golgi-mediated protein secretion (Auron et al. 1984), is exported from 
activated human monocytes (Auron et al. 1987). Two isoforms of IL-1 
termed IL-1α and IL-1β have been described which represent proteolytically 
processed forms derived from two related but distinct precursors (Dinarello 
1997).  
Most studies targeted toward the molecular mechanism of interleukin 1 
export have been focused on the β-isoform. A detailed molecular analysis of 
the export process revealed that IL-1β does not make use of an 
unconventional pathway of translocation into the lumen of the ER but rather 
appears to utilize a secretory mechanism independent of ER/Golgi-related 
vesicular transport (Rubartelli et al. 1990). This process was shown to be 
distinct from unspecific release as for example only the processed form of 
IL-1β (17 kDa) can be detected in cellular supernatants whereas the 
precursor (33 kDa) is retained by IL-1β-expressing cells. Moreover, under 
the experimental conditions applied, only the β-isoform was found to be 
secreted, whereas the α-isoform could not be detected in cellular 
supernatants (Rubartelli et al. 1990). However, despite apparently utilizing a 
distinct secretory mechanism, it was later found that IL-1α is also exported 
(Watanabe and Kobayashi 1994). 
Though IL-1β is found in certain intracellular vesicles, as judged by protease 
protection experiments, these structures appear to be unrelated to the 
ER/Golgi system as IL-1β secretion was not inhibited but rather stimulated 
by BFA (Misumi et al. 1986; Orci et al. 1991). Consistently, IL-1β was found 
not to be glycosylated, despite bearing consensus sequences for 
glycosylation. Intracellular vesicles proposed to play a role in IL-1β secretion 







releases its content upon fusion with the plasma membrane (Andrei et al. 
1999). These observations are consistent with the fact that IL-1β secretion 
is sensitive to methylamine, a drug known to interfere with endosomal 
recycling (Rubartelli et al. 1990). Based on pharmacological studies an ABC 
transporter, ABC1, has been implicated in the overall process of IL-1β 
secretion (Hamon et al. 1997; Zhou et al. 2002) and therefore might 
mediate IL-1β translocation from the cytoplasm to the lumen of the 
endolysosomal compartment. Interestingly, ABC inhibitors also appears to 
block non classical secretion of macrophage migration inhibitory factor 
(Flieger et al. 2003), an inflammatory cytokine mediating a number of 
immune and inflammatory diseases, e.g. bacterial septic shock (Bernhagen 
et al. 1998; Swope and Lolis 1999). The potential function of ABC 
transporters in these processes might be related to that of bacterial ABC 
transporters that mediate protein secretion of, for example, hemolysin 
(Hughes et al. 1992; Kuchler and Thorner 1992). 
Thioredoxins are ubiquitous intracellular enzymes that catalyze thiol-disulfide 
exchange reactions (Holmgren 1989). Additionally, extracellular populations 
of thioredoxin have been detected that, similar to IL-1β and migration 
inhibiting factor, follow an ER/Golgi-independent route of secretion 
(Rubartelli et al. 1992; Sahaf and Rosen 2000). This observation is 
consistent with additional physiological roles of thioredoxin such as its 
function as a mitogenic cytokine that requires extracellular localization 
(Pekkari et al. 2000). Secretion of thioredoxin appears to be mediated by a 
pathway distinct from IL-1β as it could neither be detected in intracellular 
vesicles, nor was the secretion process reported to be inhibited by reagents 
that interfere with the function of ABC transporters. However, as with IL-1β, 
secretion of thioredoxin is inhibited by methylamine and stimulated by BFA 
(Rubartelli et al. 1992). Interestingly, the redox state of thioredoxin does not 







Pro-angiogenic growth factors: FGF-1 and FGF-2 
FGF-1 and FGF-2 belong to a large family of heparin-binding growth factors 
(Burgess and Maciag 1989) that, apart from their mitogenic activity, are key 
activators of tumor-induced angiogenesis (Nugent and Iozzo 2000). The 
majority of the members of the FGF family are exported by ER/Golgi-
dependent secretory transport. However, FGF-1 and the 18 kDa isoform of 
FGF-2 have been shown to be secreted by an alternative pathway (Jackson 
et al. 1992; Mignatti et al. 1992; Trudel et al. 2000). While it was first 
assumed that angiogenic growth factors might be released from 
mechanically injured tissue to promote wound healing, a process that 
requires angiogenesis, various lines of evidence demonstrate that FGF-1 and 
FGF-2 are exported from cultured cells in the absence of appreciable 
amounts of cell death (Jackson et al. 1992; Mignatti et al. 1992; Florkiewicz 
et al. 1995; Trudel et al. 2000; Engling et al. 2002). Like IL-1β, FGF-1 is 
increasingly secreted under stress conditions such as heat shock treatment 
(Jackson et al. 1992; Shin et al. 1996). In contrast, FGF-2 export is not 
affected under these experimental conditions (Mignatti and Rifkin 1991). 
While serum starvation has been reported to inhibit export of both FGF-2 
and IL-1β, it was found to actually induce secretion of FGF-1 (Shin et al. 
1996). Similarly, methylamine has been found to block export only of FGF-2 
and IL-1β with no apparent effect on FGF-1 export (Rubartelli et al. 1990; 
Mignatti and Rifkin 1991; Shin et al. 1996). It was reported that expression 
of the IL-1α precursor inhibits FGF-1 release in response to temperature 
stress (Tarantini et al. 2001); in contrast, expression of the mature form of 
IL-1α did not affect FGF-1 export, suggesting that IL-1α processing is 
somehow related to FGF-1 biogenesis. However, whether FGF-1 and IL-1α 
utilize similar export mechanisms remains unclear. 
These observations point to some common characteristics in the export of 
the cargo proteins discussed, but it seems unlikely that the same machinery 







secreted by a vesicular non classical export pathway, FGF-1 and FGF-2 are 
likely to be directly translocated from the cytoplasm into the extracellular 
space. While there is also one report pointing to a role of large granules 
involved in FGF-2 export based on immune-EM (Electron Microscopy) 
analysis of mast cells (Qu et al. 1998), and another research group (Taverna 
et al. 2003; Taverna et al. 2008) demonstrated that in Sk-Hep1 cells FGF-2 
release is mediated by the shedding of membrane vesicles, this issue 
remains controversial, as intracellular FGF-2 has been localized to the 
cytoplasm in many FGF-2-secreting cell types with no apparent localization 
in vesicular structures. Moreover, very recently a report on the 
characterization of the unconventional pathway of FGF-2 and Galectin-1 
secretion (Seelenmeyer et al. 2008) puts into question the effective role of 
the so called membrane blebbing of vesicles in the release of the factors 
cited above. 
With regard to the protein components involved in the overall processes of 
non classical export pathways, most is known about the secretion of FGF-1. 
As noted above, FGF-1 export is significantly increased in response to stress 
conditions such as heat shock treatment and serum starvation. It was shown 
that secreted FGF-1 isolated from cell culture supernatants in the form of 
homodimer represents a latent, inactive form that can be reactivated 
(Jackson et al. 1995). These observations led to the discovery of a specific 
cysteine residue (Cys30) in FGF-1 that is required for both dimer formation 
and non classical export of FGF-1 (Jackson et al. 1995; Tarantini et al. 
1995). Upon heat shock treatment, two intracellular proteins have been 
shown to associate with the latent FGF-1 homodimer in the cytoplasm. 
These are a cleavage product of the transmembrane protein synaptotagmin 
consisting of its cytoplasmic domain (p40-Syt1) and the Ca2+-binding protein 
S100A13. Apparently, they are exported together with FGF-1 (Landriscina et 
al. 2001b). A direct role of p40-Syt1 and S100A13 in FGF-1 export has been 







and the expression of a dominant-negative S100A13 mutant attenuate FGF-
1 export. As with FGF-1 dimer formation, oxidation by Cu2+ cations has been 
demonstrated to trigger the formation of a complex consisting of FGF-1, 
p40-Syt1 and S100A13 (Landriscina et al. 2001a), while more recently, 
stress-induced formation of the intracellular FGF-1–p40-Syt1–S100A13 
complex has been demonstrated to cause a redistribution of cytoplasmic 
FGF-1 to the inner surface of the plasma membrane (Prudovsky et al. 2002). 
These results suggest that FGF-1–p40-Syt1–S100A13 complex formation is 
the first step in the FGF-1 export pathway, followed by direct translocation 
of this protein complex across the plasma membrane. However, the 
machinery mediating this last step remains unknown. 
Compared to FGF-1 export, much less is known about the mechanism and 
the role of specific proteins with regard to the overall process of FGF-2 
export from mammalian cells. To date the only protein that has been 
proposed to play a role in FGF-2 export is the Na+,K+-ATPase  (Florkiewicz et 
al. 1998). This conclusion was based initially on the observation that cardiac 
glycosides such as ouabain partially inhibit FGF-2 export (Smith et al. 2001). 
Further experiments demonstrated that the expression of an ouabain-
resistant α 1 subunit mutant of the Na+,K+-ATPase rescues FGF-2 export in 
the presence of ouabain (Dahl et al. 2000). Moreover, a direct or indirect 
physical interaction between the α subunit and FGF-2 was detected based 
on co-immunoprecipitation, though this association could only be observed 
upon co-overexpression of both proteins (Florkiewicz et al. 1998). Together 
with the result that overexpression of the α subunit interferes with FGF-2 
export (Florkiewicz et al. 1998), these observations are reasonably 
supportive of a role for the Na+,K+-ATPase in the overall process of FGF-2 
export. On the other hand, ouabain treatment (typically used at 10–100 µm) 
causes only partial inhibition of FGF-2 export, whereas concentrations of 
ouabain of less than 5 µm (IC50 ≈ 1 µm) completely inhibit the ATP-







the membrane potential generated by the Na+,K+-ATPase is not required for 
FGF-2 export (Florkiewicz et al. 1998). Based on these observations, it has 
been proposed that the α/β heterodimers that constitute a functional 
Na+,K+-ATPase in terms of ion transport might be able to form higher 
ordered complexes that catalyze FGF-2 export in a membrane potential-
independent manner. Alternatively, the α subunit alone might associate with 
other so far uncharacterized factors as part of a novel complex that 
mediates FGF-2 export. Unfortunately, no progress has yet been made in 
identifying such molecular structures. 
Recently, it has been pointed out that FGF-2 export could be driven by direct 
translocation from the cytoplasm across the plasma membrane into the 
extracellular space (Schafer et al. 2004). These findings imply that quality 
control measures operate at this level of the export pathway, and indeed, 
evidence has been reported that FGF-2 secretion occurs in a folded state 
(Backhaus et al. 2004). These findings offer the fascinating possibility that 
the so-far uncharacterized targeting signal of FGF-2 is somehow integrated 
in its three-dimensional structure; the export apparatus might only accept 
cargo molecules that are properly folded and, in turn, would ensure quality 
control during protein translocation across the plasma membrane.  
If no vesicular intermediate is involved in the process of secretion, how 
would FGF-2 be recruited at the plasma membrane before being released? 
This question has partially been addressed very recently, as a direct role of 
Phosphatidylinositol-4,5-bisphosphate ( PI(4,5)P2 ) has been demonstrated 
in unconventional secretion of FGF-2 (Temmerman et al. 2008). Briefly, FGF-
2 was shown to bind this phosphoinositide (which is the principal species 
associated with plasma membrane) in a lipid background that resembles the 
plasma membrane; FGF-2 secretion was impaired by reducing cellular levels 
of PI(4,5)P2, and likewise, variant forms of FGF-2, deficient for the binding to 
the phosphoinositide, were severely impaired with regards to export 







and PI(4, 5)P2, associated to the inner leaflet of the plasma membrane, 
might represent the initial step which leads to the membrane translocation 
and subsequent release of FGF-2 in the extracellular space. 
A further addition to this model regards the possible role of the extracellular 
receptor of HSPGs as a “molecular trap” which may drive the export of FGF-
2 outside the cells, as FGF-2 mutants that cannot bind to heparan sulfates 
are not secreted, and cells that do not express functional HSPGs cannot 
secrete wild-type FGF-2 (Nickel 2007). 
Galectins: components of the extracellular matrix 
The members of the galectin protein family are abundant β-galactoside-
specific lectins of the extracellular matrix implicated in many cellular 
processes such as regulation of cell proliferation, differentiation and 
apoptosis (Perillo et al. 1998; Rabinovich et al. 2002). The best 
characterized members of this family are galectin-1 and galectin-3 which are 
present as soluble proteins in the cytoplasm in a wide range of vertebrate 
cell lines and tissues. Secreted galectins are found either bound to the 
extracellular surface of the plasma membrane or as abundant components 
of the ECM (Sato et al. 1993; Mehul and Hughes 1997; Seelenmeyer et al. 
2003). Cell surface association of galectins is mediated by both N- and O-
glycosylated β-galactose-terminated oligosaccharide side chains of 
glycoproteins as well as by galactose-containing glycolipids such as GM1. 
Secreted galectins are thought to affect processes such as cell differentiation 
by cell surface counter receptor-mediated signaling (Perillo et al. 1998). 
Classical counter receptors of galectin-1 include laminin, fibronectin  and 
cell-type specific receptors such as T cell CD43 and CD45, and it has 
recently been shown that the tumor-specific cell surface antigen CA125 also 
represents a galectin counter receptor that preferentially binds galectin-1 
(Seelenmeyer et al. 2003). This way, tumor cells could differentially interact 







Similar to interleukin 1β, FGF-1 and FGF-2, galectins apparently do not 
contain signal peptides in their primary structure suitable for ER/Golgi-
mediated secretion. Consistently, galectins are synthesized on free 
ribosomes in the cytoplasm and galectin secretion has been shown not to be 
blocked by inhibitors of the ER/Golgi-dependent pathway such as BFA and 
monensin (Lindstedt et al. 1993; Sato et al. 1993; Hughes 1999). Unlike IL-
1β, galectin-1 and galectin-3 do not appear to be packaged into intracellular 
vesicles prior to export (Sato et al. 1993; Mehul and Hughes 1997; Hughes 
1999); rather, galectin-1 and galectin-3 have been shown to accumulate 
directly below the plasma membrane, followed by an export mechanism that 
appears to involve the formation of membrane-bound vesicles that pinch off 
before being released into the extracellular space (Sato et al. 1993; Mehul 
and Hughes 1997; Hughes 1999). This mechanism also distinguishes 
galectin export from FGF-1 and FGF-2 export, as there is no evidence that 
these proteins are packaged into exosomes (see above). However, there is 
no information describing exactly what causes galectin-1 and galectin-3 to 
accumulate at specific spots underneath the plasma membrane, and what 
actually causes the formation of exosomes into which these proteins appear 
to be packaged in an active fashion. Very recently, moreover, it has been 
shown that membrane blebbing is neither induced nor it is necessary for the  
release of Galectin-1 from expressing cells (Seelenmeyer et al. 2008); thus, 
the molecular mechanism which leads to the release of Galectins from cells 
is still under debate. 
It has been proposed that the interactions between Galectin-1 and its β-
galactoside counter receptors are an integral part of the export mechanism 
itself, as it has been reported that both Galectin-1 mutants deficient in β-
galactoside binding, and mutant cell lines deficient in the biogenesis of 
Galectin counter receptors are defective with regards to Galectin-1 secretion 
(Seelenmeyer et al. 2005). These data estabilish that the targeting motif of 







recognition domain. Galectin counter receptors could act either at an 
intracellular level in order to recruit cytoplasmic galectins to the non classical 
export pathway, or at an extracellular level by exerting a pulling force to 
promote directional transport of galectins across the plasma membrane. 
Other secretory proteins exported by non conventional means: HIV-Tat, 
Herpes simplex VP22 and foamy virus Bet 
Besides the classical examples of ER/Golgi-independent protein secretion 
described above, other proteins have been reported to be secreted by non 
conventional means. Such proteins include virus-encoded factors (HSV VP22, 
HIV Tat and HFV Bet) that are critical for the respective viral replication 
cycle. The molecular mechanism of the translocation process of these 
proteins does not seem to involve a proteinaceous machinery as the Antp 
PTD has been shown to cross artificial protein-free membranes (see above). 
Another unusual feature of protein transduction domains is their apparent 
ability to translocate across membranes even at 4°C, an observation 
consistent with a membrane translocation mechanism independent of 
proteinaceous machinery. In all cases, however, protein transduction 
domains appear to function in unconventional modes of protein uptake by 
mammalian cells. Similar to herpes simplex VP22, a secreted auxiliary 
protein termed Bet encoded by FVs has been shown to spread between 
cultured cells (Lecellier et al. 2002) (see above). Interestingly, both VP22 
and Bet are found in the cytoplasm of expressing cells whereas they are 
targeted to the nucleus of cells that received the protein by intercellular 
spreading (Elliott and O'Hare 1997; Lecellier et al. 2002). In both cases, this 
process is not affected by BFA, suggesting that export of VP22 and Bet from 
expressing cells does not involve the ER/Golgi system. 
In the case of HIV-Tat, a region in its primary structure, termed the basic 
transduction domain, appears to enable the protein to traverse membranes 







compartment, in facts, Tat has been demonstrated to be secreted from 
expressing cells, following an ER-Golgi independent pathway as its sequence 
lacks an N-terminal signal peptide necessary for “classical” secretion (Chang 
et al. 1997; Tyagi et al. 2001). 
The use of an alternative pathway of secretion has been suggested to be a 
way to avoid the oxidizing milieu of the ER lumen (Rubartelli et al. 1990). 
Since cysteine residues present in Tat, IL-1β and FGF-2 are essential for 
their bioactivity, the requirement of a reducing milieu for secretion is one of 
the reasons for alternative secretion pathways. Native extracellular Tat is 
biologically active, as found for IL-1β and FGF-2, and can bind heparin, 
through its Tat basic peptide. In vivo HSPG may also exert a protective 
activity and be able to store biologically active Tat. Therefore, the 
understanding of the mechanisms of its release and extracellular fate may 
help in the investigation of new strategies to inhibit its activity. 
Leishmania HASPB 
Another quite remarkable example of non classical protein export from 
eukaryotic cells is the mechanism of cell surface expression of Leishmania 
HASPB (hydrophilic acylated surface protein B) which is found associated 
with the outer leaflet of the plasma membrane only in the infectious stages 
of the parasite lifecycle (Flinn et al. 1994; Pimenta et al. 1994). The protein 
is synthesized on free ribosomes in the cytoplasm and becomes both 
myristoylated and palmitoylated at its N-terminus, which is the molecular 
basis of how HASPB is anchored in the membrane. In the proposed model, 
HASPB is transferred from the cytoplasm to the outer leaflet of the Golgi 
membrane, from where it is transported to the plasma membrane via 
conventional vesicular transport (Denny et al. 2000). This process would 
insert HASPB into the inner leaflet of the plasma membrane. At present it is 
completely unclear how HASPB is then translocated across the membrane, 







plasma membrane. Intriguingly, heterologous expression of various HASPB 
fusion proteins in mammalian cells revealed the existence of a machinery 
that is capable of translocating the protein across the plasma membrane 
(Stegmayer et al. 2005), demonstrating a conserved pathway among lower 
and higher eukaryotes. No endogenous mammalian cargo proteins that 
make use of this type of export system have been yet identified. 
Homeodomain-containing transcription factors and HMG (high mobility 
group) chromatin-binding proteins 
As an additional example of non classical protein export, two classes of 
proteins involved in the overall process of regulated gene transcription have 
been proposed to operate as extracellular factors even though they are 
normally localized to the nucleus of mammalian cells (Joliot et al. 1998; 
Muller et al. 2001). For the transcription factor Engrailed homeoprotein 
isoform 2 (En2), a potential paracrine signaling activity was postulated as a 
subpopulation of En2 has been localized to the cell periphery in caveolae-like 
structures (Joliot et al. 1997) In addition, a small but significant portion of 
total cellular En2 was found to reside in membrane-bound vesicles as judged 
by protease protection experiments (Joliot et al. 1997). Therefore, it was 
reasoned that En2, despite lacking a conventional ER signal peptide, might 
be secreted at a certain rate. This hypothesis was tested experimentally by 
coculturing COS cells expressing the chicken orthologue of En2 (cEn2) with 
rat primary neurons demonstrating intercellular transfer of cEn2 (Joliot et al. 
1998). The internalization of homeodomain-containing proteins apparently 
differs from classical endocytosis, as it seems to occur by direct translocation 
across the plasma membrane.  
About 5% of total cellular En2 becomes externalized by COS cells which is 
about the portion that is also found to be protected against protease 
treatment. An 11-amino acid sequence within the homeodomain of En2 has 







corresponding mutant protein (Joliot et al. 1998). This phenotype correlates 
with the disappearance of the mutant protein from the protease-protecting 
organelle, which probably represents a kind of a secretory compartment. 
While the homeodomain-derived peptide was originally thought to represent 
a signal for non classical export, this view has to be re-evaluated as it might 
only trigger cytoplasmic localization of En2 and may not be required 
afterwards for externalization of En2 (Maizel et al. 1999). 
HMG (High Mobility Group) proteins are intranuclear factors that mediate the 
assembly of site-specific DNA-binding proteins within chromatin (Bianchi and 
Beltrame 2000). As a surprising finding, but similar to the homeodomain-
containing transcription factors described above, HMGB1 is secreted during 
certain physiological processes such as inflammation: specifically, monocytes 
have been shown to export HMGB1 upon stimulation with bacterial 
lipopolysaccharides (Wang et al. 1999). As antibodies against HMGB1 
suppress LPS-induced endotoxemia, and injection of HMGB1 protein into 
mice causes toxic shock, HMGB1 apparently acts as a mediator of endotoxin 
lethality in mice (Wang et al. 1999). Interestingly, HMGB1 export 
competence appears to be a special property of a limited number of cell 
types (such as monocytes and macrophages) as many cell types including 
lymphocytes are not capable of secreting HMGB1 (Wang et al. 1999). Again, 
similar to homeodomain-containing transcription factors, extracellular 
HMGB1 has also been shown to act as both an autocrine and paracrine 
signaling molecule promoting differentiation processes of the HMGB1-
secreting cell or other cells nearby (Passalacqua et al. 1997). 
HMGB1 does not contain a signal peptide for translocation into the ER 
(Muller et al. 2001); similar to IL-1β, FGF-2 and galectin-3, a rise in 
intracellular Ca2+ triggers HMGB1 export (Muller et al. 2001). HMGB1 has 
been observed to redistribute from the nucleus to the cytoplasm upon 
activation of monocytes; a detailed ultrastructural analysis revealed that 







secretion can be triggered by stimuli known to promote lysosomal exocytosis 
(Gardella et al. 2002). However, unlike IL-1β secretion from monocytes, 
HMGB1 release is induced by lysophosphatidylcholine. Moreover, the kinetics 
of IL-1β and HMGB1 release from monocytes differ significantly, with IL-1β 
being secreted early after monocyte activation and HMGB1 at a later stage. 
These results have been taken to indicate that lysosomal exocytosis might 
involve distinct populations of endolysosomal vesicles, thereby allowing 
different kinetics of cargo release (Gardella et al. 2002). 
Cytoplasmic clearance of unfolded proteins by non classical secretion 
The mitochondrial matrix protein Rhodanese, a monomeric sulfotransferase 
that, following synthesis on free ribosomes in the cytoplasm, is normally 
imported into mitochondria represents another unusual example of non 
classical protein export from mammalian cells. When overexpressed in HEK-
293 cells from a strong viral promoter, about 40% of total Rhodanese was 
found to be secreted into the culture medium (Sloan et al. 1994). Export 
was shown to occur in the absence of appreciable amounts of cell death and 
to depend on neither the mitochondrial targeting sequence of Rhodanese 
nor a functional ER/Golgi system (Sloan et al. 1994). Based on the 
observation that Rhodanese acquires its enzymatic activity only after import 
into the mitochondrial matrix (and that the signal peptide cannot be an 
inhibitor of enzymatic activity as it is not cleaved off in the matrix), it was 
concluded that the population present in the cytoplasm remains unfolded 
before import into mitochondria. Therefore, it has been postulated that the 
export pathway detected for Rhodanese represents a mechanism for 
clearing the cytoplasm of unfolded proteins that apparently accumulate upon 
overexpression. More recently, a potentially similar example of cytoplasmic 
clearance of an unfolded protein population possibly generated by 
overexpression has been observed (Tanudji et al. 2002). In this case, an 







Protein) was found to be secreted in a BFA-insensitive manner. This effect 
has not been observed in stable cell lines that express moderate levels of 
GFP in a doxicycline-dependent manner (Engling et al. 2002). However, 
these different observations are not necessarily inconsistent as in the latter 
case an unfolded population of GFP is unlikely to exist. Interestingly, 
methylamine and other drugs known to inhibit non classical export of 
substrates such as IL-1β, FGF-2, thioredoxin, and the galectins (see above) 
do not block externalization of Rhodanese or unfolded GFP, again suggesting 
the existence of distinct molecular mechanisms of unconventional protein 
secretion. 
Non classical secretion in yeast. 
Yeast cells have a thick wall that maintains cell shape, protects against 
osmotic stress and requires modification for cell growth. Covalently linked 
cell-wall proteins carry the typical N-terminal signal peptide that drives their 
export; moreover, several proteins carrying an N-terminal secretion signal 
peptide, upon release from the plasma membrane, are presumably trapped 
in the cell wall at some stage. 
However, the evidence accumulated during the past decade using the 
current yeast models, clearly shows that many proteins that lack an N-
terminal signal peptide also reach the cell surface. 
In particular, C. albicans and S. cerevisiae share 11 signal-less proteins in 
common; a further 26 have been described only in the former, compared to 
five identified in the latter yeast species only. Many of the surface proteins 
lacking the N-terminal signal peptide are also found in the cytoplasm, where 








Table 1.2 : N-terminal secretion-signal-less proteins detected at 
the cell surface of Candida albicans and Saccharomyces cerevisiae 








The available evidence indicates that signal-less proteins are targeted 
outside the membrane as a result of alternative secretion processes that are 
not based on the canonical secretion-signal peptide.  
The extracellular presence of several members of at least three groups of 
proteins with different functions has been characterized: 
- a first group consists of enzymes involved in glycolysis; 
- a second group consists of heat-shock proteins with the capacity to 
function as chaperones; 
- a third group consists of translation elongation factors, i.e. proteins that 
interact with complexes of other proteins and RNA. 
The presence of so many non-conventional proteins at the yeast cell surface 
demands experimental proof that these proteins have the capacity to target 
the external medium; indeed, this has been confirmed in some cases. 
As proteins belonging to all the three groups have been described as 
important components of microbial virulence of several distinct bacteria and 
microorganisms, the connection between non-conventional surface proteins 
with microbial virulence reinforces the interest in the phenomenon of 
alternative secretion.  
 
 
Fig. 1.26 : potential routes of non conventional secretion in yeast 







Given the diversity of non-conventional cell-surface proteins in yeast, several 
possibilities for the release of these proteins have been proposed (Fig. 
1.26). 
Targeting motifs and regulation of non classical protein export 
In many cases of intracellular protein sorting, short, linear amino acid 
sequences have been identified that serve as sorting motifs, including N-
terminal signal peptides for ER translocation and the N-terminal targeting 
signals of mitochondrial proteins (Schatz and Dobberstein 1996). Currently, 
very limited information is available about motifs directing proteins to the 
various pathways of unconventional protein secretion described above. The 
most defined one is that of Leishmania HASPB, which consists of a linear 
sequence of 18 amino acids at the extreme N-terminus referred to as 
HASPB-N18 (Denny et al. 2000). This sequence is both necessary and 
sufficient to direct a corresponding fusion protein to the HASPB export 
pathway in both parasites and mammalian cells. The most recent studies 
suggest that acylation might only be required to initially insert the protein 
into the membrane, and that the translocation that follows requires an 
interaction of the proteinaceous part of HASPB-N18 with the putative export 
machinery. Based on these characteristics, the HASPB export pathway 
appears to be unrelated to all other previously described examples of non 
classical protein export. As the pathway is functional in mammalian cells, 
endogenous substrates are likely to exist. However, the 18-amino acid 
sequence found at the N-terminus of HASPB is not only absent from other 
secretory proteins exported by unconventional means but is also not found 
in any mammalian protein. 
Similar to Leishmania HASPB, the N-terminus of galectin-3 has been 
proposed to contain targeting information for non classical export (Menon 
and Hughes 1999). When the first 120 amino acids of galectin-3 are deleted, 







of this N-terminal segment to a cytosolic protein directs the corresponding 
fusion protein to the galectin-3 export pathway. A short sequence 
comprising residues 89–96 (based on the hamster amino acid sequence) 
was identified that, upon deletion, impairs galectin-3 export. However, the 
addition of this small peptide to a cytosolic protein is not sufficient to direct 
the resulting fusion protein to the galectin-3 export pathway suggesting 
that, besides the critical role of this short segment, other determinants for 
non classical export exist in the N-terminal part of galectin-3 (Menon and 
Hughes 1999). When compared to the galectin-1 amino acid sequence, no 
significant homologies can be found within the N-terminal 120 amino acids 
between the two proteins. 
In contrast to HASPB and galectin-3, the C-terminal half of FGF-1 has been 
implicated in its temperature- and stress-induced release (Shi et al. 1997). A 
domain comprising a stretch of amino acids from position 83–154 (based on 
the human FGF-1 orthologue) appears to prevent the protein from entering 
the nucleus, a step which has been suggested to be a prerequisite for 
unconventional export. When such domain was substituted with the 
corresponding C-terminal domain of FGF-2, however, secretion of the 
resulting hybrid protein was no longer observed. These data have been 
taken to mean that FGF-1 and FGF-2 are exported by distinct pathways (Shi 
et al. 1997), which is consistent with the observation that only FGF-1 release 
can be triggered by temperature stress. The actual targeting motifs for non 
classical export have not been revealed for either FGF-1 or FGF-2. 
For the homeodomain-containing transcription factor En2, it has been 
suggested that an 11-amino acid motif within the homeodomain may 
function as a signal for non classical export  (Joliot et al. 1998). As discussed 
above, this sequence was later found to be part of a nuclear export signal 
suggesting that nuclear export of En2 is a prerequisite for its unconventional 
secretion. At this point, it is not clear whether this segment of En2 (residues 







this domain regulates access of En2 to its export pathway. In either case, 
the information for En2 export must lie within the En2 homeodomain, as this 
part of the protein alone is an efficient substrate for intercellular transfer.  
Similar to En2 export, many of the proteins described here are exported in a 
regulated fashion. For example, IL-1β and HMGB1 can be released from 
monocytes upon stimulation with reagents that induce an inflammatory 
response (Rubartelli et al. 1990; Muller et al. 2001). At the same time, En2, 
IL-1β and HMGB1 are those factors among unconventionally secreted 
proteins that appear to be exported from an endosomal subcompartment 
(Joliot et al. 1998; Andrei et al. 1999; Gardella et al. 2002), which might be 
interpreted as some kind of storage mechanism from which regulated 
secretion of these factors can be triggered. On the other hand, as discussed 
above, non classical export of FGF-1 and galectin-1 are also regulated 
inducible processes, yet there is no evidence that these factors are packaged 
into intracellular vesicles prior to secretion. The export process of galectin-1 
has been shown to be regulated based on cell differentiation (Lutomski et al. 
1997). Similarly, FGF-2 export has recently been shown to be triggered by 
the expression of the Epstein–Barr virus (EBV) protein LMP-1 (Wakisaka et 
al. 2002). This mechanism requires a functional NF-κB signaling pathway, 
possibly indicating that LMP-1-mediated stimulation of FGF-2 export involves 
the induction of a protein machinery based on de novo synthesis. 
As illustrated in Fig. 1.27, at least four distinct pathways of unconventional 
protein secretion may exist in mammalian cells that are fully functional in 
the absence of an intact ER/Golgi system. These pathways are in general 
attractive targets, because it may be possible to identify inhibitors that do 
not interfere with the essential function of the classical secretory pathway.  
However, a biochemical analysis of the molecular machineries of non 
classical protein export has proven difficult because in many cases the 









Fig. 1.27: proposed mechanism for non classical protein secretion 
(Nickel and Rabouille 2009) 
 
 
In particular, it is not yet clear (with the noticeable exception of FGF-2 
(Backhaus et al. 2004)) whether unfolding of the various cargo proteins is 
required for unconventional secretion and whether the non classical 
pathways of secretion could have a quality control machinery for secreted 
proteins. In the case of the classical secretory pathway, quality control 
occurs at the level of the ER in that secretory proteins not being folded 
properly do not have access to transport vesicle-mediated exit form this 
compartment (see above) and are targeted for degradation. For FGF-2 and 
HASPB, whose export mechanisms seem to rely on plasma membrane 
resident transporters (see above), it is likely that protein translocation is in 
some way coupled to a mechanism that ensures the secretion of properly 
folded protein. Evidence comes from experiments using FGF-2 fusion 
proteins with dihydrofolate-reductase (DHFR); aminopterine-mediated 
conformation stabilization of FGF2-DHFR did not have any impact on export 
efficiency suggesting that FGF-2 membrane translocation does not occur in 
an unfolded state (Backhaus et al. 2004). Moreover, very recently, Torrado 







conformation is necessary for FGF-2 to interact with PI(4,5)P2 which 
constitutes the first step leading to membrane translocation (see above); 
thus, at least for FGF-2, the existence of an intrinsic quality control 
mechanism which ensures secretion of the protein in a properly folded 
conformation can be hypothesized. 
Caspase-1: a common regulator of unconventional protein secretion? 
Until very recently, a common regulator involved in the secretion process of 
multiple proteins was lacking; however, in 2008, the work of Keller et al. 
(Keller et al. 2008) reported that active caspase-1 might be involved as a 
regulator in the unconventional secretion of several proteins, including IL-
1β, IL-1α , thioredoxin, and FGF-2. 
Caspase-1 has a well-established function in inflammation via the activation 
of proinflammatory cytokines (Dinarello 1998). In addition, it has been 
reported to mediate either cell death (Cookson and Brennan 2001) or 
survival (Gurcel et al. 2006) upon infection by certain pathogens. The 
authors found that activation of caspase-1 by inflammasome complexes is 
directly linked to unconventional secretion of a variety of leaderless proteins, 
most likely via a direct or indirect physical interaction. 
 
 
Fig. 1.28: proposed role for caspase-1 in the secretion of 








Interestingly, many of the proteins that are secreted in a caspase-1-
dependent manner are involved in inflammation, cytoprotection, and/or 
tissue repair. Therefore, activation of caspase-1 by various environmental 
challenges, e.g., UV radiation, infection, or wounding, seems to be coupled 
to the release of proteins, which might help to restore the cell and tissue 
homeostasis. Following this intriguing hypothesis, caspase activation would 
not only induce inflammation via secretion of proinflammatory cytokines, but 
also regulate the extracellular levels of proteins involved in tissue repair and 
cytoprotection. Therefore, it may provide a direct link between inflammation 
and regenerative processes. 
Emerging roles of GRASP proteins 
GRASP proteins associate with the Golgi apparatus and have been implicated 
in the stacking of Golgi cisternae, vesicle tethering, and mitotic progression, 
however their specific functions are unclear. 
Recently, GRASP function has been studied in Dictyostelium discoideum - 
which has a single GRASP homolog GrpA – by targeted gene disruption, 
revealing that a GrpA-deficient strain grows at wild-type rates and exhibits 
normal trafficking of several secretory and lysosomal proteins (Kinseth et al. 
2007). However, despite the Golgi gross structure, as seen by fluorescent 
microscopy, is unperturbed in GrpA-deficient cells, these cells are defective 
in producing viable spores. This defect was traced back to a strong block in 
secretion of the acyl-CoA binding protein AcbA, which is cleaved outside the 
cell to produce a spore differentiation factor. AcbA lacks a conventional 
secretory signal sequence and, in GrpA-deficient cells, accumulates in the 
cytoplasm. Therefore, at least in Dictyostelium, GRASP is not generally 
required for the activity of the Golgi in conventional secretion but, instead, is 
required for an unconventional secretory pathway. This new twist on GRASP 
function may open new views and investigations on the role of GrpA 







In a possible scenario, AcbA is transported from the cytosol into the internal 
vesicles of endosomal multivesicular bodies (MVBs), which subsequently fuse 
with the plasma membrane to release the internal vesicles as exosomes. 
GrpA would be needed at some stage of this process: (Figure 1A) GrpA may 
shuttle between the Golgi and the plasma membrane and operate as part of 
the MVB fusion machinery; in this model, GRASPs act as a go-between to 
coordinate the activities of the conventional and unconventional secretory 
pathways. In the second model (Figure 1B), GrpA operates exclusively at the 
Golgi and is selectively required for the biosynthetic transport of a plasma 
membrane component of the MVB fusion machinery. Hence, further insight 
into Dictyostelium sporulation may illuminate the role of GRASPs in protein 
transport. 
Of course, variations on these models can be envisioned. For example, GrpA 
function might be required at the step of AcbA internalization into MVBs or 
for an unconventional secretory pathway that is independent of MVBs. 
Regardless, the elegant work of Kinseth et al. (2007) has revealed a 
surprising link between conventional and unconventional secretion. 
 
 








Interestingly, the D. melanogaster GRASP protein has been recently shown 
to be required for the unconventional secretion of integral plasma 
membrane α integrins (Schotman et al. 2008), a signal-peptide-containing 
protein, requiring specific spatially restricted deposition for membranes to 
undergo remodeling. At the membrane, α integrins induce the formation of 
new focal adhesion sites that are required for epithelium integrity. 
In a D. melanogaster GRASP mutant, however, the α integrin (but not the β 
integrin) subunits are not properly deposited at the plasma membrane. 
Instead, they are retained intracellularly and, as a result, the epithelium is 
disrupted, suggesting the existence of a GRASP-dependent secretory route 
that is specific for α integrin. Furthermore, this route bypasses the Golgi 
complex as it is not sensitive to BFA and is fully functional in the absence of 
syntaxin 5. Of note, the Golgi-independent transport of α integrins only 
occurs during epithelium remodeling, while under all other conditions, α and 
β integrins are transported as heterodimers through the conventional 
secretory pathway (Schotman et al. 2008). Why α integrin transport 
switches from conventional to non-conventional mechanisms during 
epithelium remodeling is currently not understood. 
Although this transport process is clearly different from AcbA secretion, 
GRASP might have a similar role to GrpA, for example, acting as a plasma 
membrane-resident tethering factor for ER-derived carriers that are enriched 
in α integrins or bind to α integrin tails in the ER, or could be involved in the 
sorting or chaperoning of a fusion factor to the plasma membrane, thereby 
mediating the fusion of late endosomes or the deposition of integrins at the 
plasma membrane. GRASP could also have a common role in the 
unconventional delivery of  integrins to the plasma membrane and in the 
release of AcbA into the extra cellular space, similarly to the proposed role 
for GrpA in tethering AcbA enriched endosomes (Fig. 1.30). 
The underlying mechanisms driving GRASP anchoring at the plasma 







compartment, eventual homologous functions of mammalian GRASPs, 
remain to be elucidated. 
 
 
Fig. 1.30: proposed role for GRASP in unconventional secretion 
(Nickel and Rabouille 2009) 
 
 
Unconventional secretion and evolution: integrating complex functions 
The maintenance of organ homeostasis and the control of an appropriate 
response to environmental alterations require the intimate coordination of 
cellular functions and tissue organization. Recently, it has become clear that 
an important component of this coordination is provided by proteins that can 
have distinct but linked functions on both sides of the plasma membrane. 
These proteins often transit the plasma membrane by mechanisms that are 
distinct from the classical ER-Golgi secretory process, and their 
multifunctionality is puzzling - why should a protein with a well-known 
function in one context function in such a distinct way in another? One 
proposed reason for this is so that the protein can coordinate the 
organization and maintenance of a global tissue function (Radisky et al. 







separated by the physical barrier of the membrane, their dual roles might 
coordinate a single tissue function and thus be equally important in an 
integrated overall purpose.  
Although not all of the proteins that are released by unconventional 
secretion have distinct but linked functions, unconventional mechanisms of 
secretion might be important in enabling dual but integrated functionality for 
single proteins: in some cases, an alternative secretion pathway might be 
required when transport through the ER-Golgi results in protein 
modifications that interfere with the extracellular function of a protein, as it 
has been shown for FGF-2 (Wegehingel et al. 2008).  
Moreover, the lack of an exocytosis signal sequence and the use of 
unconventional secretory pathways by proteins that have paired functions 
allow for greater flexibility in compartmental distribution: whereas the 
presence of a strong exocytosis signal in the protein would require 
extraordinary mechanisms by the cell to retain the protein, unconventional 
pathways might allow for flexible and dynamic regulation of protein 
localization in response to various internal and external stimuli, and thus 
might facilitate more intimate linkage of intracellular and extracellular 
functions. 
Speculatively, it has been hypothesized (Radisky et al. 2009) that 
unconventional secretion mechanisms might have developed early in 
evolution, before the formation of the ER–Golgi pathway. For these early 
cells, it would have been crucial to coordinate cellular function with 
intercellular communication. These mechanisms might have been retained 
because they allow for rapid connection between diverse processes. 
Na+,K+-ATPase structure, functions and regulation 
Na+,K+-ATPase (Na-pump) is an enzyme embedded in the plasma 







transfer through the membrane against the electrochemical gradient, in 
accord with the following equation: 
ATP + 3Nain
+ + 2Kout









Thus, Na+,K+-ATPase, which is present in all animal cells, performs the 
electrogenic exchange of intracellular Na+ for extracellular K+. 
The Na+,K+-ATPase is a member of the family of P-type ATPases; other ion 
pumps that transport biologically significant cations (gastric mucosa H, K-
ATPase, Ca-ATPases of plasma membrane and sarco (endo) plasmic 
reticulum (SERCA ATPases)), H-ATPases from fungi and plants, and some 
ATPases of prokaryotes are also members of the P-type ATPase family 
(Moller et al. 1996). 
Discovered more than 40 years ago, the Na+,K+-ATPase continues to attract 
the attention of the researchers today. However, whereas soon after the 
discovery of this enzyme most efforts were directed toward the study of the 
structure and function of the enzyme, more attention is now given to the 
problem of its regulation.  
Na+,K+-ATPase structure 
The Na+,K+-ATPase consists of two polypeptide chains: the catalytic alpha-
subunit and the beta-subunit, which is a glycoprotein that does not 
participate in the catalysis directly. The molecular masses of the alpha- and 
beta-subunit are 110 and 55 kD, respectively. Both subunits are integral 
membrane proteins and are bound to each other by noncovalent 
interactions: in purified preparations of Na+,K+-ATPase they are present in 
molar ratio 1 : 1. 
The crystal structure of the pig renal Na+,K+-ATPase has been recently 
elucidated (Morth et al. 2007). The polypeptide chain of the Na+,K+-ATPase 







alpha-helical segments; the N- and C-termini of the chain are located in the 
cytosol. Most amino acid residues are also located inside the cell forming a 
large cytoplasmic domain; significantly less of the alpha-subunit polypeptide 
chain is exposed outside the cell (Fig. 1.31). 
 
 
Fig. 1.31: proposed 3D-structure and membrane topology of the 
plasmalemmal Na+,K+-ATPase, deducted from X-ray analysis (Morth 
et al. 2007) 
 
 
The transmembrane segments embedded in the membrane are in a close 
proximity and appear to participate in the formation of the channel through 







ATPase disclosed a structure very similar to  the sarcoplasmic Ca-ATPase 
(Toyoshima et al. 2000), a protein closely related to the Na+,K+-ATPase 
alpha-subunit (the homology in amino acid sequence is only about 20%, but 
hydropathy profiles and apparent three-dimensional structure are very 
similar).  
The polypeptide chain of the beta-subunit crosses the membrane only once 
(Kirley 1989); a small N-terminal segment of the chain is located in the 
cytoplasm, whereas most of the subunit is located outside the cell (see 
review (Therien and Blostein 2000)). Amino acid residues located on the 
extracellular part of the protein in close proximity to the C-terminal fragment 
of the beta-subunit appear to participate in the association of the beta-
subunit with the alpha-subunit (Beggah et al. 1993), as does its 
transmembrane fragment, which interacts with transmembrane fragments 9-
10 of the alpha-subunit  (Sarvazyan et al. 1995). 
There are numerous experimental data demonstrating that membrane 
Na+,K+-ATPase is an oligomer (most likely an asymmetric tetramer (Askari 
2000)) consisting of 2-4 alphabeta-protomers. Both negative (Askari 2000) 
and positive (Therien and Blostein 2000) cooperative interactions are 
characteristic for this structure.  
The formation of oligomeric complexes of Na+,K+-ATPase is due to the 
interaction between the alpha-subunits of the enzyme. A peptide containing 
about 150 amino acid residues and located within the large cytoplasmic 
domain (Pro561-Gln709) appears to play a significant role in the process of 
association of alpha-subunits (Koster et al. 1995). Solubilized non-denatured 
Na+,K+-ATPase is a mixture of associating-dissociating protomers, the 
relative amount of which depends on protein and ligand concentrations. 
However, there is evidence showing that the lipid bilayer in which enzyme is 
embedded and the interaction with protein-partners control the interactions 








Fig. 1.32: proposed arrangement of the different subunit in the 
Na+,K+-ATPase oligomers (Donnet et al. 2001)  
 
 
Na+,K+-ATPase functions and regulation 
The regulation of Na+,K+-ATPase attracts attention because of the significant 
and various roles played by the pump in the functioning of different tissues. 
Na+,K+-ATPase creates a gradient of Na+ and K+ concentrations that is used 
in different ways in different tissues. The density of Na+,K+-ATPase in the 
cellular plasma membrane differs in different tissues: it varies from several 
molecules per square micrometer in erythrocytes to several thousands 
molecules per square micrometer in nephron epithelium or in the cells of 
excitable tissues. In all animal cells, Na+,K+-ATPase participates in the 
creation of resting membrane potential and in the maintenance and 
regulation of cell volume (Kabakov 1994). However, Na+,K+-ATPase also 







Na+,K+-ATPase plays a significant role in the maintenance of ion conductivity 
in excitable tissues (neurons and muscle tissues), while a Na-gradient is 
used in many tissues to provide the activity of different ion-exchange 
transport systems. The increase of intracellular Na+ concentration results in 
activation of Na+/Ca2+ exchanger (NCX) that is embedded in the plasma 
membrane of different cells including neurons and cardiac and smooth 
muscle (Moore et al. 1993).  
In the kidney, Na+,K+-ATPase is located in the basolateral membrane of 
collecting duct epithelial cells and accomplishes Na+ transports from the cell 
to the extracellular medium (Nelson and Veshnock 1987).  
Na+ concentration gradient is used in other tissues to accomplish transport 
of some metabolites (sugars, amino acids) into the cell. Inhibition of Na+,K+-
ATPase and dissipation of the Na+ concentration gradient results in a 
decreased rate of amino acid transport into the cell, and this in turn may 
lead to inhibition of cell growth. 
The idea of the existence of different functions of Na+,K+-ATPase depending 
on tissue type is supported by the discovery of Na+,K+-ATPase isoenzymes. 
Four isoforms of the alpha-subunit (Alpha1, alpha2, alpha3, and alpha4) and 
three isoforms of the beta-subunit (beta1, beta2, and beta3) encoded by 
different genes are found in vertebrates; these subunits may associate into 
alphabeta-dimers in different combinations, resulting in isoenzymes with 
different kinetic properties and different patterns of distribution in various 
tissues and within each tissue during ontogenesis (Blanco et al. 1995; 
Mobasheri et al. 2000). The expression of the various isoforms is under the 
control of various hormones (Mobasheri et al. 2000). 
The Alpha1-isoform of Na+,K+-ATPase is the predominant form in kidney, 
where especially fine regulation of Na+,K+-ATPase activity is required. This 
isoform, also present in other tissues including heart, skeletal muscle, and 
neurons, can be phosphorylated by cAMP-dependent (PKA) (Kurihara et al. 







et al. 1999), Ca-phospholipid-dependent (PKC) protein kinase (Yudowski et 
al. 2000), and by tyrosine kinases of the Src family (Feraille et al. 1999). 
Numerous attempts to find how PKA-mediated phosphorylation of Na+,K+-
ATPase in vitro affects the enzyme activity gave controversial results: most 
probably, the effect of Na+,K+-ATPase phosphorylation by PKA depends on 
the type of alpha-isoform that is phosphorylated. 
When Na+,K+-ATPase is phosphorylated by tyrosine kinases Pi is bound to 
Tyr10 of rat Na+,K+-ATPase alpha-subunit (Feraille et al. 1999). 
Phosphorylation of Tyr10 in Na+,K+-ATPase alpha-subunit in kidney 
nephrons is induced by insulin and is accompanied by an increase of Na+,K+-
ATPase activity.  
PKC phosphorylates Na+,K+-ATPase too, Pi being bound to two serine 
residues located in the N-terminal part of the Alpha1-subunit: Ser11 and 
Ser18 (Feschenko and Sweadner 1995; Feschenko and Sweadner 1997). 
The phosphorylation of Na+,K+-ATPase by PKC may be a signal for endo- 
and exocytosis: the phosphorylation of Ser18 leads in some species to 
endocytosis and combined phosphorylation of Ser11 and Ser18 to 
exocytosis. 
The phosphorylation of Na+,K+-ATPase by PKC demonstrates that Na+,K+-
ATPase is able to perceive signals that are usually transmitted in the cell 
with the participation of cell proteins containing different conserved domains 
like the SH2- or SH3-domain, the plekstrin domain, and some others. Such 
interactions of proteins inside cells are now considered one of the important 
routes of signal transduction (Pawson 1995).  
Na+,K+-ATPase interaction with other proteins 
Regulation of Na+,K+-ATPase via interactions with different protein-partners 
is still not well enough studied; the growing list of proteins for which 







described includes also the beta- and gamma-subunits of Na+,K+-ATPase 
and the cytoskeleton protein ankyrin. 
A beta subunit is part of the Na+, K+- and H+,K+-ATPases but is not included 
in other P-type ATPases, for example, in Ca-ATPase of both plasma 
membrane and sarcoplasmic reticulum. The sensitivity of Na+,K+-ATPase to 
the cations Na+ and K+ is known to change depending on the isoform of the 
beta-subunit included in the alpha-beta complex, because the beta-subunit 
affects the activation of Na+,K+-ATPase by extracellular K+ (Jaisser et al. 
1992). This subunit does not participate in the process of catalysis directly, 
nevertheless is tightly bound to the alpha-subunit and is required for the 
insertion of the catalytic subunit into the membrane and the delivery of both 
subunits to the plasma membrane (Lutsenko and Kaplan 1992). However, it 
appears that the role of the beta-subunit is not limited to these functions.  
A known partner for the Na+,K+-ATPase alpha-subunit is ankyrin  (Devarajan 
et al. 1994). Ankyrins compose a family of proteins that are linkers between 
the integral membrane proteins and the proteins of cytoskeleton (spectrin 
and fodrin fibrils). Different isoforms of ankyrins are present in different 
tissues. They differ also depending on the type of membrane to which the 
cytoskeleton is attached. One domain binds ankyrin to integral membrane 
proteins, another to spectrin (fodrin), and the third domain is a regulatory 
domain.  
Melittin, a bee venom peptide consisting of 26 amino acid residues and 
forming amphipatic alpha-helix with positive charge concentrated on the C-
terminal region also interacts with the Na+,K+-ATPase, in addition to 
numerous other proteins, and with negatively charged lipid bilayers. The 
interaction between melittin and the ATPase involves sites located in the 
catalytic subunit of the enzyme (Cuppoletti and Malinowska 1992). This 
suggests that the site of melittin binding is a binding site of some 
intracellular proteins, and melittin imitates a module of these proteins that 







Na+,K+-ATPase and cardiac glycosides 
Cardiac glycosides, specific inhibitors of Na+,K+-ATPase, are steroid O-
glycosides containing in position 17 an unsaturated ring: gamma-lactone 
with 5 carbon atoms (cardenolides) or sigma-lactone with 6 carbon atoms 
(bufadienolides). A hydrocarbon chain located in 3beta-position usually 
consists of 1-5 monosaccharides. Digoxin and ouabain, substances of plant 
origin, are well known members of this group. These compounds were first 
used for treatment of cardiac failure more than 200 years ago because at 
low (nontoxic) concentrations they improve the function of cardiac muscle 
(so-called positive inotropic effect). 
According to modern understanding, the mechanism of the effect of cardiac 
glycosides on cardiac muscle contraction is the following: partial inhibition of 
Na+,K+-ATPase by these compounds leads to some increase of intracellular 
Na+ concentration that in turn activates Na+/Ca2+ exchanger. The 
consequence of this is a significant increase of intracellular Ca2+ 
concentration and increase of cardiac muscle contractility.  
The site of cardiac glycoside binding is located on the extracellular part of 
the Na+,K+-ATPase alpha-subunit (Lingrel et al. 1994). Sensitivity to these 
inhibitors differs depending on animal species (minimal sensitivity is 
characteristic for the enzyme from rat (Emanuel et al. 1988)) and on the 
type of alpha-subunit isoform that is present in the Na+,K+-ATPase (for the 
enzyme obtained from one animal species inhibition of Na+,K+-ATPase 
containing Alpha1-isoform is 500-1000-fold higher than for the enzyme 
containing alpha2-isoform). This is mainly connected with the substitution of 
certain amino acids in the ouabain-binding site of the Na+,K+-ATPase alpha-
subunit. 
The study of these substances of plant origin specifically affecting the 
activity of an important animal cell enzyme lead to the discovery that 
animals posses endogenous digitalis (ouabain)-like factors that can 







like factors identified as isomers of ouabain were found in the hypothalamus 
and adrenocortical glands (Doris 1994).  
Na+,K+-ATPase signaling functions 
It is nowadays accepted that, in addition to pumping ions, Na+-K+-ATPase is 
engaged in assembly of multiple protein complexes that transmit signals to 
different intracellular compartments (Xie and Askari 2002).  
 
 
Fig. 1.33 : the “signalosome” assembled at the sites of ouabain-
Alpha1 interaction (Xie and Cai 2003) 
 
 
In some cell types, the signaling Na+,K+-ATPase and its protein partners are 
compartmentalized in coated pits (i.e., caveolae) in the plasma membrane, 
where the  clustering of the pump facilitates ouabain-activated signal 
transduction (Xie and Askari 2002; Liu et al. 2003; Liu et al. 2004b). 
Cholesterol depletion leads to a reduction of ouabain-induced recruitment of 







induced activation of ERKs. Clearly, the caveolar Na+,K+-ATPase represents 
the signaling pool of the pump that transmits ouabain hormonal signals 
(Wang et al. 2004). 
Binding of ouabain to the signaling Na+,K+-ATPase activates the cytoplasmic 
tyrosine kinase Src, resulting in the formation of an active "binary receptor" 
that phosphorylates and assembles other proteins into different signaling 
modules. This in turn activates multiple protein kinase cascades including 
mitogen-activated protein kinases and protein kinase C isozymes in a cell-
specific manner. It also increases mitochondrial production of reactive 
oxygen species (ROS) and regulates intracellular calcium concentration. 
Crosstalk among the activated pathways eventually results in changes in the 
expression of a number of genes. Although ouabain stimulates hypertrophic 
growth in cardiac myocytes and proliferation in smooth muscle cells, it also 
induces apoptosis in many malignant cells. The signaling function of the 
enzyme is also pivotal to ouabain-induced nongenomic effects on cardiac 
myocytes.  
Finally, it has been demonstrated that ouabain induces endocytosis of 
plasmallemal Na, K-ATP ase by a clathrin dependent mechanism that 
translocates it to intracellular compartments (Liu et al. 2004a), thus 
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MATERIALS AND METHODS 
Plasmid constructs 
Constructs expressing HSV-TK, alone or as a fusion protein with Tat11 
(Tat11-TK) or Tat86 (Tat86-TK) in the eukaryotic expression vector pCDNA3 
(Invitrogen, Carlsbad, CA) were a kind gift of Dr. E. Tasciotti (Tasciotti et al. 
2003); the starting construct was the prokaryotic vector pGEX-2T 
(Pharmacia, Uppsala, Sweden) containing Tat as a fusion protein with the 
glutathione-S-transferase (GST) and the Green Fluorescent Protein (GFP) 
(GST-Tat-GFP), with Tat inserted between BamHI and HindIII sites, and GFP 
inserted between HindIII and EcoRI. From this plasmid, GFP was replaced 
with TK obtained by PCR amplification with primers containing BamHI and 
EcoRI sites at their extremities, producing pGEX-Tat86-TK. In this plasmid, 
Tat86 was replaced with Tat11 (aa sequence YGRKKRRQRRR, preceded by 
an initiator methionine) produced as a pair of complementary 
oligonucleotides with flanking BamHI and HindIII sites. Plasmid pGEX-TK 
was obtained by substituting the Tat86-GFP cassette with a PCR product 
corresponding to TK with flanking HindIII and EcoRI sites. To obtain the 
pCDNA3 versions of these two constructs, the Tat11-TK and TK cassettes 
were excised with BamHI and EcoRI and cloned into the respective sites of 
the vector. Tat11-CRE expressing vector was a gift of Dr. E. Tasciotti 
(ICGEB, Trieste).  
The rat Alpha1 subunit cds was obtained by PCR amplification from a 
construct expressing the above cds in the eukaryotic vector pCB6 (Brewer 
and Roth 1991) (a gift from Prof. Levenson, Penn State College of Medicine, 
Hershey, PA); briefly, the upper primer, spanning the ATG of the protein, 
contained a BamHI restriction site, while the lower, spanning the stop 
codon, contained a site for HindIII; the amplicon was then cloned in 
pCDNA3 expression vector and sequenced.  
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A rat Alpha1 point mutant (D716N), lacking catalytic activity, had been 
already described (Lane et al. 1993); briefly, the point missense mutation 
(GA) at nucleotide position 2447 (leading to the substitution of the Asp at 
position 716 with Asn, in the third, large cytoplasmic loop of the protein) 
was introduced by two-step PCR mediated mutagenesis, using PCR primers 
carrying the designed substitution; the second step was performed using the 
same primers described for the deletion mutants. The amplicon was then 
digested with HindIII and NotI, and cloned in pCDNA3. Alpha1 ∆CTERM 
lacks the fragment spanning aminoacids 784-3040 (comprising the last two 
C-terminal cytoplasmic fragments as well as a transmembrane region 
between them); lower primer was designed containing a nonsense mutation 
(i.e. a STOP codon) at aminoacid position 784 (correspondent to nucleotide 
2352) and the restriction site for NotI. The truncated cds of rat Alpha1 was 
amplified from the pCDNA3-Alpha1 vector with these primers and upper 
primer, containing the site for HindIII.  
Alpha1 deletion mutant was cloned in pCDNA3 vector between HindIII and 
NotI sites.  
FLAG epitope was inserted as follows: complementary oligonucleotides 
encoding the FLAG sequence lacking the ATG were designed, annealed, and 
the resulting dsDNA was cloned into the Alpha1 mutant vectors (as well as 
the pCDNA3 vector encoding the wild type Alpha1) between the NotI and 
BamHI sites, resulting in vectors expressing wild type, catalytic mutant or 
deletion mutant Alpha1 proteins tagged with the FLAG epitope at the C-
terminus (named respectively pCDNA3-Alpha1-FLAG, pCDNA3-Alpha1 
∆CTERM FLAG, and pCDNA3-Alpha1 D716N-FLAG). 
Constructs expressing either Tat86- or Tat11-GFP in pCDNA3 have been 
described elsewhere (Fittipaldi et al. 2003); a construct expressing Tat86 
protein mutated in its basic region, referred to as Tat86 Basic Mutant, in the 
eukaryotic vector pCDNA3, was a gift from M.I. Gutierrez (Mitola et al. 
2000); the three constructs, expressing the larger cytoplasmic regions of rat 
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Alpha1 subunit of Na+,K+-ATPase, as fusion proteins with GST in the 
prokaryotic vector pGEX1T (Pharmacia, Uppsala, Sweden) were a gift from 
Prof. P. Devarajan (Devarajan et al. 1994); the construct encoding a single 
chain Ig tagged with the SV5 peptide (Sc-VHD16-SV5), in the eukaryotic 
vector pCDNA3, was a kind gift of Prof. O. Burrone (Sepulveda et al. 2003);  
The pAlpha1-CFP construct (where Alpha1 is fused to Cyan Fluorescent 
Protein, CFP) was obtained as follows: the Alpha1 CDS was amplified from 
the pCDNA3-Alpha1 construct and cloned in pECFP-N1 vector (Clontech, 
Mountain View, CA) between BamHI and EcoRI sites; pYFP-Tat11 construct 
(where Tat11 is fused to Yellow Fluorescent Protein, YFP) was obtained by 
annealing of two oligonucleotides encoding for the Tat11 sequence, followed 
by their cloning into the pEYP-C1 vector (Clontech, Mountain View, CA) 
between the BamHI and the EcoRI sites; pCDNA3-Tat86-YFP construct was 
obtained from pCDNA3-Tat86-GFP construct, by substitution of the EGFP 
cassette in the starting pGEX-Tat86-GFP construct with the YFP form the 
pEYP-N1 vector (Clontech, Mountain View, CA); the resulting Tat86-YFP 
cassette was then cloned in pCDNA3 between BamHI and EcoRI sites. 
A sequence corresponding to the fusion of the three C-terminal cytoplasmic 
peptides of the Alpha1 subunit, linked by a glycine residue, named P1-P2-
P3, was obtained by annealing of two oligos collectively encompassing the 
whole region, followed by PCR amplification of the fragments using external 
primers containing restriction sites in order to allow cloning. 
The P1-P2-P3 fragment was then cloned in pFLAG-CMV2 vector, between 
NotI and EcoRI sites, obtaining the pFLAG-P1-P2-P3 construct, and in the 
pGEX-2T vector, between HindIII and EcoRI sites, obtaining the pGEX-P1-
P2-P3 construct. 
Recombinant fusion proteins 
The recombinant fusion protein representing GST-Tat, GST, and respectively 
Alpha1 cytoplasmic fragment 1, 2 and 3, and P1-P2-P3 fused to GST were 
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produced and purified from BL21 bacteria transformed with the 
corresponding vectors. Bacterial cultures were grown in terrific broth + 
ampicillin and protein production was induced with IPTG 0.5 mM for 3 hours 
at 30°C with OD600 between 0.6 and 0.8. Bacteria were then resuspended 
in lysis buffer (50 mM Tris-HCl pH 8.0, 100 mM NaCl, 5% glycerol, 2 mM 
dithiothreitol) and sonicated by 4 pulses of 30 seconds each. Bacterial 
lysates were mixed with 50% (vol/vol) slurry of glutathione cross-linked 
agarose beads and the GST-fusion proteins were allowed to bind the beads 
at 4°C on a rotating wheel for 1 hour. The suspension was loaded on an 
empty plastic column (Bio-Rad, Richmond, CA), letting the unbound proteins 
pass through, and the beads were washed with 400 bed volumes of lysis 
buffer. The fusion proteins bound to GST agarose beads were then 
resuspended in an adequate amount of lysis buffer and stored at -80°C prior 
their use. The integrity and purity of the proteins were assessed by sodium-
dodecyl-sulphate gel electrophoresis (SDS-PAGE) followed by coomassie 
staining. 
The pCDNA3-Tat86 and the pCDNA3-Tat86BM (tat86 Basic mutant) were 
used as templates to produce the in vitro [35S] Tat86 and Tat86 BM proteins 
for in vitro binding by using the TNT Reticulocyte Lysate System (Promega, 
Madison, WI). 
Synthetic peptides 
Synthetic peptides corresponding to residues 824-843, 939-951 a 1007-1023 
of Alpha1 C-terminus (thereafter named P1, P2 and P3, respectively) were 
obtained from Peptide Synthesis Facility at ICGEB – Trieste. Peptides were 
synthesized on solid phase (preloaded NovaSyn TGT, Novabiochem) by 
Fmoc/t-Bu chemistry using a home-built automatic synthesizer based on a 
Gilson Aspec XL SPE system. The peptide-resin  were cleaved/deprotected 
using a modified Reagent H mixture (trifluoroacetic acid 80%, phenol 3%, 
thioanisole 3%, 3,6-dioxa-1,8-octanedithiol 8%, water 2.5%, 
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methylethylsulphide 2%, hydroiodic acid 1.5% w/w) for 3 h. The peptides 
were then precipitated by diethylether, washed and freeze-dried. The crude 
peptides were purified by preparative RP-HPLC on a 25x300 mm column 
(Load&Lock system, Varian) packed with VariTide RPC resin (Polymer 
Laboratories - Varian) using a gradient from 0.1% TFA in water to 0.1% TFA 
in acetonitrile. The purified fractions were checked by ESI-MS, pooled and 
freeze-dried. 
For all the three peptides, an N-Biotinylated, an N-Fluoresceinated and a 
non-conjugated form were synthesized. 
As negative controls, we used a biotinylated MPO Mimicking Peptide (Biotin-
Ala-RNLKLARKLMEQYGT) corresponding to aa 622-637 of Human 
Myeloperoxidase (ACCESSION AAI30477), synthesized by Espichem 
(Firenze) (a gift of Dr. Lorena Tedeschi) and a synthetic FLAG peptide 
(Sigma Aldrich). 
In vitro GST-pull down assays 
Binding of GST-fused Alpha1 fragments and P1-P2-P3 to [35S]-Tat86 and 
[35S]-Tat86 BM was performed as follows: briefly, 1 µg of recombinant 
proteins, after pretreatment in a solution containing DNase I 0.25 U/µl and 
RNase 0.2 µg/µl to remove contaminant bacterial nucleic acids, were 
incubated with 600 c.p.m. of in vitro translated Tat in a solution containing 
0.2 mg/ml ethidium bromide. Following extensive washes, the reaction 
mixture was resolved by SDS–PAGE electrophoresis and analyzed by 
PhosphoImager. 
Binding and washes were performed in NETN buffer (20 mM Tris-HCl pH 
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In vitro biotin pull down assays 
Synthetic biotinylated peptides, corresponding to aminoacids 824-843, 939-
951 and 1007-1023 of Na+,K+-ATPase Alpha1 subunit, were used for binding 
assays as follows: 25 µl of streptavidin resin (UltraLink Plus streptavidin 
beads, Pierce, ), were pretreated with 3 mg of BSA for 10’ at room 
temperature, and subsequently incubated with 50 µg of peptide at 22°C for 
1 hour; after 3 washing with NETN buffer, the peptide-coated beads were 
incubated with either 600 c.p.m. of in vitro radiolabeled translated Tat as 
previously described, or with 250 ng of recombinant GST-Tat, for 2 hours at 
4°C. Following extensive washes, the reaction mixture was resolved by SDS–
PAGE electrophoresis and analyzed either by PhosphoImager, or blotted and 
analyzed by western analysis using an anti-GST antibody. 
Antibodies and reagents 
Polyclonal antibody against HSV-TK was purchased from William C. 
Summers Laboratory (Yale University, US); monoclonal antibody against 
tubulin was from Sigma; monoclonal antibody against SV5 peptide was a 
kind gift from Prof. Oscar Burrone (ICGEB, Trieste, Italy); Monoclonal 
antibody against HIV-1 Tat (5A5.3) was obtained through the AIDS 
Research and Reference Reagent Program (Division of AIDS, NIAID, NIH 
from Dr. Jon Karn.); monoclonal antibody against Na+,K+-ATPase subunit 
was from Upstate (Lake Placid, NY); monoclonal antibody against GM-130 
was from Transduction Laboratories (Lexington, KY); monoclonal anti-FLAG 
antibody and anti-FLAG conjugated agarose were from Sigma; rabbit 
polyclonal anti-GST antibody was from Santa Cruz biotechnology. 
Horseradish peroxidase (HRP)-conjugated secondary antibodies for western 
blotting were from Santa Cruz biotechnology and Alexa 488-coupled 
secondary antibodies used for confocal microscopy came from Molecular 
Probes Inc. (Eugene, OR). The protease inhibitor cocktail was from Roche 
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(Strasbourg, France). All other reagents were from Sigma unless otherwise 
specified. 
Fluorescence microscopy 
For FRET experiments, U2OS cells were grown on four-well glass chamber 
slides (LabTek II-Nalge Nunc) and transfected as described below; upon 
expression of the transfected proteins, cells were fixed in PFA 2% and 
mounted in Vectashield mounting medium (Vector Laboratories Inc., 
Burlingame, CA). 
For immunofluorescence analysis, U2OS cells were grown on chamber slides, 
fixed, and incubated twice for 10 min with PBS 0,1% Triton X-100 to 
permeabilize cell membranes; after extensive wash with PBS+ (0.1% 
glycine, 0.5% BSA), cells were incubated with primary antibody (either anti-
GM130 or anti-FLAG, 1:500) for 1h at 37°C. Cells are then washed again in 
PBS+ and incubated with secondary antibody (goat anti-mouse, Alexa488 
conjugated, 1:2000) for 1 hour at 37°C. Following extensive wash with 
PBS+, slides are mounted with Vectashield and analyzed. All antibodies were 
diluted in PBS+. 
Fluorescent images were acquired using a TCS-SL Leica confocal 
microscope. 
FRET analysis 
Fluorescent images of samples fixed with 2% paraformaldehyde were 
acquired using a TCS-SL Leica confocal microscopy. The quantitative FRET 
analysis was performed using the ImageJ software that elaborates the FRET 
efficiency by applying the formula: 
% FRET efficiency=(1–Fda/Fd)x100 
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where Fda stands for the fluorescence emitted by the donor fluorophore 
before bleaching and Fd for the emission of the donor fluorophore after 
bleaching (Karpova et al. 2003). 
(Fda and Fd were calculated by subtracting the background fluorescence 
from the effective fluorescence of the selected ROI). 
Cell cultures and transfections 
CHO K1 and PsgA-745 (Rostand and Esko 1997) were obtained from the 
American Type Culture Collection (ATCC; Manassas, VA) and maintained in 
Kaighn’s modification of Ham’s F12 medium. HEK 293T and U2OS (obtained 
from the ATCC) and HL3T1 cells (a HeLa cells derivative stably transfected 
with a silent LTR-CAT cassette), a kind gift of B. Felber (Felber and Pavlakis 
1988), were maintained in DMEM; human osteogenic sarcoma (HOS) CD4+ 
CCR5+ cell line was maintained in DMEM (Gibco, UK); human acute 
lymphoblastic T-cell leukaemia (CEM) CD4+ cell line was maintained in 1640 
RPMI medium (Gibco, UK). 
All culture media were supplemented with 10% fetal calf serum, 2 mM L-
glutamine, and 50 µg/ml gentamicin. 
U2OS cells (5 × 104) were seeded into four-well glass chamber slides 
(LabTek II-Nalge Nunc) and transfected with the Polyfect transfection kit 
(Qiagen) for 24 h; in all transfections, an adequate quantity of empty vector 
pcDNA3 was used to achieve a similar DNA amount. 
HEK 293T cells were transfected using the classical Calcium-Phosphate 
protocol (Molecular Cloning: a laboratory manual – Eds. Sambrook J. & 
Russell D.V., 16.14-16.20, Cold Spring Harbor Laboratory Press, Cold Spring 
Harbor, New York, USA, 2001) incubated for 36 hours, and then processed 
for secretion or co-immunoprecipitation experiments. 
 
 




Cells were pretreated with the different drugs (10 µM BFA, 25 µM ouabain, 1 
mM methylamine, 50 µM curcumin, 20µM EIPA, 10 µM glyburide, and 20 
µg/ml heparin) for 30 min in OPTIMEM, and then fresh OPTIMEM containing 
the same drugs was added to the cell cultures. After the time of incubation 
(4 hours), the medium was collected and the cells were harvested and 
processed for western blotting.  
Secretion assay 
HEK 293T or CHO A-745 cells were seeded in 6-cm plates (106) one day 
prior transfection; cells were transiently transfected with either Tat11-TK, 
Tat86-TK or TK construct and with Sc-VHD16-SV5 construct as a positive 
control of classical secretion. The CaP-DNA complexes were incubated for 12 
hours, then the medium was replaced with fresh DMEM, and the cells were 
incubated for 24 more hours. The secretion assays were performed by 
washing the cells (3 washes of 10 minutes) with Optimem containing 20 
µg/ml heparin to prevent secreted tat protein binding to the extracellular 
heparan sulfate proteoglycans upon transfection (Tyagi et al. 2001), and 
incubating the cells with 2 ml of Optimem + heparin for the needed time 
lapses. Following incubation, cell culture supernatants were collected and 
concentrated using Amicon Ultra 10 concentrator (Millipore) according to the 
manufacturer’s instructions; the concentrated fraction was then processed 
for western blotting. As a control of protein expression, the cellular fraction 
was collected, lysed in NHEN buffer (20 mM Hepes pH 7.5, 300 mM NaCl, 
0.5% NP-40, 20% glycerol, 1 mM EDTA) containing protease inhibitors 
(Roche), the total protein concentration was assessed by the Bradford assay 
(BioRad), and 30 µg of each samples were processed for Western Blotting. 
 
 




For the fluorescent peptides uptake experiment, synthetic biotinylated 
peptides, corresponding to aminoacids 824-843, 939-951 and 1007-1023 of 
Na, K ATPase Alpha1 subunit, and conjugated to fluorescein, were diluted in 
OPTIMEM and incubated with cells for 4 hours at 37°C. Cells were then 
trypsinized, washed with DMEM and twice with PBS, and processed for flow 
cytometry. 
For the internalization experiment in presence of ouabain, cells were plated 
in 6-well plated to about 60% confluence, pretreated with 25 µM ouabain for 
30 min, and incubated with either recombinant GFP fusion proteins or 
TRITC-labeled transferrin plus 25 µM ouabain for 4 hours. Cells were then 
washed twice with PBS, trypsinized, again washed with PBS, washed with 2 
M NaCl to completely take off surface bound proteins, again washed twice 
with PBS, and finally, analyzed by flow cytometry using a FACScan flow 
cytometer (BD Biosciences). For the surface staining experiment with anti TK 
antibody, cells were detached from the plates with PBS, washed twice in PBS 
containing 1% FCS, then incubated in anti-TK antibody for 30 min on ice; 
cells were then washed again twice with PBS 1% FCS, and incubated with 
secondary antibody (goat anti-rabbit conjugated with AlexaFluor 488) for 30 
min on ice; cells were washed twice in PBS 1% FCS, fixed in PFA 2% and 
analyzed by flow cytometry. The antibodies were both diluted in PBS 1% 
FCS. A total of 10,000 cells per sample were considered. 
Immunoprecipitation 
For immunoprecipitation, cell pellets were lysed in a NHEN buffer (20 mM 
Hepes pH 7.5, 300 mM NaCl, 0.5% Nonidet P40, 20% glycerol, 1mM EDTA, 
1 mM PMSF) containing protease inhibitors (Roche). The protein 
concentration of the extracts was determined by the Bradford assay 
(BioRad). Anti-TK and anti-Alpha1 antibodies were incubated overnight at 
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4°C with cell extracts (2-3 mg); following incubation, Protein-A Trisacryl 
beads (Pierce Technologies Inc., Rockfors, IL) was used to bind the 
immunocomplexes, according to the manufactor’s instructions. After 
incubation, the beads were washed 5 times with NHEN buffer, and then 
processed for SDS-PAGE and Western Blotting using appropriate antibodies. 
Anti-FLAG M2-Agarose beads (Sigma) were incubated overnight at 4°C with 
cell extracts (2.5–4.5 mg). After incubation, the beads were washed 5 times 
with NHEN buffer, and then the immunocomplexes were analyzed by 
Western blotting using the appropriate antibodies. 
CAT ELISA 
For testing the biological activity of secreted Tat protein, 293T cells were 
transfected with a pCDNA3 construct expressing Tat86 and a pCDNA3 
expressing either wild type or deleted mutant of Alpha1; after 24 hours of 
incubation, cells were washed and the medium substituted with fresh 
medium plus heparin 20 µg/ml and, for the secretion inhibition experiments, 
supplemented with 25 µM ouabain; after 4 hours, the surnatant was 
collected and added to HL3T1 cells with the addition of 100 µM chloroquine; 
as HL3T1 cells stably express a bacterial chloramphenicol- acetyltransferase 
gene (CAT) fused to HIV LTR, after 24 hours of incubation, Tat-driven 
transactivation was assayed by inducing long terminal repeat (LTR)-
dependent chloramphenicol acetyltransferase (CAT) production and 
quantifying the levels of CAT protein by using a CAT ELISA kit (Roche 
Diagnostics, Meylan, France). 
Virus preparation 
Viral stocks of the Bal-luciferase vectors were prepared by the standard 
calcium-phosphate method of transfection in HEK 293T cells using  pNL4.3-
luciferase plasmid (Connor et al. 1995; He and Landau 1995) and the M-
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tropic Bal envelope encoding plasmid at a ratio 3:1. The supernatant 
containing virions were collected 48 hours after transfection, centrifuged 5 
minutes at 1500 rpm and filtered with 45 µm Millipore filter. Cells were 
infected for 4 hours. 
Viral stocks of the viral clones HIV-1BRU (Petit et al. 1999) were prepared by 
the standard calcium-phosphate method of transfection in HEK293T cells. 
The supernatant containing virions were collected 48 hours after 
transfection, centrifuged 5 minutes at 1500 rpm and filtered with 45 µm 
Millipore filter. Before infection viral stocks were treated with DnaseI 
(Invitrogen) 40U/ml for 1 hour at room temperature. Cells were infected for 
4 hours. 
Infections 
For single-round infections, HOS CCR5+ cells were infected with pNL4.3-
luciferase pseudotyped with the M-tropic Bal envelope. Prior infection, the 
virus was pre-incubated with an equimolar mix of P1, P2 and P3 peptides 
(Pmix) in a 15 µg/ml concentration, at 37°C for 1 hour; cells were incubated 
with the virus for 4 hours, washed, and fresh medium containing 15 µg/ml 
Pmix was added; after 24 hours, the cells were harvested and the 
expression level of luciferase was tested with DualGlo Luciferase assay kit 
(Promega, Madison, WI) according to manufactor’s instructions. Luciferase 
activity was calculated after normalization against the activity of the co-
transfected Renella luciferase. 
For infections with wild type virus, for each time point, 106 CEM cells were 
infected with an equal amount of HIV-1BRU for 4 hours; where indicated, the 
infection was performed in presence of 10 µg/ml of Pmix, or of FLAG 
peptide, as a negative control. After the infection, the medium containing 
the virus was washed and substituted with fresh medium, containing the 
corresponding peptide preparation. At t=0 and subsequently, every 3 days 
until the 12th day, the supernatants were collected tested, while cells were 
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diluted 1:2 and fresh peptides were added to the culture media. The amount 
of virus was evaluated by measuring the RT activity in the supernatants 
following standard protocols. 
Luciferase assay 
HeLa P4 cells, stably expressing a copy of LTR-driven luciferase gene, were 
transfected with pCDNA3 Tat and a vector expressing Renella luciferase 
under the control of CMV promoter for normalization purposes; after 48 
hours of incubation, cells were lysed and luciferase assays were carried out 
with DualGlo Luciferase assay kit (Promega, Madison, WI) according to 
manufactor’s instructions. Luciferase activity was calculated after 
normalization against the activity of the co-transfected Renella luciferase. 
Statistical analysis 
Significativity of data was assessed by calculating P values from two-tailed 


























Heterologous proteins fused to HIV-1 Tat are released from the 
expressing cells 
One of the peculiar features of HIV-1 Tat, which is very unusual for a 
transcription factor, is the characteristics of being released by the expressing 
cells in the absence of cell lysis (Ensoli et al. 1993; Chang et al. 1997) and 
being able to enter neighboring cells, where it is transported to the nucleus 
in a transcriptionally active form (Tyagi et al. 2001). Of notice, the fusion of 
heterologous proteins to Tat also imparts these proteins the intercellular 
trafficking capacity of wild type Tat (Tyagi et al. 2001; Krosl et al. 2003; 
Tasciotti and Giacca 2005). We have previously observed that the minimal 
region of Tat capable of mediating both cellular release and internalization of 
heterologous proteins corresponds to amino acids 48-59 (hereafter named 
Tat11), encompassing the 9-aa-long, basic region of the protein (Tyagi et al. 
2001; Tasciotti et al. 2003); Fig. 3.1A. 
To start investigating the mechanisms involved in the release of Tat-fusion 
proteins, we transfected HEK293T cells with constructs expressing the TK 
reporter protein of the herpes simplex virus type 1 (HSV-1) carrying an N-
terminal extension corresponding to Tat11 or to the 86-aa-long, full length 
Tat protein of the widely investigated HIV-1 laboratory strain HX2B (Tat86); 
we have previously shown that both these constructs are biologically active 
both in vitro (Tasciotti et al. 2003) and in vivo (Tasciotti and Giacca 2005). 
At 36 h after transfection, a considerable portion of both fusion proteins 
(~2-10%) was found in the cell culture supernatant in the absence of 
detectable cell lysis, as concluded by the lack of cellular tubulin protein in 






Fig. 3.1: Release of Tat86- and Tat11-fusion proteins from the 
expressing cells 
(A) Schematic representation of the major functional domains of HIV-1 Tat. Acidic, 
acidic domain; Cys-rich, cysteine-rich domain; core, core domain; basic, basic 
domain. Tat has 101 aa in several clinical isolates and 86 aa in the laboratory strain 
HX2B. The amino acid sequence of the basic domain of the protein, which imparts 
the protein intercellular trafficking capability, is indicated. The lower part of the panel 
shows a schematic representation of the two Tat proteins used in this study (Tat11, 
corresponding to the Tat basic domain plus two additional amino acids at both 
extremities, and Tat86). 
(B) Tat86-TK and Tat11-TK are released from the expressing cells and bind 
extracellular HSPG upon secretion. The immunoblots in the upper panel show the 
amount of proteins released in the cell culture supernatants of cells transfected with 
Tat86-TK, Tat11-TK or scVH16-SV5, treated or untreated with 25 µM soluble heparin. 
The immunoblots in the lower part show the levels of intracellular protein expression 
in the same samples. WCL: whole cell lysates. The asterisk indicates an additional 
band present in the Tat86-TK immunoblots, probably corresponding to a degradation 
product. The absence of immunoreactivity for tubulin in the supernatants indicates 
the absence of appreciable cell lysis under the adopted experimental conditions. 
 
 
Of interest, the amount of Tat-TK proteins free in the supernatant was 
increased by cell treatment with soluble heparin, consistent with the notion 
that this polyanion acts as a competitive inhibitor of cell surface HSPGs, 
which sequester soluble Tat (Chang et al. 1997), and that heparinase III 
releases the attached protein (Chang et al. 1997). For comparison, cells 
were also transfected with a plasmid expressing a single-chain Fv antibody 
(scFv) tagged with the SV5 epitope (ScVH16-SV5). This protein, which 
contains a signal peptide and is thus secreted through the ER-Golgi 
compartments, also accumulated in the cell culture supernatant, but its 





Fig. 3.1B shows the intracellular levels of expression of the three 
investigated proteins. 
Kinetics of Tat-fusion protein release 
Next we wanted to investigate the kinetics of Tat-fusion protein release. 
HEK293T cells were co-transfected to express both Tat86-TK and ScVH16-
SV5; after 36 h, cells were extensively washed with fresh medium containing 
heparin, to remove HSPG-bound proteins, and fresh medium containing 
heparin was added. The scFV and Tat86-TK proteins were expressed at 
comparable levels by the cells, however the kinetics of their appearance in 
the cell culture supernatants was drastically different. As shown in the upper 
part and quantified in the lower part of Fig. 3.2A, the levels of the 
extracellular Tat-fusion protein peaked as early as 30 min after the addition 
of fresh medium and slightly decreased in the subsequent 2 h. In contrast, 
secreted scFv appeared at later times and its levels progressively increased. 
Analogous findings were also detected when cells were co-transfected with 
Tat11-TK and ScVH16-SV5, thus indicating that the release kinetics is a 
property imparted by the Tat basic domain (Fig. 3.2B). As compared to 






Fig. 3.2: Kinetics of Tat-fusion protein release 
(A) Kinetics of extracellular accumulation of Tat86-TK and the scFv antibody ScVH16-
SV5, which is secreted through the ER-Golgi, in cells co-transfected to express both 
proteins. The immunoblots in the upper panel show the levels of the two proteins in 
the cell culture supernatants at different time points. In the lower panel, the 
immunoblots show the levels of Tat86-TK, ScVH16-SV5 and tubulin in whole cell 
lysates (WCL) from the same cells as a control of protein expression. The asterisk 
indicates unspecific bands recognized by the primary antibody. 
(B) Same as in panel (A) in cells transfected with Tat11-TK and ScVH16-SV5. 
 
 
Tat secretion is independent from HSPG binding 
Finally, we also ascertained that proteins other than TK had the same 
behavior when fused to Tat. Indeed, under similar experimental conditions, 
both Tat11-GFP (not shown) and Tat11-Cre (Fig. 3.3A) were found to 






Fig. 3.3: Tat secretion is independent from HSPG binding 
(A) Kinetics of extracellular accumulation of Tat11-Cre and the scFv antibody 
ScVH16-SV5, which is secreted through the ER-Golgi, in cells co-transfected to 
express both proteins. The immunoblots in the upper panel show the levels of the 
two proteins in the cell culture supernatants at different time points. In the lower 
panel, the immunoblots show the levels of Tat11-Cre, ScVH16-SV5 and tubulin in 
whole cell lysates (WCL) from the same cells as a control of protein expression. 
(B) Tat11-TK secretion is independent from HSPG binding. The kinetics of Tat11-TK 
and ScVH16-SV5 accumulation was assessed by immunoblotting on supernatants of 
CHO-A745 cells, genetically defective for HSPG synthesis, transfected to express both 
proteins. The levels of intracellular protein expression were assessed by western 
blotting on whole cell lysates (WCL). 
(C) Tat11-TK binds to HSPG upon secretion. The amount of secreted protein was 
assessed in presence of growing amounts of soluble heparin in the cell culture 
supernatants. The levels of intracellular protein expression were assessed by western 
blotting on whole cell lysates (WCL). 
 
 
The apparent lack of accumulation of Tat-fusion proteins in the supernatant 
over time likely reflects a steady-state equilibrium between the amount of 
released protein that remains bound to extracellular HSPGs despite the 
presence of soluble heparin inhibitor, and that undergoing internalization 
through the interaction with cell membrane-associated HSPGs (Tyagi et al. 
2001; Fittipaldi et al. 2003). Consistent with this possibility, we observed 





proteoglycans due to a genetic defect in their biosynthetic pathway (Rostand 
and Esko 1997), release progressively increasing amounts of Tat11-TK in 
their supernatants (Fig. 3.3B). Moreover, when we evaluated Tat11-TK 
secretion in the presence of growing quantities of soluble heparin in the cell 
culture media, the amount of secreted protein showed a progressive 
increase (Fig. 3.3C). 
Collectively, these results show that heterologous proteins containing Tat or 
the Tat basic domain possess the property of being progressively released 
from the producing cells, independent from the production of HSPGs. 
Tat secreted from HEK293Tcells is able to transactivate LTR-CAT 
genes in HL3T1 cells 
In co-cultures experiments employing Tat-GFP-expressing cells together with 
LTR-CAT-expressing cells, the Tat-GFP protein was shown to traffic from the 
producing cells to the responding cells, in which it determined a detectable 
level of CAT activation; these results demonstrated that Tat is secreted from 
the expressing cells in a biological active form (Tyagi et al. 2001). 
In order to study Tat secretion in vivo, we first wanted to test whether 
transiently transfected HEK293Tcells were able to secrete Tat and this 
protein could be easily detected in the extracellular medium, without 
employing co-culture techniques. Moreover, as unconventional secretion has 
been shown to be a way of disposal of the excess of unfolded, 
overexpressed proteins in transfected cells (Tanudji et al. 2002), we wanted 
to test the functionality of secreted Tat. For this reason, we developed an 
ELISA-CAT assay, using HL3T1 cells (HeLa cells stably expressing an 
integrated LTR-CAT gene) as a recipient for the cell culture medium 
previously incubated with Tat- expressing cells. Briefly, HEK293Tcells were 
transfected with an expressing vector encoding for Tat, and after 24 hours 
of incubation the supernatants was transferred to HL3T1 cells. Then, the 





protein resulting from the transactivation of the LTR (scheme of the 
experiment in Fig. 3.4A).  
 
 
Fig. 3.4:  Tat secreted from HEK293T is able to transactivate LTR-
CAT genes in HL3T1 cells 
(A) Scheme of the experimental procedure followed for the secretion assay 
employing HL3T1 as a reporter of Tat transactivation activity. HEK293T cells were 
transfected with a Tat expressing vector. After 24 hours, the medium was collected 
and transferred to HL3T1 cells in the presence of choroquine, in order to enhance 
protein delivery. After 24 hours, cells were collected, and the lysates used for CAT-
ELISA assay in order to determine the amount of CAT enzyme. As a positive control, 
HL3T1 cells transfected with the same Tat expressing vector were lysed and 
processed for CAT-ELISA assay.  
(B) Level of LTR transactivation, quantified as fold of CAT activation over mock. The 
first column is the level relative to mock-treated HL3T1 cells; the second is relative to 
HL3T1 transfected cells; the third represents the amount of CAT enzyme in HL3T1 
cells treated with the supernatant of Tat-transfected HEK293T cells. Western blot 
using an anti-Tat antibody, showing the levels of Tat protein expression in 





As a positive control we used HL3T1 cells transfected with a Tat- expressing 
vector (pcDNA3-Tat, (Fittipaldi et al. 2003)). The amount of CAT protein was 
determined by an ELISA assay against the CAT antigen. 
The results are shown in Fig. 3.4B. They clearly indicate that secreted Tat 
is present in the cell culture medium of Tat-transfected cells, and is able to 
cross the cell membrane of HL3T1 cells, where it is targeted to the nucleus 
and transactivates the LTR-driven reporter gene. The lower level of 
transactivation obtained in comparison to the positive control was expected, 
as only a small portion of expressed Tat is released by HEK293T cells and 
therefore is available for CAT transactivation. The western blot performed on 
whole cell lysates with an anti-Tat antibody proves the expression of Tat 
protein in transfected cells. 
Tat is excluded from the Golgi apparatus 
In order to confirm previous data indicating that Tat secretion proceeds 
through a pathway which is independent from the classical pathway of 
protein secretion, we wanted to analyze the intracellular localization of 
transfected Tat in respect to the Golgi apparatus, which is the final 
compartment where proteins targeted for secretion are stored. For this 
purpose, HeLa cells were transfected with a Tat11-GFP fusion protein 
expressing vector, fixed, and analyzed by immunofluorescence using an 
antibody against GM-130, a resident glycoprotein of the Golgi apparatus. In 
contrast to GFP (Fig. 3.5B), Tat-GFP showed a preminent nuclear-nucleolar 
localization (Fig. 3.5A). No co-localization of Tat-GFP with GM-130 was 








Fig. 3.5: Tat is excluded from the Golgi compartment in transfected 
cells 
HeLa cells transfected with either Tat11-GFP- (A) or GFP- (B) expression vectors 
were fixed, processed for immunofluorescence with an Alexa488-labeled anti-GM130 
antibody, and then analyzed by confocal microscopy for co-localization of GFP and 
Alexa488-derived fluorescence.  
 
 
These results confirm that Tat is not found inside the Golgi apparatus even 
when overexpressed; thus the protein must otherwise be secreted through a 
different route. 
Tat binds heparan sulfate proteoglycans at the cell surface 
In order to characterize the process of Tat secretion from HEK293T cells, we 
took advantage of recombinant proteins containing Tat86 or Tat11 fused to 
HSV-TK. As characterized previously (Tasciotti et al. 2003), these proteins 
are secreted from transfected cells and retain the ability to cross cell 
membranes, thus spreading among cells. We decided to use TK as a 
reporter gene due to the availability of an anti-TK antibody that readily 
detects the fusion proteins with high specificity and sensitivity. 
In a set of initial experiments, we wanted to confirm previous findings 
(Chang et al. 1997; Tyagi et al. 2001) on the binding of secreted Tat to cell 






Fig. 3.6: Secreted Tat binds cell surface HSPGs 
HEK293T cells were transfected with Tat86-TK, Tat11-TK or TK expressing vectors, 
and subsequently processed as follows: cells were non-enzymatically detached from 
plates, incubated with an anti-TK antibody, washed and incubated with an alexa488-
conjugated secondary antibody. Cells were then processed by flow cytometry to 




HEK293T cells, transfected with Tat86-TK, Tat11-TK or TK expression 
vectors, were treated with anti-TK primary antibody and Alexa-488 
conjugated anti-rabbit secondary antibody, and assayed by flow cytometry 
for surface staining. The results, shown in Fig. 3.6, indicate that, while TK 
expressing cells showed no increase in fluorescence compared to control, 
non transfected cells, fluorescence of Tat86-TK and Tat11-TK expressing 
cells was increased, implying the presence of TK- fusion proteins bound to 
the cell surface. 
The cellular Na+,K+-ATPase inhibitor ouabain blocks extracellular 
release of Tat86 and Tat11 fusion proteins 
To assess the involvement of distinct cellular machineries in the release of 
Tat, a panel of metabolic drugs, interfering with trafficking of proteins, 





fusion protein release in HEK293T transfected with Tat11-TK or Tat86-TK 
together with the scFv antibody (Figs. 3.7A and 3.7C respectively). 
Glyburide (GLY) and methylamine (METH), which interfere with the non-
classical secretion of other proteins (Rubartelli et al. 1990; Hamon et al. 
1997; Zhou et al. 2002), did not affect either the export of Tat11-TK or the 
secretion of the antibody. No effect was either detected by 5-(N-ethyl-N-
isopropyl) amiloride (EIPA), a drug interfering with macropinocytosis (West 
et al. 1989) and known to limit HIV-1 replication in cultured cells (Ewart et 
al. 2004). In contrast, BFA (BFA), which interferes with the Golgi vesicular 
system and inhibits the ER-Golgi secretion pathway (Misumi et al. 1986), 
severely impaired the scFv antibody secretion, but did not exert any 
detectable effect on Tat11 and Tat86 fusion protein release. 
Most notably, cell treatment with the cardiac glycoside ouabain (OUA) at 25 
µm, a concentration sufficient to abrogate the function of the cell membrane 
Na+,K+-ATPase and to block the non-classical secretion of FGF-2 (Dahl et al. 
2000), blocked (>8 fold inhibition) Tat11-TK release, while leaving scFv 
antibody secretion unaffected (Fig. 3.7A for blots and Fig. 3.7B for 
quantification). Similar results were also observed when using Tat86-TK 
(Figs. 3.7C and 3.7D). The effect of ouabain appeared specific for the 
Na+,K+-ATPase, since cell treatment with curcumin, a broad inhibitor of P-







Fig. 3.7: The cellular Na+,K+-ATPase inhibitor ouabain blocks 
extracellular release of Tat86 and Tat11 fusion proteins 
(A) Sensitivity of Tat11-TK release from expressing cells treated with several drugs 
known to interfere with vesicular transport. The amount of secreted protein was 
assessed by western blot on cell culture supernatants, while protein expression and 
loading was checked on whole lysates.  
(B) Ouabain treatment significantly decreases Tat11-TK release from expressing 
cells; the amount of secreted Tat11-TK, normalized over the amount of expressed 
protein, was assessed in untreated and ouabain-treated cells, after 4 h incubation. 
Non-parametric T-student test was run on the result of three independent 
experiments. 
(C) Sensitivity of Tat86-TK release from expressing cells treated with several drugs 
known to interfere with vesicular transport. The amount of secreted protein was 
assessed by western blot on cell culture supernatants, while protein expression and 
loading was checked on whole lysates. The histograms report the result of three 
independent experiments. 
(D) Ouabain treatment significantly decreases Tat11-TK release from expressing 
cells; the amount of secreted Tat11-TK, normalized over the amount of expressed 







Ouabain-sensitive interaction of Tat with the Alpha1 subunit of the 
cellular Na+,K+-ATPase 
The specific cellular target of ouabain is the Alpha1 subunit of the Na+,K+-
ATPase, which has been also previously involved in the unconventional 
release of FGF-2 (Dahl et al. 2000). Thus, we wanted to investigate whether 
Tat might directly interact with this protein and whether this interaction 
might be involved in extracellular Tat release. To test this hypothesis, we 
performed co-immunoprecipitation experiments between Tat86-TK and the 




Fig. 3.8: Ouabain-sensitive interaction of Tat with the Alpha1 
subunit of the cellular Na+,K+-ATPase 
(A) Tat co-immunoprecipitates with endogenous Alpha1 subunit of Na+,K+-ATPase, 
and their binding is sensitive to ouabain. The antibodies used for 
immunoprecipitation and subsequent western blots are indicated on the right side. 
Expression of proteins was assayed on whole lysates. The cells used were HEK293T 
cells transfected with Tat86-TK, either treated or not with ouabain. The bands 
marked with (*) are degradation products of either proteins, recognized by the 
specific antibodies. 
(B) Tat co-immunoprecipitates with the rat isoform of Alpha1, and the binding is not 
sensitive to ouabain. The antibodies used for immunoprecipitation and subsequent 
western blots are indicated on the right. Expression of proteins was assayed on 
whole lysates. The cells used were HEK293T cells co-transfected with TK, Tat11-TK 
or Tat86-TK, and rAlpha1. The bands marked with (*) are degradation products of 







Indeed, we found that Alpha1 was present in the anti-Tat86-TK 
immunoprecipitate and, most notably, that cell treatment with 25 µM 
ouabain for 4h prior of harvesting the cells for immunoprecipitation 
completely abolished the interaction between the two proteins (Fig. 3.8A). 
Thus, Tat interacts with the Na+,K+-ATPase Alpha1 subunit and the cardiac 
glycoside ouabain, which specifically inhibits the release of Tat into the 
extracellular compartment, disrupts this interaction.  
The results so far obtained indicate that ouabain both inhibits the 
extracellular release of Tat and prevents the interaction between Tat and 
the Alpha1 subunit in human cells. Since the rat Na+,K+-ATPase is know to 
be insensitive to ouabain treatment, due to the presence of natural amino 
acid variations in its Alpha1 subunit (Emanuel et al. 1988), we wondered 
whether this protein still interacted with Tat and whether its expression in 
human cells might overcome the inhibition that ouabain imparts on Tat 
release. Human HEK293T cells were transfected with vectors expressing rat 
Alpha1 together with either Tat11-TK or Tat86-TK. When Alpha1 was then 
immunoprecipitated with a specific antibody, both Tat-fusion proteins were 
also present in the immunoprecipitates. Of notice, however, and in contrast 
with human Alpha1 (Fig. 3.8A), the addition of ouabain did not modify the 
interaction between rat Alpha1 and the Tat proteins (Fig. 3.8B). 
Ouabain treatment does not affect Alpha1 or Tat intracellular 
localization 
To rule out the possibility that the ouabain effect might be due to a 
modification of the intracellular localization of either Alpha1 subunit or Tat 
induced by the drug, we wanted to study the intracellular localization of both 






Fig. 3.9: Ouabain treatment does not affect Alpha1 or Tat 
intracellular localization 
Left: intracellular localization of Tat-YFP. U2OS cells were transfected with a vector 
encoding for a Tat-YFP fusion protein, fixed in 2% PFA and analyzed by confocal 
microscopy. Where indicated, cells were treated with 25 µM ouabain for 4 h before 
fixation (lower panel). 
Right: intracellular localization of human Alpha1 subunit. The cDNA encoding for the 
human apha1 subunit cds was cloned and expressed in U2OS cells as a FLAG-tagged 
protein. Cells were then fixed in 2% PFA and subjected to anti-FLAG 
immunofluorescence, prior their examination by confocal microscopy. In the lower 
panel, cells treated with ouabain 25 µM for 4 h prior fixation. 
 
 
We used U2OS cells, transiently transfected with a YFP-fused Tat protein 
expressing vector, and treated them with ouabain. Upon treatment, the 
slides were analyzed by confocal microscopy after fixation (Fig. 3.9, left).  
To study the localization of the human Alpha1, the cDNA encoding for the 
complete coding sequence of the protein was amplified from HEK293 total 
RNA, cloned as a FLAG tagged protein, and overexpressed in U2OS cells, 
which were subsequently treated with ouabain. After fixation, cells were 
subjected to immunofluorescence against the FLAG epitope, and then 





change in distribution was observed for either protein, leading to the 
conclusion that the ouabain inhibiting effect on Tat-Alpha1 interaction is not 
due to the relocalization of either of the two protein partners. 
Ouabain does not interfere with Tat internalization 
In order to further explore the effect of ouabain on the biological activity of 
Tat, we tested its effect on the internalization pathway of a recombinant 
GST-Tat11-GFP protein, which had been previously shown to be internalized 
by cells through caveolar endocytosis (Ferrari et al. 2003; Fittipaldi et al. 
2003). Cells were co-incubated for 4 h with the recombinant protein and 
ouabain, and then trypsinized, washed and analyzed by flow cytometry to 
determine the amount of internalized fluorescent protein. As a control of 
membrane integrity, we used a GST-GFP recombinant protein which is not 
internalized and therefore does not confer fluorescence to treated cells. 
TRITC-labeled transferrin was used to evaluate the effect of ouabain 
treatment on clathrin-mediated endocytosis. 
 
 
Fig. 3.10: Ouabain does not interfere with Tat internalization 
(A) HEK293T cells were incubated for 4 h with 25 µM ouabain and GST-Tat11-GFP or 
GST-GFP; after incubation, cells were tryspinized and washed in order to detach any 
recombinant protein bound to the cell surface, and analyzed by flow cytometry in 
order to determine the amount of fluorescence. Untreated HEK293T cells were used 
as a control. 
(B) Same experiments were conducted with TRITC-Transferrin as a control of 





As a result, no effect whatsoever was observed on the internalization of 
either Tat11-GFP or Transferrin when cells were treated with ouabain (Fig. 
3.10), showing that the effect of ouabain on Tat release was specific and 
not due to some disturbance of the overall cell membrane permeability. 
Visualization of the interaction of Tat with the Na+,K+-ATPase 
Alpha1 subunit by fluorescence resonance energy transfer (FRET)  
FRET imaging using GFP spectral mutants provides the ability to localize and 
monitor ion binding and molecular protein–protein interactions in living cells 
(Sekar and Periasamy 2003). An appealing approach to detect FRET is 
acceptor photobleaching (Bastiaens and Jovin 1996; Bastiaens et al. 1996; 
Wouters et al. 1998; Kenworthy and Edidin 1999; Kenworthy 2001). This 
technique is based on the principle that energy transfer is reduced or 
eliminated when the acceptor is bleached, thereby yielding an increase in 
donor fluorescence (Fig. 3.11, A, B and C). Such an increase in 
fluorescence following bleaching is particularly diagnostic of FRET, because, 
in most circumstances, fluorescence normally decreases following a bleach.  
 
Fig. 3.11: FRET detection by acceptor photobleaching 
(A, B, C): Scheme of FRET experiment with the YFP-CFP pair, using acceptor 
photobleaching. Putatively interacting proteins are fused to YFP and CFP; if 
interaction takes place, excitation of CFP results in FRET and subsequent excitation 






In order to confirm the interaction between Tat and the rat Alpha1 subunit 
in vivo, we performed FRET experiments to determine whether we could 
detect a physical contact between the two proteins in transfected cells.  
For this purpose, we cloned Tat and Tat11 as fusions to YFP, and Alpha1 
fused to CFP, and transfected these proteins into U2OS cells. After 24 h, the 
cells were fixed, and the quantitative FRET analysis was performed by 










Fig. 3.12: Tat interacts with rat Alpha1 subunit in vivo 
U2OS cells were transfected with the indicated plasmids, then, after 24 h, cells were 
fixed and analysed by confocal microscopy.  
(A) Cells transfected with YFP-Tat11 and Alpha1-CFP. The upper panel shows cyan 
fluorescence, and the lower yellow fluorescence. The pre- and post-bleaching status 
is indicated. 
(B) Cells transfected with Tat86-YFP and Alpha1-CFP. The upper panel shows cyan 
fluorescence, and the lower yellow fluorescence. The pre- and post-bleaching status 
is indicated. 
(C) From the left, cells transfected with either YFP-Tat11 or Tat86-YFP, and CFP-N1, 
and cells transfected with Alpha1-CFP and YFP-C1. 
(D) Quantification of FRET efficiency for each experimental condition. 
 
 
Both Tat and Tat11 showed a strong interaction, localized in the nucleolar 
region (Fig. 3.12A and B, and 3.12D for quantification), while no FRET 
was measured when CFP-N1 or YFP-C1 were transfected (Fig. 3.12C and 
3.12D for quantification). Thus, an in vivo physical interaction between the 
two proteins appears to exist, at least after protein overexpression by 
transfection. In evaluating these results, however, it needs to be observed 
that the localization of transfected Alpha1, which is nuclear, appears 
different from the physiological localization of the protein at the cell 
membrane.  
Alpha1 catalytic function is not necessary for Tat release 
The Alpha1 subunit of the Na+,K+-ATPase contains an ATP binding site, a 
phosphorylation site, and the amino acids essential for the binding of cations 
and cardiac glycosides (Blanco et al. 1994; Devarajan et al. 1994; Lingrel et 
al. 1994; Koster et al. 1995; Fotis et al. 1999; Yudowski et al. 2000; 
Murtazina et al. 2001) (Fig. 3.13A). An Asp to Asn mutation in the ATP 
binding site (mutant D716N) impairs the catalytic activity of the enzyme, 
blocking its ability to hydrolyze ATP, while still permitting the correct 
localization of the Alpha1 subunit onto the cellular membranes (Lane et al. 
1993). Mutant D716N was still found able to bind both Tat86-TK and Tat11-





indicates that the interaction between Tat and Alpha1 occurs independent of 
the enzymatic activity of the Na+,K+-ATPase.  
 
 
Fig. 3.13: Alpha1 catalytic function is not necessary for Tat release 
(A) Schematic representation of the rat Alpha1 D716N construct, highlighting the 
residue mutated in order to inactivate the catalytic site. 
(B) Tat co-immunoprecipitates with D716N mutant and their binding is not sensitive 
to ouabain. The antibodies used for immunoprecipitation and subsequent western 
blots are indicated on the right side. Expression of proteins was assayed on whole 
lysates. The cells used were HEK293T cells co-transfected with TK, Tat11-TK or 
Tat86-TK, and rAlpha1 D716N-FLAG. Cells were treated or not with ouabain as 
indicated. The bands marked with (*) are degradation products of either proteins, 
recognized by the specific antibodies. 
 
Tat-Alpha1 interaction is crucial for Tat secretion 
Since rat Alpha1 binds Tat in a ouabain-insensitive manner, we wondered 
whether its overexpression might rescue the inhibition that ouabain imposes 
on the secretion of Tat-fusion proteins in human cells. To ascertain this 
possibility, HEK293T cells were transfected with Tat86-TK or Tat11-TK, 
together with the rat Alpha1 subunit. Indeed, the overexpression of this 
protein restored the cellular release of the Tat proteins in cells treated with 
ouabain (Fig. 3.14A and 3.14B for Tat11-TK and Tat86-TK respectively). 
Of notice, the D716N Alpha1 mutant was equally effective as the wild type 
protein in rescuing ouabain inhibition, again indicating that the effect of 
Alpha1 on Tat release is independent from its enzymatic activity. Secretion 





Superimposable results were also obtained when studying the release of 
Tat86-TK under exactly the same experimental conditions (Fig. 3.14B).  
 
 
Fig. 3.14: Tat-Alpha1 interaction is crucial for Tat secretion 
(A) D716N catalytic mutant is able to rescue ouabain-blocked secretion of Tat11-TK. 
Cells were transfected with Tat11-TK and either rAlpha1-FLAG or rAlpha1 D716N-
FLAG, then treated with ouabain; the amount of secreted protein was assessed by 
immunoblot on cell culture supernatants, while protein expression was assessed on 
whole lysates. 
(B) D716N catalytic mutant is able to rescue ouabain-blocked secretion of Tat86-TK. 
Cells were transfected with Tat86-TK and either rAlpha1-FLAG or rAlpha1 D716N-
FLAG, then treated with ouabain; the amount of secreted protein was assessed by 
immunoblot on cell culture supernatants, while the protein expression was assessed 
on whole lysates. 
(C) D716N catalytic mutant is able to rescue ouabain-blocked secretion of Tat86. 
HL3T1 cells were treated with the surnatants of HEK293T cells, transfected with Tat 
alone, or cotransfected with either rAlpha1-FLAG or rAlpha1 D716N-FLAG; cells were 
treated with ouabain, and their supernatant incubated with HL3T1 cells. The levels of 
LTR activation were assessed by ELISA assay on CAT levels. As a control of LTR 






Finally, we also wanted to verify whether the marked inhibition that ouabain 
exerts on the release of Tat-fusion proteins also impairs the transcellular 
transactivation properties of wild type Tat. For this purpose, we transiently 
transfected HEK293T cells with an expression vector for the 86 aa form of 
Tat (Tat86); 24 h after transfection, cells were either left untreated or  
treated with 25 µM ouabain for 4 h, and the resulting cell conditioned media 
were collected and added to human HL3T1 cells, a HeLa cell derivative cell 
line carrying a silent HIV-1 LTR-CAT construct (Felber and Pavlakis 1988). 
Conditioned medium from cells expressing Tat86 activated LTR transcription 
in the reporter cell line, as assessed by CAT quantification, while ouabain 
treatment completely abrogated such effect (Fig. 3.14C). This result is 
consistent with the conclusion that transfected HEK293T might secrete 
transcriptionally active Tat, and that such release is blocked by ouabain 
treatment. No decrease of CAT activity in the reporter cell line after ouabain 
treatment was observed when the Tat86-expressing cells were co-
transfected with a vector encoding rat Alpha1, either wild type of 
catalytically inactive, thus confirming that the ouabain-sensitive interaction 
between Tat and endogenous Alpha1 is crucial for the process of Tat release 
(Fig. 3.14C). 
Collectively, the results so far obtained are consistent with the conclusions 
that the Tat basic domain specifically recognizes the Na+,K+-ATPase Alpha1 
subunit in a ouabain-sensitive manner and that this interaction, rather than 
the catalytic activity of the enzyme, is essential to mediate the release of 
active Tat or Tat-fusion proteins in the extracellular environment. 
The Tat basic region binds the Alpha1 C-terminal domain 
Next we wanted to better define the regions of Tat and Na+,K+-ATPase 
Alpha1 subunit involved in the interaction between the two proteins. Alpha1 
is a large, integral membrane protein with 10 transmembrane-spanning 





Morth et al. 2007). We focused our attention on the cytoplasmic domains of 
the protein which were the most likely candidates for Tat binding, as the 
rest of the protein is either embedded in the phospholipidic bilayer, or 
protruding into the extracellular space (Fig. 3.15A). 
 
 
Fig. 3.15: Tat binds rat Na+,K+-ATPase Alpha1 subunit in vitro – 
Mapping of the interacting regions 
(A) Scheme of the aplha1 subunit structure and membrane topology; the cytoplasmic 
domains are indicated. 
(B) Schematic representation of the rAlpha1 fragments used for the pull-down assay 
showed in (C) and (D).  
(C) Tat binds the C-terminal cytoplasmic region of the rat Alpha1 subunit in vitro. 
rAlpha1-GST fragments or GST alone were incubated with [35S]-Tat86, extensively 
washed, and then resolved by SDS-PAGE. The panel shows the gel exposed to a 
phosphoimager. The graph shows the amount of bound proteins expressed as 
percentages of radiolabeled input.  
(D) Tat binds the C-terminal cytoplasmic fragments of the rat Alpha1 subunit. 
rAlpha1-GST fragments or GST alone were incubated with [35S]-Tat86 basic mutant, 
extensively washed, and then resolved by SDS-PAGE. The panel shows the gel 
exposed to a phosphoimager. The graph shows the amount of bound proteins 
expressed as percentages of radiolabeled input. 
 
 
GST-fused Alpha1 fragments corresponding to the three main cytoplasmic 





short cytoplasmic peptides (P1-P2-P3) of the rat apha1 subunit  (Fig. 
3.15B) were used in GST-pull down experiments using in vitro translated  
[35S]- labeled Tat, or an [35S]-Tat basic mutant, in which the basic residues 
of the Tat11 peptide had been replaced by alanines (Demarchi et al. 1999) 
(Fig. 3.15C). 
Labeled Tat showed a stronger binding with the C-terminal Alpha1 
cytoplasmic fragment (Fig. 3.15C); in contrast, the Tat basic mutant 
showed barely detectable interaction with any of the Alpha1 fragments, with 
a binding signal comparable to background (Fig. 3.15D). 
These experiments clearly indicate that Tat interacts in vitro with the C-
terminal region of the rat Alpha1 subunit, and that the basic region of the 
protein is responsible for this interaction, consistent with all the binding and 
protein export data presented so far. 
Interaction between Tat and the cytoplasmic portion of Alpha1 C-
terminal domain 
To further characterize the region of binding between Tat and the C-
terminus of the Alpha1 subunit, we analyzed in vitro the affinity between Tat 
and three synthetic peptides, corresponding to the three small cytoplasmic 
stretches (residues 824-843, 939-951 and 1007-1023, named P1, P2 and P3, 
respectively) residing in the C-terminal domain of the Alpha1 protein, as an 
interaction preceding the release of Tat is most likely to take place in the 
cytosolic environment. To perform the binding assays, synthetic biotinylated 
peptides were bound to streptavidin beads and subsequent pull down assays 
were performed employing both radiolabeled, in vitro translated Tat, and 
recombinant GST-Tat produced in E. coli.  
Following incubation and extensive washes, Tat protein showed an increased 
affinity towards the peptide-coated beads, if compared to beads alone, or 






Fig. 3.16: Interaction between Tat and the cytoplasmic portion of 
the Alpha1 C-terminal domain 
(A) Tat binds the three cytoplasmic peptides in the C-terminus of the Alpha1 protein. 
Biotinylated peptides were bound to streptavidin beads, incubated with [35S]-Tat86, 
extensively washed, and then resolved by SDS-PAGE. The panel shows the gel 
exposed to a phosphoimager. The graph shows the amount of bound proteins 
expressed as percentages of radiolabeled input.  
(B) Tat binds the three cytoplasmic peptides in the C-terminus of the Alpha1 protein 
through its basic domain. Biotinylated peptides were bound to streptavidin beads, 
incubated with [35S]-Tat86 basic mutant, extensively washed, and then resolved by 
SDS-PAGE. The panel shows the gel exposed to a phosphoimager. The graph shows 
the amount of bound proteins expressed as percentages of radiolabeled input. 
(C) Tat binds the three cytoplasmic peptides in the C-terminus of the Alpha1 protein. 
Biotinylated peptides were bound to streptavidin beads, incubated with GST-Tat, 
extensively washed, resolved by SDS-PAGE and blotted. The panel shows the results 
of a western blot against GST. The graph shows the amount of bound proteins 
expressed as percentages of loaded input.  
(D) GST does not bind the three cytoplasmic peptides in the C-terminus of the 
Alpha1 protein. Biotinylated peptides were bound to streptavidin beads, incubated 
with GST, extensively washed, resolved by SDS-PAGE and blotted. The panel shows 
the results of a western blot against GST. The graph shows the amount of bound 






Moreover, binding was shown to be specific for Tat, as a GST recombinant 
protein, used as a negative control, showed low or no affinity for the 
peptides (Fig. 3.16D).  
Finally, as a mutant version of Tat, lacking the basic stretch of amino acids 
(previously described and named Tat Basic Mutant – mutant R5A (Demarchi 
et al. 1999)), showed reduced affinity for the peptide-bound beads (Fig. 
3.16B), we could conclude that the binding between Tat and the 
cytoplasmic portion of the C-terminus of Alpha1 is mediated by its basic 
region.  
In all different assays, a slightly increased affinity for Tat was shown by 
peptide P2; however, as no dramatic differences were revealed among the 
affinity of the three peptides (no more than 10% difference in all assays), 
we conclude that all three peptides are capable of independent binding to 
Tat.  
3D modeling of C-terminal peptides in Alpha1 subunit tertiary 
structure 
The 3D structure of the C-terminal peptides with respect of the tertiary 
structure of the Alpha1 protein was obtained by loading the PDB file 
corresponding to the crystal structure of the pig Na+,K+-ATPase recently 
published  (Morth et al. 2007)(PDB entry # 3b8e) on Protein Workshop Java 
Applet, a tool for molecular modeling available at the online RCSB Protein 






Fig. 3.17: Spatial arrangement of Alpha1 C-terminal cytoplasmic 
peptides 
(A) Multiple alignment sequences corresponding to Alpha1 C-terminal cytoplasmic 
peptides in Human, Pig and Rat ortholog of Alpha1 subunit. 
(B) 3D modeling of pig Alpha1 tertiary structure, as resolved by X-ray crystallography 
(Morth et al. 2007). The regions corresponding to the three C-terminal cytoplasmic 
peptides are highlighted; a bottom view of the C-terminal region is shown. 
 
  
As shown in Fig. 3.17, the three small cytoplasmic coils are in close 
proximity one to another, and therefore it is plausible to hypothesize that 
they could form an interacting “surface” for Tat; in this scenario, the binding 
of Tat to only one of the three peptides could be less efficient than the 
binding to the whole native region, as found in the Alpha1 subunit 
embedded in the cellular membrane. 
Tat fails to co-immunoprecipitate an Alpha1 mutant lacking the C-
terminus 
Once the binding of Tat to a specific region of the Alpha1 subunit was 
demonstrated in vitro, we wanted to understand whether the same region 
was also responsible of Tat-Alpha1 interaction in vivo. For this purpose, we 
obtained a deletion mutant lacking the C terminus (Fig. 3.18A) tagged with 
a FLAG epitope. The levels of expression and subcellular localization of this 
mutant was first analyzed, along with those of the flagged wild type protein, 





FLAG antibody. All the proteins were found to be expressed at comparable 
levels and to localize at the cell membrane (3.18B). 
When co-transfected with Tat11-TK, the C-terminus deleted mutant was not 
able to co-immunoprecipitate the Tat fusion protein, unlike wild type Alpha1, 
thus confirming that, also inside the cells, the interaction of Alpha1 with the 
Tat basic domain requires the integrity of the C-terminal region of the 
protein, similar to the in vitro results (Fig. 3.18C). Identical results were 




















Fig. 3.18:  Tat fails to co-immunoprecipitate an Alpha1 mutant 
lacking the C-terminus 
(A) Schematic representation of the constructs; the deletion mutant of rat Alpha1, 
the wild type, as well as the catalytic mutant and the P1-P2-P3 fusion protein, fused 
to FLAG epitope. The residues at which deletions, fusion or mutations were designed 
are highlighted. 
(B) Intracellular localization of rat Alpha1 mutant, wild type and fusion protein. Upon 
transfection, U2OS cells were fixed and subjected to IF against the FLAG epitope; the 
slides were analyzed by confocal microscopy. 
(C) rAlpha1 C-terminal deletion mutants fail to co-immunoprecipitate Tat86-TK. The 
antibodies used for immunoprecipitation and subsequent western blots are indicated 
on the right side. Expression of proteins was assayed on whole lysates. The cells 
used were HEK293T cells co-transfected with Tat86-TK and either full-length 
rAlpha1-FLAG or the truncated mutant. FLAG-CDK9 was used as a control of FLAG 
immunoprecipitation.  
(D) rAlpha1 C-terminal deletion mutant fails to co-immunoprecipitate Tat11-TK. The 
antibodies used for immunoprecipitation and subsequent western blots are indicated 
on the right side. Expression of proteins was assayed on whole lysates. The cells 
used were HEK293T cells co-transfected with Tat11-TK, and either full-length 
rAlpha1-FLAG or the truncated mutant. FLAG-CDK9 was used as a control of FLAG 
immunoprecipitation. 
Alpha1 deletion mutant fails to rescue Tat86 secretion in ouabain 
treated cells 
Next we wondered whether the rat deletion mutant, when expressed in 
human cells, was still able to rescue the inhibition that ouabain imposes on 
Tat release. After transfection of HEK293T cells with either wild type rat 
Alpha1 or mutant together with Tat11-TK, no release of the Tat fusion 
protein was observed in the cell culture supernatants in the presence of 
ouabain in the cells expressing the mutant, unlike the wild type protein (Fig. 
3.19A). Consistent with our previous observations, secretion of the scFv 






Fig. 3.19: Alpha1 deletion mutant fails to rescue Tat86 secretion in 
ouabain treated cells 
(A) rAlpha1 C-terminal deletion mutant fails to rescue Tat11-TK secretion in ouabain 
treated cells. Cells were transfected with Tat11-TK and either rAlpha1-FLAG or the 
truncated mutant, then treated with ouabain; the amount of secreted protein was 
assessed by immunoblot on cell culture supernatants, while the protein expression 
was assessed on whole lysates. The bands marked with (*) represent degradation 
products. 
(B) rAlpha1 C-terminal deletion mutants fail to rescue Tat86 secretion in ouabain 
treated cells. HL3T1 cells were treated with the supernatants of HEK293T cells, 
transfected with Tat alone, or cotransfected with either rAlpha1-FLAG or the deletion 
mutant; cells were treated with ouabain, and their supernatant incubated with HL3T1 
cells. The levels of LTR activation were assessed by ELISA assay on CAT levels. As a 
control of LTR activation, HL3T1 cells were transfected with Tat. 
 
 
Thus, binding the C terminal region of Na+,K+-ATPase Alpha1 subunit is an 
essential requisite for Tat-fusion proteins to be released extracellularly. 
Finally, we performed a transcellular transactivation experiment in which the 
supernatants of HEK293T cells, transfected with wild type Tat86 and either 
the wild type or the mutant form of Alpha1 and treated with ouabain, were 
subsequently incubated for 24 h with reporter HL3T1 cells (Fig. 3.19B). The 
lysates of HL3T1 were used to perform an ELISA-CAT assay to quantify the 
levels of transactivation, compared to cells incubated with the supernatants 
of untransfected cells. HL3T1 cells transfected with a plasmid expressing 
Tat86 were used as a positive transactivation control. The results obtained 





Alpha1 were able to maintain levels of CAT activation in the presence of 
ouabain comparable with those obtained with the supernatants of ouabain-
untreated cells. When the mutant was transfected, however, the 
supernatants possessed virtually no LTR transactivation activity. 
Thus, the Tat-rat Alpha1 interaction, mediated by the Alpha1 C-terminus, is 
necessary for the secretion of wild type Tat86 when the interaction of Tat 
with endogenous human Alpha1 is disrupted by ouabain treatment. 
A fusion protein corresponding to the Na+,K+-ATPase Alpha1 C-
terminal loops binds Tat and impairs transactivation 
To test binding of Tat to the three C-terminal, short cytoplasmic loops of the 
Na+,K+-ATPase Alpha1 subunit in vivo, a plasmid expression vector was 
obtained, encoding for the P1-P2-P3 fusion protein, corresponding to the 
Na+,K+-ATPase Alpha1 C-terminal loops linked by a glycine residue, under 
the control of the constitutive CMV promoter, and fused to FLAG epitope. 
Expression of the P1-P2-P3 encoding plasmid was verified upon expression 
in U2OS cells. 
 
 
Fig. 3.20: Intracellular localization of FLAG-P1-P2-P3 fusion 
protein. 
U2OS cells were transfected with the FLAG-P1-P2-P3 construct and, after 24 hours, 
fixed and subjected to immunofluorescence against the FLAG epitope. A wide field 







As shown in Fig. 3.20, immunofluorescence against the FLAG epitope 
showed a diffuse localization of the protein, which was present in both the 
cytoplasmic and the nuclear compartments of the cells, with the exclusion of 
the nucleoli. 
The FLAG-P1-P2-P3 construct was then co-expressed in HEK293T cells with 
TK, Tat11-TK or Tat86-TK, and the lysates were used immunoprecipitation 
experiments using an anti-FLAG antibody. Western blot using an anti-TK 
antibody showed that co-immunoprecipitation with P1-P2-P3 occurred when 
using both Tat11-TK and Tat86-TK, but not TK (Fig. 3.21). 
 
 
Fig. 3.21: FLAG-P1-P2-P3 fusion protein interacts with Tat 
P1-P2-P3 fusion protein binds Tat86-TK and Tat11-TK in vivo. The antibodies used 
for immunoprecipitation and subsequent western blotting are indicated on the right 
side. Expression of proteins was assayed on whole lysates. The cells used were 




Since these co-immunoprecipitation experiments indicated that the P1-P2-P3 
fusion protein, once expressed intracellularly, was able to bind the basic 
region of Tat, we wondered whether the overexpression of this protein 
might also affect Tat transactivation. To test this possibility, HeLa cells 
expressing an LTR-driven luciferase gene were transfected with different 





expressing the P1-P2-P3 protein (300 and 600 ng). These results revealed 
that, at any of the three Tat plasmid concentrations, the co-expression of 
the higher dose of the P1-P2-P3 plasmid significantly inhibited the 
transcriptional activation of the LTR-reporter construct (Fig. 3.22). Cell 
viability was unaffected by P1-P2-P3 transfection at the highest 
concentration (not shown). 
In particular, when Luciferase activity (normalized over Renilla) was taken 
into account, the co-transfection of 600 ng P1-P2-P3 significantly reduced 




Fig. 3.22: Expression of FLAG-P1-P2-P3 fusion protein interferes 
with Tat transcriptional activity 
C-Terminal cytoplasmic region of Na+,K+-ATPase interferes with transactivation. HeLa 
cells expressing an LTR-driven luciferase gene were transfected with different 
amounts of both Tat and FLAG-P1-P2-P3, in order to assess the possible effect of an 
interaction between the two proteins in the transactivating activity of Tat; a plasmid 
expressing the Renilla Luciferase gene under the control of a CMV promoter was co-
transfected. The measured activities were standardized by the expression of Renilla; 
the histograms show the mean values of three independent experiments, together 
with the standard error. 
 
 
These results support the general conclusion that binding between Tat and 





the possibility that the overexpression of the fusion protein diverts Tat from 
its transactivation function at the HIV-1 LTR promoter, thus acting as a 
competitive inhibitor. 
Internalization of fluorescent peptides 
The observation that the fusion protein P1-P2-P3 was able to decrease Tat 
transactivation, albeit at a high molar ratio to Tat, prompted us to wonder 
what the effect of short peptides corresponding the Alpha1 C-terminal loops 
might be on Tat extracellular release. At difference with the endogenously 
expressed P1-P2-P3 protein, peptides can be administered exogenously at 
high concentration and their binding to Tat should not be subject to possible 
structural constrains imposed by their fusion in the P1-P2-P3 construct. In 
addition, our in vitro binding data (Fig. 3.16 C) showed that any of the 
three C-terminal intracytoplasmic loops of the Alpha1 subunit was able to 
independently bind Tat. 
To text the efficacy of intracellular internalization of the individual P1, P2 
and P3 peptides, these were synthesized conjugated to fluorescein and 
administered to HEK293T cells at the concentrations of 2, 5 or 10 µg/ml. 
After 4 h, cells were submitted to prolonged trypsinization and extensively 
washed to remove extracellular fluorescence, and then analyzed by flow 
cytometry. All three peptides showed a remarkable capacity of dose-







Fig. 3.23: Internalization of fluoresceinated Alpha1 peptides 
Cell internalization was analyzed for each single peptide at different concentrations; 
the FACS analysis for three different concentrations is shown. 
 
 
Intracellular cell fluorescence after 4 h treatment with an equimolar mixture 
of the P1, P2 and P3 peptides (hereafter named Pmix) is shown in Fig. 
3.24. Of notice, the flow cytometry profiles show increase of fluorescence in 
the vast majority of cells, indicating that internalization of Pmix is a general 






Fig. 3.24: A mixture of the three Alpha1 peptides (Pmix) is highly 
effective in being internalized by recipient cells 
A mixture of the three Alpha1 C-terminal peptides, conjugated to fluorescein, is 
efficiently internalized upon addition to the cell culture medium. An equimolar mix of 
the three peptides, at the indicated concentrations, was added to Optimem medium, 
and incubated with HEK293T cells for 4 hours. Cells were then trypsinized, 
extensively washed, and analyzed by flow cytometry. 
 
Synthetic peptides corresponding to the Na+, K+-ATPase Alpha1 C-
terminal loops block Tat export  
As all Alpha1 C-terminal peptides showed high cell permeability, next we 
tested the effects of cell treatment with the individual peptides or with Pmix 
on the release of Tat. Cells were transfected with Tat11-TK together with 
the single chain antibody ScVH16-SV5 and treated with 5 or 10 µg/ml of the 
P1, P2 and P3 peptides. Cell treatment with any of the three peptides, at the 
higher concentration, showed marked inhibition of extracellular Tat-fusion 
protein release, while leaving the secretion of the control scFv antibody 
undisturbed; an almost complete block was observed when using Pmix at 






Fig. 3.25: Cell treatment with Alpha1 peptides inhibits Tat release. 
HEK293T cells expressing Tat11-TK and the ScVH16-SV5 scFc antibody were treated 
with the individual Alpha1 C-terminus P1, P2 and P3 peptides, or with a mixture of 
the three (Pmix), at the indicated concentrations. The amount of secreted proteins 
was measured by western blotting in the cell culture supernatants at 4 h after 
peptide incubation. For each experimental condition, the level of intracellular protein 
expression was assessed by western blotting on whole cell lysates (WCL). 
 
 
Based on these results, we tested the effects of a broader Pmix 
concentration range (from 2 to 15 µg/ml) on the secretion of Tat86-TK. Cell 
treatment with Pmix inhibited extracellular Tat release in a dose-dependent 
manner, while canonical secretion of ScVH16-SV5 was unaffected (Fig. 
3.26). Of notice, transfection of the P1-P2-P3 tripartite fusion protein was 
ineffective in this assay, consistent with the possibility that the affinity of this 








Fig. 3.26: Inhibition of extracellular Tat release by peptides 
corresponding to the C-terminus of Alpha1. 
(A) Inhibition of Tat86-TK release. HEK293T cells expressing Tat86-TK and ScVH16-
SV5 were incubated with the P1, P2 and P3 peptide mix (Pmix) and, after 4 h, the 
levels of Tat86-TK protein in the supernatant was analyzed by western blotting. The 
effect of P1-P2-P3 protein expression was analyzed upon transfection of the 
encoding plasmid. The levels of intracellular protein expression were assessed by 
western blotting on whole cell lysates (WCL).  
(B) Inhibition of Tat11-TK release. The experiment was performed as in panel A by 







Synthetic peptides corresponding to the Na+, K+-ATPase Alpha1 C-
terminal loops inhibit HIV-1 replication 
Next we wondered whether the exogenous administration of the Pmix 
peptides might affect HIV-1 infection. A first set of experiments was 
performed by a single round infection assay in HOS CCR5 cells using an HIV-
1-NL4-Luc virus carrying the M-tropic Bal envelope. When cells were pre-
incubated with Pmix, however not with a control FLAG peptide (10 µg/ml in 
each case), before viral infection a significant decrease in luciferase activity, 
measured 24 h post-infection, was observed (Fig. 3.27). 
 
 
Fig. 3.27: A soluble mix of the three alpha 1 peptides inhibits HIV-1 
infection 
Addition of Pmix during single-round infection with M-tropic HIV-based vector 
expressing Luciferase gene impairs viral gene expression. HOS CCR5+ cells were 
infected with an HIV based vector where Nef is replaced by Luciferase gene (pNL4.3 
E-R-), pseudotyped with the M-tropic Bal envelope. Prior to infection, the virus was 
pre-incubated with an equimolar mix of P1, P2 and P3 peptides (Pmix). Cells were 
incubated with the virus for 4 h, washed, and fresh medium containing Pmix was 







In a subsequent experiment, we wanted to analyze the effect of the Pmix 
and FLAG (control) peptides on the infection of CEM CD4+ T cells with wild 
type HIV-1BRU. Over the course of 12 days after infection, half of the cell 
medium was replaced every second day with fresh medium containing either 
Pmix or FLAG peptides at a concentration of 10 µg/ml. Viral infection was 
monitored by measuring reverse transcriptase activity in the cell culture 
supernatant. The Pmix peptides were found to markedly suppress viral 




Fig. 3.28: Addition of Pmix during infection with wild type HIV-1BRU 
impairs viral replication. 
CEM cells were infected with HIVBRU for 4 hours; where indicated, the infection was 
performed in presence of 10 µg/ml of Pmix, or of FLAG peptide, as a negative 
control. After infection, the medium containing the virus was washed and substituted 
with fresh medium, containing the corresponding peptide preparation. At t=0 and, 
subsequently, every 3 days until the 12th day, the supernatants were tested for RT 




These results collectively indicate that the suppression of extracellular Tat 





ATPase Alpha1 subunit C-terminal domain is able to impair HIV-1 infection, 
























HIV-1 Tat protein is a small viral transcriptional activator which binds a cis-
acting RNA element (TAR) present at the 5'-end of each viral transcript at 
the LTR promoter. Through this interaction, Tat activates HIV-1 transcription 
by promoting the assembly of transcriptionally active complexes at the LTR 
(see Introduction). 
In addition to its role in promoting viral RNA transcription, Tat possesses 
unusual intercellular trafficking properties when expressed in cells (Ensoli et 
al. 1993; Chang et al. 1997) or added extracellularly as a recombinant 
protein (Tyagi et al. 2001; Ferrari et al. 2003; Fittipaldi et al. 2003). This 
ability to cross cell membranes depends on the integrity of the basic domain 
of the protein (aa 49-57), and is the basis for the biotechnological utilization 
of Tat basic region as a “protein transduction domain” (PTD) for the delivery 
of heterologous proteins, drugs, viral vectors and nanoparticles (Becker-
Hapak et al. 2001; Tasciotti et al. 2003; Fittipaldi and Giacca 2005; Tasciotti 
and Giacca 2005). Both biochemical and genetic studies have indicated that 
the internalization of  large molecules fused to extracellular Tat involves 
binding of the Tat basic domain to cell surface heparan sulfate proteoglycan 
(HSPG) receptors, followed by internalization by different endocytic routes, 
the most prominent one appearing to be caveolar endocytosis (Ferrari et al. 
2003; Fittipaldi et al. 2003). 
As Tat-expressing cells release traceable amounts of biologically active Tat 
(Ensoli et al. 1993; Chang et al. 1997; Tyagi et al. 2001; Tasciotti et al. 
2003), an intriguing hypothesis could be that Tat release might be involved 
in the regulation of HIV-1 infection or even the modulation of HIV-1 
pathogenesis in vivo.  
Tat binds to the heparan sulfate proteoglycans attached to the cell surface 





function as a storage for functional Tat, which, by means of this 
accumulation, could locally reach high concentrations. As a matter of fact, 
infected cells presenting Tat bound to HSPGs on their surface, as well as 
cells treated with recombinant Tat, show increased permissivity to HIV-1 
infection, and higher viral replication rates (Marchio et al. 2005); this 
property of extracellular Tat seems to be mediated by its binding to the V1-
V2 loop of the gp120 protein. 
The mechanisms underlying Tat release from the expressing cells have 
remained largely elusive so far; as the protein does not contain a N-terminal 
signal peptide, its secretion is independent from the integrity of the ER-Golgi 
pathway (Chang et al. 1997). Similar to its uptake, Tat release also depends 
upon the integrity of the basic region of the protein (Tasciotti et al. 2003; 
Tasciotti and Giacca 2005) however is independent of HSPG production and 
trafficking, since it also occurs in cells genetically defective in proteoglycan 
biosynthesis (Tyagi et al. 2001). 
Characterization of the unconventional pathway of Tat secretion 
The existence of a non conventional mechanism, independent from the ER-
Golgi system, for the export of soluble proteins, has been known for more 
than 10 years. The molecular machinery underlying this process, however, is 
still poorly understood, even if it is quite clear that several distinct pathways 
may be involved for different proteins. For example, while FGF-2 secretion 
seems to be driven by direct membrane translocation (Schafer et al. 2004), 
the export of Galectin-1 is likely to occur through membrane blebbing 
(Hughes 1999); IL-1β and FGF-1 secretion, instead, is heat-shock gated, and 
seems to proceed through a vesicular intermediate (Prudovsky et al. 2003). 
To investigate the mechanisms involved in the release of Tat-fusion proteins, 
we started studying the kinetics of release of Tat-fusion proteins  from 





proteins (~2-10%) was found in the cell culture supernatants in the absence 
of detectable cell lysis. Of interest, the amount of Tat-TK proteins free in the 
supernatant was increased by cell treatment with soluble heparin (Fig. 
3.3C), consistent with the notion that this polyanion acts as a competitive 
inhibitor of cell surface and extracellular matrix HSPGs, which sequester 
soluble Tat (Chang et al. 1997), and that heparinase III releases the 
attached protein (Chang et al. 1997).  
While a single-chain Fv antibody (scFv) (a positive control for ER-Golgi 
dependent secretion) and Tat86-TK proteins were expressed at comparable 
levels by the cells, however, the kinetics of their appearance in the cell 
culture supernatants was drastically different. The levels of the extracellular 
Tat-fusion protein peaked as early as 30 min after the addition of fresh 
medium and slightly decreased in the subsequent 2 h (Fig. 3.2). In 
contrast, secreted scFv appeared at later times and its levels progressively 
increased. Analogous findings were also detected when cells were co-
transfected with Tat11-TK and ScVH16-SV5, thus indicating that the release 
kinetics is a property imparted by the Tat basic domain. As compared to 
Tat86-TK, however, the overall efficiency of Tat11-TK release was 
significantly higher.  
Recent evidence (Seelenmeyer et al. 2005; Zehe et al. 2006) demonstrated 
that the binding to a cell surface receptor is a necessary step for FGF-2 and 
Galectin-1 export. The mechanism is not completely clear, however, the 
authors hypothesize a “molecular trap” (Nickel 2007) capturing the secreted 
molecules and avoiding their binding to cell surface counter receptors. 
Moreover, this binding could limit the abundance of free factors in the 
extracellular milieu and, through the microenvironment of the cell 
membrane, maintain a gradient leading proteins outside the cells without 
needing energy supply. While for Tat, however, such dependence from 
HSPG binding has never been demonstrated, on the contrary, work 





could be revealed either in presence of heparinase III (which detaches the 
heparin moiety of HSPGs) (Chang et al. 1997) or in cell lines genetically 
defective in HSPG biosynthesis (Tyagi et al. 2001). Thus, in the case of Tat, 
HSPG binding does not serve to create a positive gradient at the site of 
export, as the heparin-bound protein can promptly re-enter the cell by 
caveolar endocytosis (Fittipaldi et al. 2003). This feature clearly 
distinguishes, in the case of Tat, the pathways of release and uptake. 
As proteins other than TK had the same behavior when fused to Tat (Fig. 
3.3A) we concluded that the apparent lack of accumulation of Tat-fusion 
proteins in the supernatant over time likely reflects a steady-state 
equilibrium between the amount of released protein that remains bound to 
extracellular HSPGs despite the presence of soluble heparin inhibitor, and 
that undergoing internalization through the interaction with cell membrane-
associated HSPGs (Tyagi et al. 2001; Fittipaldi et al. 2003). Consistent with 
this possibility, we observed that CHO A745 cells, which do not express 
detectable amount of proteoglycans due to a genetic defect in their 
biosynthetic pathway (Rostand and Esko 1997), release progressively 
increasing amounts of Tat11-TK in their supernatants (Fig. 3.3B).  
Collectively, these results show that heterologous proteins containing Tat or 
the Tat basic domain possess the property of being progressively released 
from the producing cells, independent from the production of HSPGs; 
however, upon secretion, Tat binds to the extracellular surface by means of 
its association with the HSPGs (as demonstrated by the surface-staining 
experiments shown in Fig. 3.6). There are experimental evidences for the 
presence of Tat on the envelope of the new virions budding from infected 
cells (Marchio et al. 2005), which could serve several functions in the 
process of cell infection by HIV-1. 
In co-cultures experiments employing Tat-GFP-expressing cells and LTR-
CAT-expressing cells, the Tat-GFP protein has been shown to traffic from 





detectable level of CAT activation, thus demonstrating that Tat is secreted 
from expressing cells in a biological active form (Tyagi, et al., 2001). Here 
we extended these experiments by testing the functionality of secreted Tat 
found in the cell-free supernatants. When HL3T1 cells, stably expressing an 
LTR-CAT reporter gene, were incubated with the cell culture supernatants of 
Tat expressing cells, secreted Tat was able to cross cell membranes of 
HL3T1 cells, where it was targeted to the nucleus and transactivated the 
LTR-driven reporter gene (Fig. 3.4). Collectively, these result confirm that, 
upon its release, Tat preserves its functionality and biological activity on the 
LTR promoter. 
Since the Tat-GFP fusion protein was excluded from the Golgi apparatus 
(Fig. 3.5), as shown by lack of co-localization in immunofluorescence 
experiments where an integral Golgi protein (GM130) was labeled, release of 
the protein had to proceed through a pathway which was independent from 
the classical, Golgi-dependent, route. 
Ouabain blocks extracellular Tat release 
We then studied the sensitivity of Tat fusion protein release to some 
metabolic drugs in order to define similarities and differences between the 
release of Tat and that of other proteins known to be secreted by 
unconventional means (Fig. 3.7). 
Beyond being, as expected, insensitive to BFA, a drug which blocks the 
classical pathway of secretion disrupting the Golgi apparatus (Misumi et al. 
1986; Orci et al. 1991), Tat secretion was not affected by either 
methylamine (a drug which blocks the endosomal recycling (Rubartelli et al. 
1990; Hamon et al. 1997; Zhou et al. 2002)), or glyburide (a sulfonylurea 
interfering with an ABC transporter (Hamon et al. 1997; Flieger et al. 
2003)). These data support the notion that several distinct mechanism of 





number of publications have described the sensitivity of IL-1β and FGF-2 
release to methylamine (Rubartelli et al. 1990; Hamon et al. 1997; Zhou et 
al. 2002), thus implying a vesicular intermediate in the secretion of these 
factors, while this drug had no effect in the case of FGF-1 (Shin et al. 1996), 
Galectin-1 (Sato et al. 1993; Mehul and Hughes 1997; Hughes 1999) and, 
now, Tat. On the contrary, Galectin-1 secretion was highly sensitive to 
glyburide, an inhibitor of the ABC-1 transporter (Flieger et al. 2003); this 
drug, however, had no effect on the release of Tat, further confirming the 
conclusion that, most probably, the “non classical pathway”, unlike the 
“classical” one, does not rely on a single molecular machinery to drive 
proteins outside the cells. Quite remarkably, extracellular Tat release 
showed high sensitivity to ouabain, a specific inhibitor of the Na+,K+-ATPase 
pump; the same drug is also known to inhibit the unconventional release of 
FGF-2  by a mechanism that so far has remained elusive (Florkiewicz et al. 
1998; Dahl et al. 2000; Trudel et al. 2000; Smith et al. 2001) (Fig. 3.7C 
and D). 
The role of the Na+,K+-ATPase in extracellular Tat release 
Na+,K+-ATPase is an enzyme built into the plasma membrane which 
catalyzes ATP hydrolysis coupled with Na+ and K+ transfer through the 
membrane against the electrochemical gradient. The site of cardiac 
glycoside binding is located on the extracellular part of the enzyme alpha-
subunit (Lingrel et al. 1994) and the sensitivity to these inhibitors differs 
depending on animal species (minimal sensitivity to ouabain is characteristic 
for the enzyme from rat). 
As we found that Tat secretion is not sensitive to curcumin (Fig. 3.7), an 
inhibitor of all P-type ATPases (also including the Na+,K+-ATPase), it can be 
concluded that the inhibitory effect exerted by ouabain was due to a 
perturbation of the Tat-Alpha1 interaction, rather than to an involvement of 





observation also directed our attention towards a specific role of the Alpha1 
subunit, which is bound by ouabain, in the overall process of Tat secretion. 
This conclusion is also in line with the findings showing no effect on FGF-2 
secretion by the obliteration of the transmembrane potential of Na+ and K+ 
ions generated by the Na+,K+-ATPase (Florkiewicz et al. 1998). This 
observation once more highlights an analogy in the mechanism of secretion 
of the two proteins, which share several structural and functional features. 
Similar to Tat, FGF-2 possesses a basic peptide stretch, binds HSPGs on the 
extracellular matrix (Zehe et al. 2006),  is a leaderless secreted protein 
(Engling et al. 2002; Backhaus et al. 2004; Schafer et al. 2004) and displays 
angiogenic activity (Nugent and Iozzo 2000). 
Next we wanted to investigate the possibility that a physical interaction 
between Tat and the apha1 protein existed. This was indeed proven by co-
immunoprecipitation experiments, which also demonstrated that the Tat and 
Alpha1 interaction was disrupted by the addition of ouabain to the cells 
expressing the two proteins (Fig. 3.8). When the ouabain-insensitive, rat 
isoform was used, the interaction between the two protein was unaffected 
by the addition of the drug. 
As ouabain and ouabain-like hormones have been demonstrated to trigger 
the endocytosis of plasmallemal Na+,K+-ATPase by a clathrin dependent 
mechanism that translocates the enzyme to intracellular compartments (Liu 
et al. 2004a), we investigated whether the inhibiting effect shown on the 
binding between Tat and Alpha1 could be due to a change of localization of 
either of the two proteins, which might interfere with their interaction. 
However, when the localization of either Tat, as a fusion protein with YFP, or 
a FLAG-tagged version of Alpha1, was studied in the presence of ouabain, 
no significant modification of their normal localization was revealed (Fig. 
3.9). 
Ouabain did not interfere with Tat endocytosis, either, thus showing that its 





and not to some general, unspecific perturbation of intracellular vesicle 
trafficking (Fig. 3.10). 
Finally, FRET experiments also revealed that Tat and rat Alpha1 physically 
interact in vivo (Fig. 3.12). In these experiments, however, which were 
performed by tagging Alpha1 with CFP, localization of Alpha1 was mainly 
nuclear and nucleolar, and not on the cell membrane. We speculate that a 
proteolytic degradation of alpha-CFP may occur, leading to the presence of 
small C-terminal fragments, still fused with CFP, which could still bind Tat 
and, because of this interaction, be translocated in the nucleus and the 
nucleolus where overexpressed Tat is known to accumulate. 
While searching for the role of ouabain and Alpha1 in the process of Tat 
release, we found that the expression of a ouabain-resistant Alpha1 isoform 
was able to rescue Tat secretion in the presence of ouabain, thus pointing 
out that the effect of the drug was clearly mediated by its interaction with 
Alpha1 (Fig. 3.14). Moreover, a point mutant of rat Alpha1, unable to bind 
and hydrolyze ATP, thus lacking catalytic activity as a cation pump, was also 
able to rescue Tat secretion in ouabain treated cells, as well as it was 
capable to bind Tat, thus confirming that the structure of Alpha1, more than 
its function as a cation pump, had a crucial role in Tat secretion (Fig. 3.13 
and Fig. 3.14).  
Taken together, these findings show that a ouabain-sensitive interaction 
takes place between Tat and the Alpha1 subunit of the Na+,K+-ATPase, and 
that such interaction is critical for the block of Tat secretion observed in 
ouabain treated cells. The similar effect exerted on FGF-2 secretion by 
ouabain (Florkiewicz et al. 1998), as well as the interaction observed 
between FGF-2 and the Alpha1 subunit (Dahl et al. 2000), suggest that a 
similar pathway of non classical secretion may be followed by the two 





Alpha1 is a large, integral membrane protein with  transmembrane-spanning 
domains plus cytoplasmic regions (Morth et al. 2007). To map the 
interaction between the two proteins in a specific region of the apha1 
subunit, we focused our attention on the cytoplasmic domains of the protein 
which were the most likely candidates for Tat binding, as the rest of the 
protein is either embedded in the phospholipidic bilayer, or protrudes into 
the extracellular space (Fig. 3.15). The GST-pull down assays pointed out 
binding of three Alpha1 fragments, mapping in the C-terminal region of the 
protein, with Tat, and specifically with its basic domain; a mutant version of 
Tat, in which the basic residues of the PTD were mutated to alanines, was 
unable to bind the alpha-1 cytoplasmic domains in vitro (Fig. 3.15 and 
3.16). 
Very recently, when the crystal structure of the Na+,K+-ATPase was 
elucidated, some unique features of the Alpha1 C-terminal region were 
highlighted (Morth et al. 2007). In particular, the existence of a “C-terminal 
switch”, sensitive to membrane potential, and interacting with the Na+ 
binding site, was demonstrated, since a protein carrying a deletion of the 
five most C-terminal residues of the chain (residues 1018-1023) showed 
remarkably less affinity to Na+. Can this highly electropositive stretch, whose 
function is to modulate ion transport, be involved in the binding and release 
of Tat? An interesting speculation might be that, through its interaction with 
the C-terminal region, Tat is brought in the proximity of the pump channel, 
through which it could somehow achieve membrane crossing. The 
hypothetical mechanism exploiting such ion channel for a larger molecule 
with the dimension of Tat-fusion proteins however remains obscure. 
When an in vivo interaction assay was performed (Fig. 3.18), an Alpha1 
truncation mutant, lacking the C-terminal region was able neither to 
immunoprecipitate Tat in the lysates of expressing cells, nor to rescue Tat 
secretion in ouabain treated cells, thus proving that the effect of the drug 





Alpha1. In this respect, it is worth noting that, despite having been known 
as a specific inhibitor of the Na+,K+-ATPase for more than 30 years, the 
molecular mechanism leading to the blockage of ion transport triggered by 
ouabain is still unclear. The cardiac glycoside (as well as endogenous 
ouabain-like hormones) binds a specific site on the extracellular side of the 
pump, located within in the third extracellular hairpin (transmembrane 
segments 5 and 6), with an involvement also of the first and second 
transmembrane segments (which do not directly take part in binding 
themselves however may act by modulating the accessibility of the ouabain-
binding site). Little is known, however, on the events leading to the 
inhibition of the pump function: a possible link between the cardiac 
glycoside binding site and the cation transport sites of the Na+,K+-ATPase, 
therefore suggesting  structural base for cardiac glycoside inhibition of the 
enzyme, may be such that ouabain binding to the implicated region blocks 
the movement of the H5 and H6 transmembrane domains which may be 
required for energy transduction and cation transport (Palasis et al. 1996; 
Lingrel et al. 1997; Lingrel et al. 1998).  
At least two possibilities exist to explain ouabain inhibition of Tat release and 
Tat-Alpha1 interaction: in a first scenario, ouabain binding imparts some 
spatial modification in Alpha1 3D structure, thus modifying somehow the 
affinity of the C-Terminus for Tat. Alternatively, ouabain binding could 
trigger the detachment of some third part factor or complex of factors (or 
the recruitment of some inhibitor) which may be necessary for Tat release. 
Even if our experiments with the D716N catalytic mutant and the peptide-
mediated inhibition of Tat release seem to make the first possibility more 
likely, however, the possible existence of some other factors involved in the 
process of release (and the presence of which could be somehow regulated 
by ouabain) cannot be formally excluded and must be taken into account. 
The experiments entailing mapping of the Tat-Alpha1 interaction domain 





Tat interacts with the C-terminal intracytoplasmic loops of Alpha1 (Fig. 
3.18). This notion was later confirmed by co-expressing a FLAG-tagged 
fusion of the three C-terminal short cytoplasmic stretches, spanning residues 
824-843, 939-951, 1007-1023, of the Alpha1 sequence, and showing their 
co-immunoprecipitation with Tat and Tat11 fusion proteins (Fig. 3.21). 
Most notably, in a model cell line expressing an LTR-controlled reporter 
gene, co-expression of the P1-P2-P3 fusion protein led to significant 
reduction of transactivation (Fig. 3.22).  
Finally, we were also able to demonstrate that cell treatment with synthetic 
peptides corresponding to the C-terminal region of Alpha1 block extracellular 
Tat release (Fig. 3.24). This remarkable result not only once more 
highlights the relevance of Alpha1-Tat interaction in extracellular Tat 
release, but also paves the way to the possibility of pharmacologically 
inhibiting Tat trafficking. This was best exemplified by the experiments in 
which cell treatment with the Alpha1 peptide mixture inhibited HIV-1 
infection both in a single-round infection assay (Fig. 3.27) or during chronic 
infection of susceptible cells (Fig. 3.28). Further experiments are clearly 
required to understand better the molecular correlates of these 
observations. In particular, it will be important to understand whether 
inhibition occurs through diminishing HIV-1 virion infectivity, or by 
modulating the susceptibility of non-infected cells.  
Lately, a novel function has been demonstrated for the Alpha1 subunit as a 
signal transducer of hormonal stimulation by ouabain-like molecules in 
different cell types and tissues (Xie and Askari 2002). Of particular interest, 
ouabain signaling seems to proceeds through a particular pool of Alpha1 
which is bound to caveolin-1 through its N-terminus (Wang et al. 2004; Cai 
et al. 2008) and therefore, at the cell membrane, resides in lipid rafts 
domains; of notice, the same domains also mediate Tat endocytosis, and 
transcytosis (Hansen et al. 1999) of extracellular substances across tight-





mechanism by which ouabain signaling through caveolar Alpha1 and Tat-
mediated trafficking could be linked remains unclear, still the possibility that 
Alpha1 could supply the link between Tat internalization and release, 
possibly coordinating its intracellular and extracellular activities, is appealing. 
Given the intriguing similarity with the pathway of FGF-2 release as well as 
with FGF-2 structure, an interesting speculation could be that Tat may hijack 
the secretion pathway evolved for FGF-2, by means of mimicking its 
structure, in the same way by which viral components often use the cellular 
machinery to achieve viral functions. 
In recent years, the interaction with acidic domains in the phospholipidic 
components of the inner membrane leaflet has turned out to be a crucial 
step that may precede membrane crossing by proteins devoid of a signal 
peptide. In particular, Temmerman and coworkers  have demonstrated that 
partially folded FGF-1 possesses higher affinity for acidic phospholipids in the 
inner leaflet of the cell membrane and that this interaction  results in more 
efficient extracellular export of the growth factor (Temmerman et al. 2008). 
In this perspective, the Alpha1 C terminal region might function as a docking 
site promoting a spatial juxtaposition of Tat to the inner membrane leaflet, 
which in turn could lead to membrane translocation. Very recently, it has 
been proposed that, under specific pH conditions, a single tryptophan 
residue in the sequence of Tat could mediate its insertion into the plasma 
membrane (Yezid et al. 2009). In this context, the involvement of the 
Alpha1 subunit has great relevance, since it could provide a preferential 
route through which cytosolic Tat may be targeted to the membrane for its 
export. Of interest, the properties of Alpha1 C-terminal peptides, which in 
our assays were able to cross the cell membrane and localize inside the cells 
(Figs. 3.23 and 3.24 ), could suggest the existence of a sort of 
“translocable region” in the Alpha1 C-terminus, which could somehow 





More investigation is clearly needed to uncover the mechanism by which this 
transmembrane protein could drive or regulate the membrane crossing of 
cargo proteins. However, our findings open a totally new chapter in the 
understanding the mechanisms leading to unconventional protein release, as 
they reveal an unexpected new role of the Alpha1 subunit of the Na+,K+-
ATPase, traditionally seen only as a cationic pump essential for the 
maintenance of transmembrane potential. 
Intercellular trafficking and lentiviral biology: Why is Tat secreted? 
In recent years, peculiar trafficking properties have been demonstrated for a 
number of accessory viral proteins of various pathogens, including both 
viruses and bacteria. Most noticeably, regulatory proteins of all the three 
families of complex retroviruses (HFV Bet, HTLV-1 Tax and HIV-1 Tat) as 
well as the HIV-1 accessory proteins Vpr and Nef, have the ability to cross 
cell membranes and traffic to nearby cells, where they mediate a number of 
pleiotropic effects not necessarily related to the cytopathic effects of the 
respective viruses.  
While at first these proteins have been regarded as “accessory” or 
“auxiliary”, as they are not necessary for the assembly of mature virions and 
are often dispensable for virus replication in vitro, subsequent in vivo studies 
have made clear that these proteins are instead fundamental players in the 
onset and development of the infection. Of particular interest are the overall 
effects on the immune system, where, according to our current 
understanding, the combined activities of Tat, Vpr and Nef (which can all be 
released and therefore also act on uninfected, bystander cells), would 
enhance the survival of infected cells, while at the same time promoting the 
death of uninfected immune cells, or the anergy of the effectors of the 
immune CTL response (Li et al. 1995; Curtain et al. 1997; Collins et al. 
1998; Poggi et al. 1998; Zocchi et al. 1998; Bennasser and Bahraoui 2002; 





and down-modulation could explain both the lack of anti-HIV CTL response 
and the rapid immune depletion, associated with HIV infection, which can 
hardly be otherwise explained by only taking into account the virus 
replication-associated cell death. 
Moreover, these small, membrane permeable proteins, also exert cytotoxic 
effects on different cell types, such as renal cells, spindle and endothelial 
cells, neurons, and glial cells (reviewed in (Foreman 2001; Jones and Power 
2006) (King et al. 2006); (Zuo et al. 2006) (Kino and Chrousos 2004)). 
These effects accounts for most of the pathological aspects of the HIV-
induced illness which are unrelated to viral propagation.  
In the case of Tat, there are evidences (Marchio et al. 2005) that 
extracellular Tat, either in soluble form, or bound to the extracellular matrix 
of virus-producing cells (and therefore, most likely, also on the surface of 
budding virions), can enhance virus infectivity and increase the rate of viral 
replication; in particular, it has been suggested that secreted Tat could bind 
the HSPGs on uninfected cells, where it could function by promoting virus 
spread and infection by means of its specific binding with the viral envelope 
protein gp120 (see also (Nappi et al. 2009)).  
Moreover, as extracellular Tat is mainly internalized by caveolar endocytosis 
(Fittipaldi et al. 2003), one could hypothesize that the presence of Tat 
bound to the viral surface could promote virus uptake by the caveolar 
pathway, and its transmission by transcytosis, a process which starts with 
caveolar endocytosis. This might constitute a mechanism for the spread of 
HIV-1 through epithelial and blood-brain barriers despite the presence of 
tight junctions between lining cells.  
Finally, since a possible link between extracellular, HSPG-bound Tat and the 
extravasation of lymphoid cells has been recently provided (Urbinati et al. 





enhance viral spread and persistence in tissues such as, for example, the 
CNS. 
For all the above mentioned reasons, the Tat protein appears a very 
appealing target for the development of novel therapeutic strategies aimed 
at limiting viral spread and replication during the course of HIV-1 infection. 
In particular, since Tat functions both at the nuclear level (where it drives 
the transcriptional activation of viral genes) and in the extracellular 
compartment (where it exerts the pleiotropic activities described above), the 
development of drugs capable to block Tat, either intracellularly or 
extracellularly, is highly desirable. Such drugs could stop viral replication on 
one hand while, on the other hand, might contribute to contrast the 
pathogenetic mechanisms involved in HIV-1 disease development. 
The attempts aimed at designing anti-Tat drugs, however, have led to 
largely disappointing results so far. The protein has no known enzymatic 
activity and possesses a highly flexible structure - no Tat crystals have been 
obtained yet, indicative of its flexible conformation adapting to different 
cellular protein partners -, which prevents the easy possibility of designing or 
selecting highly effective drugs. Of the few small compounds that, over the 
last several years, have been reported to inhibit Tat or block Tat-TAR 
interaction, none has so far advanced toward clinical experimentation. Use 
of a decoy RNA sequence, consisting of a multimerized TAR element, has 
been described as a mean to divert Tat from its natural target at the HIV-1 
promoter (Lisziewicz et al. 1993). This decoy, however, requires to be 
expressed intracellularly upon delivery using viral vectors, with obvious 
limitations in terms of applicability. Finally, anti-Tat vaccination has been 
proposed as a mean of both preventing HIV-1 replication and targeting 
extracellular Tat, however the experimentation in this respect (reviewed in 
(Ensoli and Cafaro 2002; Caputo et al. 2004)) has so far generated very 





As we found that a soluble mix of Alpha1 C-terminal peptides, when added 
to cells, was internalized and was able to block Tat release (Figs. 3.25 and 
3.26) and to impair HIV-1 infection (Figs. 3.27 and 3.28), these peptides 
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